false2024FY0001653477P0Dhttp://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNethttp://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNethttp://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNetP1Yhttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2024#LongTermDebtCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesngvt:segmentxbrli:purengvt:mmbtusngvt:leasengvt:claim00016534772024-01-012024-12-3100016534772024-06-3000016534772025-02-1400016534772023-01-012023-12-3100016534772022-01-012022-12-3100016534772024-12-3100016534772023-12-310001653477us-gaap:CommonStockMember2021-12-310001653477us-gaap:AdditionalPaidInCapitalMember2021-12-310001653477us-gaap:RetainedEarningsMember2021-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001653477us-gaap:TreasuryStockCommonMember2021-12-3100016534772021-12-310001653477us-gaap:RetainedEarningsMember2022-01-012022-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:CommonStockMember2022-01-012022-12-310001653477us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001653477us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001653477us-gaap:CommonStockMember2022-12-310001653477us-gaap:AdditionalPaidInCapitalMember2022-12-310001653477us-gaap:RetainedEarningsMember2022-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001653477us-gaap:TreasuryStockCommonMember2022-12-3100016534772022-12-310001653477us-gaap:RetainedEarningsMember2023-01-012023-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:CommonStockMember2023-01-012023-12-310001653477us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001653477us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001653477us-gaap:CommonStockMember2023-12-310001653477us-gaap:AdditionalPaidInCapitalMember2023-12-310001653477us-gaap:RetainedEarningsMember2023-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001653477us-gaap:TreasuryStockCommonMember2023-12-310001653477us-gaap:RetainedEarningsMember2024-01-012024-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:CommonStockMember2024-01-012024-12-310001653477us-gaap:TreasuryStockCommonMember2024-01-012024-12-310001653477us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310001653477us-gaap:CommonStockMember2024-12-310001653477us-gaap:AdditionalPaidInCapitalMember2024-12-310001653477us-gaap:RetainedEarningsMember2024-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001653477us-gaap:TreasuryStockCommonMember2024-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberngvt:PerformanceMaterialsMember2022-01-012022-12-310001653477ngvt:AutomotiveIndustryMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310001653477srt:MinimumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-12-310001653477srt:MaximumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-12-310001653477srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310001653477srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310001653477ngvt:ProductionControlSystemEquipmentandHardwareLaboratoryTestingEquipmentMember2024-12-310001653477srt:MinimumMemberngvt:ProductionControlSystemEquipmentandHardwareLaboratoryTestingEquipmentMember2024-12-310001653477srt:MaximumMemberngvt:ProductionControlSystemEquipmentandHardwareLaboratoryTestingEquipmentMember2024-12-310001653477ngvt:ControlsystemsInstrumentationMeteringEquipmentMember2024-12-310001653477ngvt:ProductionVesselsandKilnsStorageTanksPipingMember2024-12-310001653477ngvt:BlendingEquipmentStorageTanksPipingShippingEquipmentandPlatformsSafetyEquipmentMember2024-12-310001653477srt:MinimumMemberngvt:BlendingEquipmentStorageTanksPipingShippingEquipmentandPlatformsSafetyEquipmentMember2024-12-310001653477srt:MaximumMemberngvt:BlendingEquipmentStorageTanksPipingShippingEquipmentandPlatformsSafetyEquipmentMember2024-12-310001653477ngvt:MachineryandEquipmentSupportStructuresandFoundationsMember2024-12-310001653477srt:OtherPropertyMember2024-12-310001653477srt:MinimumMembersrt:OfficeBuildingMember2024-12-310001653477srt:MaximumMembersrt:OfficeBuildingMember2024-12-310001653477srt:MinimumMemberus-gaap:BuildingMember2024-12-310001653477srt:MaximumMemberus-gaap:BuildingMember2024-12-310001653477srt:MinimumMemberngvt:ManufacturingandOfficeEquipmentMember2024-12-310001653477srt:MaximumMemberngvt:ManufacturingandOfficeEquipmentMember2024-12-310001653477srt:MinimumMemberngvt:WarehousingandStorageFacilitiesMember2024-12-310001653477srt:MaximumMemberngvt:WarehousingandStorageFacilitiesMember2024-12-310001653477srt:MinimumMemberngvt:RailCarsMember2024-12-310001653477srt:MaximumMemberngvt:RailCarsMember2024-12-310001653477srt:MinimumMember2024-12-310001653477srt:MaximumMember2024-12-310001653477srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2024-12-310001653477srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2024-12-310001653477srt:MinimumMember2024-01-012024-12-310001653477srt:MaximumMember2024-01-012024-12-310001653477ngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477ngvt:PerformanceMaterialsMember2022-01-012022-12-310001653477ngvt:RoadTechnologiesMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:RoadTechnologiesMemberngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477ngvt:RoadTechnologiesMemberngvt:PerformanceMaterialsMember2022-01-012022-12-310001653477ngvt:IndustrialSpecialtiesMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:IndustrialSpecialtiesMemberngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477ngvt:IndustrialSpecialtiesMemberngvt:PerformanceMaterialsMember2022-01-012022-12-310001653477ngvt:PerformanceChemicalsMember2024-01-012024-12-310001653477ngvt:PerformanceChemicalsMember2023-01-012023-12-310001653477ngvt:PerformanceChemicalsMember2022-01-012022-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2024-01-012024-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2023-01-012023-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2022-01-012022-12-310001653477srt:NorthAmericaMember2024-01-012024-12-310001653477srt:NorthAmericaMember2023-01-012023-12-310001653477srt:NorthAmericaMember2022-01-012022-12-310001653477srt:AsiaPacificMember2024-01-012024-12-310001653477srt:AsiaPacificMember2023-01-012023-12-310001653477srt:AsiaPacificMember2022-01-012022-12-310001653477us-gaap:EMEAMember2024-01-012024-12-310001653477us-gaap:EMEAMember2023-01-012023-12-310001653477us-gaap:EMEAMember2022-01-012022-12-310001653477srt:SouthAmericaMember2024-01-012024-12-310001653477srt:SouthAmericaMember2023-01-012023-12-310001653477srt:SouthAmericaMember2022-01-012022-12-310001653477country:US2024-01-012024-12-310001653477country:US2023-01-012023-12-310001653477country:US2022-01-012022-12-310001653477country:CN2024-01-012024-12-310001653477country:CN2023-01-012023-12-310001653477country:CN2022-01-012022-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueMeasurementsNonrecurringMember2023-12-310001653477us-gaap:FairValueMeasurementsNonrecurringMember2024-12-310001653477ngvt:PrivatelyHeldCompaniesMember2024-12-310001653477ngvt:PrivatelyHeldCompaniesMember2023-12-3100016534772023-01-012023-03-310001653477ngvt:WickliffeKentuckyManufacturingFacilityMember2024-12-310001653477srt:StandardPoorsAAPlusRatingMember2024-12-310001653477srt:StandardPoorsAAMinusRatingMember2024-12-310001653477srt:StandardPoorsARatingMember2024-12-310001653477srt:StandardPoorsAMinusRatingMember2024-12-310001653477srt:StandardPoorsBBBPlusRatingMember2024-12-310001653477srt:StandardPoorsAAPlusRatingMember2023-12-310001653477srt:StandardPoorsAAMinusRatingMember2023-12-310001653477srt:StandardPoorsARatingMember2023-12-310001653477srt:StandardPoorsAMinusRatingMember2023-12-310001653477srt:StandardPoorsBBBPlusRatingMember2023-12-310001653477ngvt:DebtObligationsMember2024-12-310001653477ngvt:DebtObligationsMember2023-12-310001653477ngvt:DebtObligationsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001653477ngvt:DebtObligationsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001653477us-gaap:InterestRateSwapMember2024-09-300001653477ngvt:VariableInterestRateMember2024-12-310001653477ngvt:VariableInterestRateMember2023-12-310001653477ngvt:SeniorNotesIssued2018Member2024-12-310001653477ngvt:SeniorNotesIssued2018Member2023-12-310001653477us-gaap:FairValueInputsLevel2Memberngvt:SeniorNotesIssued2018Member2024-12-310001653477us-gaap:FairValueInputsLevel2Memberngvt:SeniorNotesIssued2018Member2023-12-310001653477us-gaap:CostOfSalesMember2023-01-012023-12-310001653477us-gaap:MachineryAndEquipmentMember2024-12-310001653477us-gaap:MachineryAndEquipmentMember2023-12-310001653477ngvt:BuildingsAndLeaseholdImprovementsMember2024-12-310001653477ngvt:BuildingsAndLeaseholdImprovementsMember2023-12-310001653477us-gaap:LandAndLandImprovementsMember2024-12-310001653477us-gaap:LandAndLandImprovementsMember2023-12-310001653477us-gaap:ConstructionInProgressMember2024-12-310001653477us-gaap:ConstructionInProgressMember2023-12-310001653477ngvt:PerformanceMaterialsMember2022-12-310001653477ngvt:PerformanceChemicalsMember2022-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2022-12-310001653477ngvt:PerformanceMaterialsMember2023-12-310001653477ngvt:PerformanceChemicalsMember2023-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2023-12-310001653477ngvt:PerformanceMaterialsMember2024-12-310001653477ngvt:PerformanceChemicalsMember2024-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2024-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2022-12-310001653477us-gaap:TrademarksAndTradeNamesMember2022-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2023-01-012023-12-310001653477us-gaap:TrademarksAndTradeNamesMember2023-01-012023-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2023-01-012023-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2023-12-310001653477us-gaap:TrademarksAndTradeNamesMember2023-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2024-01-012024-12-310001653477us-gaap:TrademarksAndTradeNamesMember2024-01-012024-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2024-01-012024-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2024-12-310001653477us-gaap:TrademarksAndTradeNamesMember2024-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310001653477us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310001653477us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001653477us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001653477ngvt:RestructuringAndOtherIncomeChargesNetMember2024-01-012024-12-310001653477ngvt:RestructuringAndOtherIncomeChargesNetMember2023-01-012023-12-310001653477ngvt:RestructuringAndOtherIncomeChargesNetMember2022-01-012022-12-310001653477us-gaap:InterestRateSwapMember2022-01-012022-12-310001653477us-gaap:CurrencySwapMember2024-01-012024-12-310001653477us-gaap:CurrencySwapMember2023-01-012023-12-310001653477us-gaap:CurrencySwapMember2022-01-012022-12-310001653477us-gaap:ForeignExchangeContractMember2024-12-310001653477us-gaap:ForeignExchangeContractMember2023-12-310001653477us-gaap:CommodityContractMemberus-gaap:SwapMember2024-12-310001653477us-gaap:CommodityContractMember2024-12-310001653477us-gaap:CommodityContractMember2023-12-310001653477us-gaap:InterestRateSwapMember2024-12-310001653477us-gaap:InterestRateSwapMember2023-12-310001653477us-gaap:InterestRateSwapMember2022-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CurrencySwapMember2024-01-012024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CurrencySwapMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CurrencySwapMember2022-01-012022-12-310001653477us-gaap:CurrencySwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:CurrencySwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:CurrencySwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CommodityContractMember2024-01-012024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CommodityContractMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:CommodityContractMember2022-01-012022-12-310001653477us-gaap:CommodityContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:CommodityContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:CommodityContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2024-01-012024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2022-01-012022-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:CurrencySwapMember2024-01-012024-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:CurrencySwapMember2023-01-012023-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:CurrencySwapMember2022-01-012022-12-310001653477us-gaap:CurrencySwapMemberngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:CurrencySwapMemberngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:CurrencySwapMemberngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMember2024-01-012024-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMember2023-01-012023-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMember2022-01-012022-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477ngvt:AccumulatedGainLossNetInvestmentHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommodityContractMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommodityContractMember2023-12-310001653477us-gaap:LineOfCreditMember2024-12-310001653477us-gaap:LineOfCreditMember2023-12-310001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2024-12-310001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2023-12-310001653477ngvt:FinanceLeaseObligationsMember2024-12-310001653477ngvt:FinanceLeaseObligationsMember2023-12-310001653477ngvt:SecuritizationDebtReceivableMember2024-12-310001653477ngvt:SecuritizationDebtReceivableMember2023-12-310001653477ngvt:OtherDebtMember2024-12-310001653477ngvt:OtherDebtMember2023-12-310001653477us-gaap:RevolvingCreditFacilityMember2022-06-220001653477us-gaap:RevolvingCreditFacilityMember2022-06-230001653477us-gaap:RevolvingCreditFacilityMember2022-06-232022-06-230001653477srt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2022-06-232022-06-230001653477srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMember2024-01-012024-12-310001653477us-gaap:RevolvingCreditFacilityMember2023-01-012023-12-310001653477us-gaap:RevolvingCreditFacilityMember2024-12-310001653477us-gaap:RevolvingCreditFacilityMember2023-12-310001653477us-gaap:RevolvingCreditFacilityMember2022-12-310001653477us-gaap:SecuredDebtMember2022-01-012022-12-310001653477us-gaap:SecuredDebtMember2022-12-310001653477ngvt:A2026SeniorNotesMemberus-gaap:SeniorNotesMember2022-04-270001653477ngvt:A2026SeniorNotesMemberus-gaap:SeniorNotesMember2024-12-310001653477ngvt:A2026SeniorNotesMemberus-gaap:SeniorNotesMember2022-04-272022-04-270001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2020-10-280001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2020-10-282020-10-280001653477ngvt:SecuritizationDebtReceivableMember2023-10-020001653477srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2024-12-310001653477srt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2024-12-310001653477ngvt:OmnibusIncentivePlanMember2016-05-150001653477ngvt:OmnibusIncentivePlanMember2024-12-310001653477us-gaap:PerformanceSharesMember2024-01-012024-12-3100016534772016-12-092016-12-090001653477us-gaap:EmployeeStockMember2016-12-092016-12-090001653477us-gaap:EmployeeStockMember2023-04-270001653477us-gaap:EmployeeStockMember2023-05-040001653477us-gaap:EmployeeStockMember2024-12-310001653477us-gaap:EmployeeStockMember2024-01-012024-12-310001653477us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001653477us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001653477us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001653477us-gaap:EmployeeStockMember2023-01-012023-12-310001653477us-gaap:EmployeeStockMember2022-01-012022-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2024-01-012024-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2023-01-012023-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2022-01-012022-12-310001653477us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-12-310001653477us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-12-310001653477us-gaap:EmployeeStockOptionMember2024-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMembersrt:MinimumMember2024-01-012024-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMembersrt:MaximumMember2024-01-012024-12-310001653477us-gaap:PerformanceSharesMembersrt:MinimumMember2024-12-310001653477us-gaap:PerformanceSharesMembersrt:MaximumMember2024-12-310001653477us-gaap:PerformanceSharesMember2024-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2023-12-310001653477us-gaap:PerformanceSharesMember2023-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2024-01-012024-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2024-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMemberngvt:NonEmployeeDirectorMember2024-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2024-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-12-310001653477us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-3100016534772022-07-250001653477us-gaap:PropertyPlantAndEquipmentMember2024-12-310001653477us-gaap:PropertyPlantAndEquipmentMember2023-12-310001653477us-gaap:OtherAssetsMember2024-12-310001653477us-gaap:OtherAssetsMember2023-12-310001653477us-gaap:PropertyPlantAndEquipmentMember2024-01-012024-12-310001653477us-gaap:OtherAssetsMember2024-01-012024-12-310001653477us-gaap:PropertyPlantAndEquipmentMember2023-01-012023-12-310001653477us-gaap:OtherAssetsMember2023-01-012023-12-310001653477ngvt:CorporateHeadquartersMember2024-12-310001653477us-gaap:CostOfSalesMember2024-01-012024-12-310001653477us-gaap:CostOfSalesMember2022-01-012022-12-310001653477us-gaap:NonqualifiedPlanMember2024-01-012024-12-310001653477us-gaap:QualifiedPlanMemberngvt:ScenarioOneMember2024-01-012024-12-310001653477us-gaap:QualifiedPlanMemberngvt:ScenarioTwoMember2024-01-012024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2022-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2024-01-012024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2023-01-012023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2022-01-012022-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2024-01-012024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2023-01-012023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2022-01-012022-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2024-01-012024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2023-01-012023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2022-01-012022-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2024-01-012024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2023-01-012023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2022-01-012022-12-310001653477srt:ScenarioForecastMember2025-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BalancedFundsMember2024-12-310001653477us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BalancedFundsMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2024-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMember2023-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2023-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BalancedFundsMember2023-12-310001653477us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BalancedFundsMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2023-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001653477ngvt:EmployeeSeveranceAndOtherEmployeeRelatedCostsMember2024-01-012024-12-310001653477ngvt:OtherChargesIncomeMember2024-01-012024-12-310001653477ngvt:AssetDisposalChargesMember2024-01-012024-12-310001653477ngvt:EmployeeSeveranceAndOtherEmployeeRelatedCostsMember2023-01-012023-12-310001653477ngvt:OtherChargesIncomeMember2023-01-012023-12-310001653477ngvt:AssetDisposalChargesMember2023-01-012023-12-310001653477ngvt:EmployeeSeveranceAndOtherEmployeeRelatedCostsMember2022-01-012022-12-310001653477ngvt:OtherChargesIncomeMember2022-01-012022-12-310001653477ngvt:AssetDisposalChargesMember2022-01-012022-12-310001653477ngvt:AssetDisposalChargesMemberngvt:PerformanceChemicalsMember2024-01-012024-12-310001653477ngvt:OtherChargesIncomeMemberngvt:PerformanceChemicalsMember2024-01-012024-12-3100016534772023-11-0100016534772023-01-012024-12-310001653477ngvt:PerformanceChemicalsMember2023-01-012024-12-310001653477ngvt:MultipleRestructuringChangesMemberngvt:PerformanceChemicalsMember2024-12-310001653477ngvt:RestructuringAssetRelatedMemberngvt:PerformanceChemicalsMember2024-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMemberngvt:PerformanceChemicalsMember2024-12-310001653477us-gaap:OtherRestructuringMemberngvt:PerformanceChemicalsMember2024-12-310001653477srt:ScenarioForecastMemberngvt:PerformanceChemicalsMember2025-12-310001653477srt:MinimumMembersrt:ScenarioForecastMemberngvt:PerformanceChemicalsMember2025-12-310001653477srt:MaximumMembersrt:ScenarioForecastMemberngvt:PerformanceChemicalsMember2025-12-310001653477us-gaap:OtherRestructuringMemberngvt:AlternativeFattyAcidTransitionMember2024-01-012024-12-310001653477us-gaap:OtherRestructuringMemberngvt:AlternativeFattyAcidTransitionMember2023-01-012023-12-310001653477ngvt:AssetDisposalChargesMemberngvt:AlternativeFattyAcidTransitionMember2024-01-012024-12-310001653477ngvt:AssetDisposalChargesMemberngvt:AlternativeFattyAcidTransitionMember2023-01-012023-12-310001653477us-gaap:OtherRestructuringMemberngvt:NorthCharlestonPlantTransitionMember2024-01-012024-12-310001653477us-gaap:OtherRestructuringMemberngvt:NorthCharlestonPlantTransitionMember2023-01-012023-12-310001653477ngvt:AssetDisposalChargesMemberngvt:NorthCharlestonPlantTransitionMember2024-01-012024-12-310001653477ngvt:AssetDisposalChargesMemberngvt:NorthCharlestonPlantTransitionMember2023-01-012023-12-310001653477ngvt:BusinessTransformationCostsMember2024-01-012024-12-310001653477ngvt:BusinessTransformationCostsMember2023-01-012023-12-310001653477ngvt:BusinessTransformationCostsMember2022-01-012022-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2023-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2024-01-012024-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2024-12-310001653477ngvt:OtherChargesIncomeMember2023-12-310001653477ngvt:OtherChargesIncomeMember2024-12-310001653477ngvt:RestructuringMember2023-12-310001653477ngvt:RestructuringMember2024-01-012024-12-310001653477ngvt:RestructuringMember2024-12-310001653477ngvt:OtherIncomeChargesNetMember2023-12-310001653477ngvt:OtherIncomeChargesNetMember2024-01-012024-12-310001653477ngvt:OtherIncomeChargesNetMember2024-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2022-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2023-01-012023-12-310001653477ngvt:OtherChargesIncomeMember2022-12-310001653477ngvt:RestructuringMember2022-12-310001653477ngvt:RestructuringMember2023-01-012023-12-310001653477ngvt:OtherIncomeChargesNetMember2022-12-310001653477ngvt:OtherIncomeChargesNetMember2023-01-012023-12-310001653477ngvt:AcquisitionsAndOtherStrategicInvestmentsMember2024-01-012024-12-310001653477ngvt:AcquisitionsAndOtherStrategicInvestmentsMember2023-01-012023-12-310001653477ngvt:AcquisitionsAndOtherStrategicInvestmentsMember2022-01-012022-12-310001653477ngvt:AcquisitionsAndOtherStrategicInvestmentsMember2022-01-012023-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod1Member2024-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod1Member2024-01-012024-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod2Member2024-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod2Member2024-01-012024-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod3Member2024-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod3Member2024-01-012024-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod4Member2024-12-310001653477ngvt:BASFLawsuitMember2019-02-140001653477ngvt:BASFLawsuitMemberus-gaap:SettledLitigationMember2021-09-152021-09-1500016534772021-09-152021-09-1500016534772020-11-012020-11-300001653477us-gaap:SettledLitigationMember2024-12-310001653477srt:NorthAmericaMember2024-12-310001653477srt:NorthAmericaMember2023-12-310001653477srt:AsiaPacificMember2024-12-310001653477srt:AsiaPacificMember2023-12-310001653477us-gaap:EMEAMember2024-12-310001653477us-gaap:EMEAMember2023-12-310001653477srt:SouthAmericaMember2024-12-310001653477srt:SouthAmericaMember2023-12-310001653477country:US2024-12-310001653477country:US2023-12-310001653477country:GB2024-12-310001653477country:GB2023-12-310001653477country:CN2024-12-310001653477country:CN2023-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2023-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2023-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2023-12-310001653477us-gaap:OperatingSegmentsMember2024-12-310001653477us-gaap:OperatingSegmentsMember2023-12-310001653477us-gaap:CorporateNonSegmentMember2024-12-310001653477us-gaap:CorporateNonSegmentMember2023-12-310001653477us-gaap:AllowanceForCreditLossMember2023-12-310001653477us-gaap:AllowanceForCreditLossMember2024-01-012024-12-310001653477us-gaap:AllowanceForCreditLossMember2024-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2023-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2024-01-012024-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2024-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-01-012024-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-12-310001653477us-gaap:AllowanceForCreditLossMember2022-12-310001653477us-gaap:AllowanceForCreditLossMember2023-01-012023-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2022-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2023-01-012023-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310001653477us-gaap:AllowanceForCreditLossMember2021-12-310001653477us-gaap:AllowanceForCreditLossMember2022-01-012022-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2021-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2022-01-012022-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-3100016534772024-10-012024-12-31

false2025FY0001653477P0Dhttp://fasb.org/us-gaap/2025#ImpairmentOfLongLivedAssetsHeldForUseP1Yhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#LongTermDebtCurrenthttp://fasb.org/us-gaap/2025#LongTermDebtCurrenthttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2025#LongTermDebtAndCapitalLeaseObligationsiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesngvt:segmentxbrli:purengvt:mmbtusngvt:leasengvt:claimngvt:renewalTerm00016534772025-01-012025-12-3100016534772025-06-3000016534772026-02-1800016534772024-01-012024-12-3100016534772023-01-012023-12-3100016534772025-12-3100016534772024-12-310001653477us-gaap:CommonStockMember2022-12-310001653477us-gaap:AdditionalPaidInCapitalMember2022-12-310001653477us-gaap:RetainedEarningsMember2022-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001653477us-gaap:TreasuryStockCommonMember2022-12-3100016534772022-12-310001653477us-gaap:RetainedEarningsMember2023-01-012023-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001653477us-gaap:CommonStockMember2023-01-012023-12-310001653477us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001653477us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001653477us-gaap:CommonStockMember2023-12-310001653477us-gaap:AdditionalPaidInCapitalMember2023-12-310001653477us-gaap:RetainedEarningsMember2023-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001653477us-gaap:TreasuryStockCommonMember2023-12-3100016534772023-12-310001653477us-gaap:RetainedEarningsMember2024-01-012024-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001653477us-gaap:CommonStockMember2024-01-012024-12-310001653477us-gaap:TreasuryStockCommonMember2024-01-012024-12-310001653477us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310001653477us-gaap:CommonStockMember2024-12-310001653477us-gaap:AdditionalPaidInCapitalMember2024-12-310001653477us-gaap:RetainedEarningsMember2024-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001653477us-gaap:TreasuryStockCommonMember2024-12-310001653477us-gaap:RetainedEarningsMember2025-01-012025-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-12-310001653477us-gaap:CommonStockMember2025-01-012025-12-310001653477us-gaap:AdditionalPaidInCapitalMember2025-01-012025-12-310001653477us-gaap:TreasuryStockCommonMember2025-01-012025-12-310001653477us-gaap:CommonStockMember2025-12-310001653477us-gaap:AdditionalPaidInCapitalMember2025-12-310001653477us-gaap:RetainedEarningsMember2025-12-310001653477us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001653477us-gaap:TreasuryStockCommonMember2025-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberngvt:PerformanceMaterialsMember2025-01-012025-12-310001653477us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:AutomotiveIndustryMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-12-310001653477srt:MinimumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2025-12-310001653477srt:MaximumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2025-12-310001653477srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2025-12-310001653477srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2025-12-310001653477ngvt:ProductionControlSystemEquipmentandHardwareLaboratoryTestingEquipmentMember2025-12-310001653477srt:MinimumMemberngvt:ProductionControlSystemEquipmentandHardwareLaboratoryTestingEquipmentMember2025-12-310001653477srt:MaximumMemberngvt:ProductionControlSystemEquipmentandHardwareLaboratoryTestingEquipmentMember2025-12-310001653477ngvt:ControlsystemsInstrumentationMeteringEquipmentMember2025-12-310001653477ngvt:ProductionVesselsandKilnsStorageTanksPipingMember2025-12-310001653477ngvt:BlendingEquipmentStorageTanksPipingShippingEquipmentandPlatformsSafetyEquipmentMember2025-12-310001653477srt:MinimumMemberngvt:BlendingEquipmentStorageTanksPipingShippingEquipmentandPlatformsSafetyEquipmentMember2025-12-310001653477srt:MaximumMemberngvt:BlendingEquipmentStorageTanksPipingShippingEquipmentandPlatformsSafetyEquipmentMember2025-12-310001653477ngvt:MachineryandEquipmentSupportStructuresandFoundationsMember2025-12-310001653477srt:OtherPropertyMember2025-12-310001653477srt:MinimumMembersrt:OfficeBuildingMember2025-12-310001653477srt:MaximumMembersrt:OfficeBuildingMember2025-12-310001653477srt:MinimumMemberus-gaap:BuildingMember2025-12-310001653477srt:MaximumMemberus-gaap:BuildingMember2025-12-310001653477srt:MinimumMemberngvt:ManufacturingandOfficeEquipmentMember2025-12-310001653477srt:MaximumMemberngvt:ManufacturingandOfficeEquipmentMember2025-12-310001653477srt:MinimumMemberngvt:WarehousingandStorageFacilitiesMember2025-12-310001653477srt:MaximumMemberngvt:WarehousingandStorageFacilitiesMember2025-12-310001653477srt:MaximumMemberus-gaap:VehiclesMember2025-12-310001653477srt:MinimumMemberngvt:RailCarsMember2025-12-310001653477srt:MaximumMemberngvt:RailCarsMember2025-12-310001653477srt:MinimumMember2025-12-310001653477srt:MaximumMember2025-12-310001653477srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2025-12-310001653477srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2025-12-310001653477srt:MinimumMember2025-01-012025-12-310001653477srt:MaximumMember2025-01-012025-12-310001653477ngvt:PerformanceMaterialsMember2025-01-012025-12-310001653477ngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477ngvt:PavementTechnologiesMemberngvt:PerformanceMaterialsMember2025-01-012025-12-310001653477ngvt:PavementTechnologiesMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:PavementTechnologiesMemberngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477ngvt:RoadMarkingsMemberngvt:PerformanceMaterialsMember2025-01-012025-12-310001653477ngvt:RoadMarkingsMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477ngvt:RoadMarkingsMemberngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477ngvt:PerformanceChemicalsMember2025-01-012025-12-310001653477ngvt:PerformanceChemicalsMember2024-01-012024-12-310001653477ngvt:PerformanceChemicalsMember2023-01-012023-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2025-01-012025-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2024-01-012024-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2023-01-012023-12-310001653477srt:NorthAmericaMember2025-01-012025-12-310001653477srt:NorthAmericaMember2024-01-012024-12-310001653477srt:NorthAmericaMember2023-01-012023-12-310001653477srt:AsiaPacificMember2025-01-012025-12-310001653477srt:AsiaPacificMember2024-01-012024-12-310001653477srt:AsiaPacificMember2023-01-012023-12-310001653477us-gaap:EMEAMember2025-01-012025-12-310001653477us-gaap:EMEAMember2024-01-012024-12-310001653477us-gaap:EMEAMember2023-01-012023-12-310001653477srt:SouthAmericaMember2025-01-012025-12-310001653477srt:SouthAmericaMember2024-01-012024-12-310001653477srt:SouthAmericaMember2023-01-012023-12-310001653477country:US2025-01-012025-12-310001653477country:US2024-01-012024-12-310001653477country:US2023-01-012023-12-310001653477country:CN2025-01-012025-12-310001653477country:CN2024-01-012024-12-310001653477country:CN2023-01-012023-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:FairValueMeasurementsRecurringMember2025-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477ngvt:PrivatelyHeldCompaniesMember2025-12-310001653477ngvt:PrivatelyHeldCompaniesMember2024-12-310001653477ngvt:PrivatelyHeldCompaniesMember2025-10-012025-12-310001653477ngvt:PrivatelyHeldCompaniesMember2024-01-012024-12-310001653477ngvt:PrivatelyHeldCompaniesMember2025-01-012025-12-3100016534772022-10-012022-12-310001653477ngvt:StrategicInvestmentsMember2025-01-012025-12-310001653477ngvt:WickliffeKentuckyManufacturingFacilityMember2025-12-310001653477srt:StandardPoorsAAPlusRatingMember2025-12-310001653477srt:StandardPoorsAAMinusRatingMember2025-12-310001653477srt:StandardPoorsARatingMember2025-12-310001653477srt:StandardPoorsAMinusRatingMember2025-12-310001653477srt:StandardPoorsBBBPlusRatingMember2025-12-310001653477srt:StandardPoorsAAPlusRatingMember2024-12-310001653477srt:StandardPoorsAAMinusRatingMember2024-12-310001653477srt:StandardPoorsARatingMember2024-12-310001653477srt:StandardPoorsAMinusRatingMember2024-12-310001653477srt:StandardPoorsBBBPlusRatingMember2024-12-310001653477ngvt:DebtObligationsMember2025-12-310001653477ngvt:DebtObligationsMember2024-12-310001653477ngvt:DebtObligationsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-12-310001653477ngvt:DebtObligationsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001653477us-gaap:InterestRateSwapMember2024-09-300001653477ngvt:VariableInterestRateMember2025-12-310001653477ngvt:VariableInterestRateMember2024-12-310001653477ngvt:SeniorNotesIssued2018Member2025-12-310001653477ngvt:SeniorNotesIssued2018Member2024-12-310001653477ngvt:SeniorNotesIssued2018Memberus-gaap:FairValueInputsLevel2Member2025-12-310001653477ngvt:SeniorNotesIssued2018Memberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:CostOfSalesMember2025-01-012025-12-310001653477us-gaap:CostOfSalesMember2024-01-012024-12-310001653477us-gaap:MachineryAndEquipmentMember2025-12-310001653477us-gaap:MachineryAndEquipmentMember2024-12-310001653477ngvt:BuildingsAndLeaseholdImprovementsMember2025-12-310001653477ngvt:BuildingsAndLeaseholdImprovementsMember2024-12-310001653477us-gaap:LandAndLandImprovementsMember2025-12-310001653477us-gaap:LandAndLandImprovementsMember2024-12-310001653477us-gaap:ConstructionInProgressMember2025-12-310001653477us-gaap:ConstructionInProgressMember2024-12-310001653477us-gaap:PropertyPlantAndEquipmentMember2025-01-012025-12-310001653477us-gaap:OtherIntangibleAssetsMember2025-01-012025-12-310001653477ngvt:PerformanceMaterialsMember2024-12-310001653477ngvt:PerformanceChemicalsMember2024-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2024-12-310001653477ngvt:PerformanceMaterialsMember2025-12-310001653477ngvt:PerformanceChemicalsMember2025-12-310001653477ngvt:AdvancedPolymerTechnologiesSegmentMember2025-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2023-12-310001653477us-gaap:TrademarksAndTradeNamesMember2023-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2024-01-012024-12-310001653477us-gaap:TrademarksAndTradeNamesMember2024-01-012024-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2024-01-012024-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2024-12-310001653477us-gaap:TrademarksAndTradeNamesMember2024-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2025-01-012025-12-310001653477us-gaap:TrademarksAndTradeNamesMember2025-01-012025-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2025-01-012025-12-310001653477ngvt:CustomerContractsAndRelationshipsMember2025-12-310001653477us-gaap:TrademarksAndTradeNamesMember2025-12-310001653477us-gaap:TechnologyBasedIntangibleAssetsMember2025-12-310001653477ngvt:RestructuringAndOtherIncomeChargesNetMember2024-01-012024-12-310001653477ngvt:RestructuringAndOtherIncomeChargesNetMember2023-01-012023-12-310001653477us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-12-310001653477us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310001653477us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001653477us-gaap:ForeignExchangeContractMember2025-12-310001653477us-gaap:ForeignExchangeContractMember2024-12-310001653477us-gaap:CommodityContractMemberus-gaap:SwapMember2025-12-310001653477us-gaap:CommodityContractMember2025-12-310001653477us-gaap:CommodityContractMember2024-12-310001653477us-gaap:InterestRateSwapMember2025-12-310001653477us-gaap:InterestRateSwapMember2024-12-310001653477us-gaap:CurrencySwapMemberus-gaap:SalesMember2025-01-012025-12-310001653477us-gaap:CurrencySwapMemberus-gaap:SalesMember2024-01-012024-12-310001653477us-gaap:CurrencySwapMemberus-gaap:SalesMember2023-01-012023-12-310001653477us-gaap:CommodityContractMemberus-gaap:CostOfSalesMember2025-01-012025-12-310001653477us-gaap:CommodityContractMemberus-gaap:CostOfSalesMember2024-01-012024-12-310001653477us-gaap:CommodityContractMemberus-gaap:CostOfSalesMember2023-01-012023-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2025-01-012025-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2024-01-012024-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-01-012023-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001653477us-gaap:LineOfCreditMember2025-12-310001653477us-gaap:LineOfCreditMember2024-12-310001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2025-12-310001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2024-12-310001653477ngvt:FinanceLeaseObligationsMember2025-12-310001653477ngvt:FinanceLeaseObligationsMember2024-12-310001653477ngvt:SecuritizationDebtReceivableMember2025-12-310001653477ngvt:SecuritizationDebtReceivableMember2024-12-310001653477ngvt:OtherDebtMember2025-12-310001653477ngvt:OtherDebtMember2024-12-310001653477us-gaap:RevolvingCreditFacilityMember2022-06-220001653477us-gaap:RevolvingCreditFacilityMember2022-06-230001653477us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2022-06-232022-06-230001653477us-gaap:RevolvingCreditFacilityMember2025-01-012025-12-310001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2020-10-280001653477ngvt:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2020-10-282020-10-280001653477ngvt:SecuritizationDebtReceivableMember2023-10-020001653477ngvt:SecuritizationDebtReceivableMember2023-12-310001653477us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2025-12-310001653477us-gaap:RevolvingCreditFacilityMember2025-12-310001653477us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2025-12-310001653477ngvt:OmnibusIncentivePlanMember2025-02-100001653477ngvt:OmnibusIncentivePlanMember2024-12-310001653477ngvt:OmnibusIncentivePlanMember2025-12-310001653477us-gaap:PerformanceSharesMember2025-01-012025-12-3100016534772016-12-092016-12-090001653477us-gaap:EmployeeStockMember2016-12-092016-12-090001653477us-gaap:EmployeeStockMember2023-04-270001653477us-gaap:EmployeeStockMember2023-05-040001653477us-gaap:EmployeeStockMember2025-12-310001653477us-gaap:EmployeeStockMember2025-01-012025-12-310001653477us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001653477us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001653477us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001653477us-gaap:EmployeeStockMember2024-01-012024-12-310001653477us-gaap:EmployeeStockMember2023-01-012023-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2025-01-012025-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2024-01-012024-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2023-01-012023-12-310001653477srt:MinimumMemberus-gaap:EmployeeStockOptionMember2025-01-012025-12-310001653477srt:MaximumMemberus-gaap:EmployeeStockOptionMember2025-01-012025-12-310001653477srt:MinimumMemberngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2025-01-012025-12-310001653477srt:MaximumMemberngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2025-01-012025-12-310001653477srt:MinimumMemberus-gaap:PerformanceSharesMember2023-12-310001653477srt:MaximumMemberus-gaap:PerformanceSharesMember2023-12-310001653477us-gaap:PerformanceSharesMember2023-01-012023-12-310001653477us-gaap:PerformanceSharesMember2024-12-310001653477us-gaap:PerformanceSharesMember2024-01-012024-12-310001653477us-gaap:PerformanceSharesMember2025-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2024-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2025-01-012025-12-310001653477ngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2025-12-310001653477ngvt:NonEmployeeDirectorMemberngvt:RestrictedStockUnitsandNonemployeeDirectorDeferredStockUnitsMember2025-12-310001653477ngvt:RestrictedStockUnitsNonemployeeDirectorDeferredStockUnitsandPerformancebasedRestrictedStockUnitsMember2025-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310001653477us-gaap:AccumulatedTranslationAdjustmentMember2025-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001653477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001653477ngvt:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceAndAccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToParentMember2025-01-012025-12-310001653477ngvt:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceAndAccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToParentMember2024-01-012024-12-310001653477ngvt:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceAndAccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToParentMember2023-01-012023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310001653477us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310001653477us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001653477us-gaap:CommodityContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-12-310001653477us-gaap:CommodityContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310001653477us-gaap:CommodityContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2025-01-012025-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-01-012024-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310001653477us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-3100016534772022-07-250001653477us-gaap:PropertyPlantAndEquipmentMember2025-01-012025-12-310001653477us-gaap:OtherAssetsMember2025-01-012025-12-310001653477us-gaap:PropertyPlantAndEquipmentMember2024-01-012024-12-310001653477us-gaap:OtherAssetsMember2024-01-012024-12-310001653477ngvt:CorporateHeadquartersMember2025-12-310001653477us-gaap:CostOfSalesMember2023-01-012023-12-310001653477us-gaap:NonqualifiedPlanMember2025-01-012025-12-310001653477ngvt:ScenarioOneMemberus-gaap:QualifiedPlanMember2025-01-012025-12-310001653477ngvt:ScenarioTwoMemberus-gaap:QualifiedPlanMember2025-01-012025-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2024-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2025-01-012025-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2025-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-12-310001653477us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:QualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-01-012025-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-01-012025-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310001653477us-gaap:NonqualifiedPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001653477srt:ScenarioForecastMember2026-12-310001653477us-gaap:CashAndCashEquivalentsMember2025-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310001653477us-gaap:MutualFundMember2025-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310001653477us-gaap:BalancedFundsMember2025-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310001653477us-gaap:OtherInvestmentsMember2025-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310001653477us-gaap:FairValueInputsLevel1Member2025-12-310001653477us-gaap:FairValueInputsLevel2Member2025-12-310001653477us-gaap:FairValueInputsLevel3Member2025-12-310001653477us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310001653477us-gaap:CashAndCashEquivalentsMember2024-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310001653477us-gaap:MutualFundMember2024-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:MutualFundMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310001653477us-gaap:BalancedFundsMember2024-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:BalancedFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310001653477us-gaap:OtherInvestmentsMember2024-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310001653477us-gaap:FairValueInputsLevel1Member2024-12-310001653477us-gaap:FairValueInputsLevel2Member2024-12-310001653477us-gaap:FairValueInputsLevel3Member2024-12-310001653477us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310001653477ngvt:EmployeeSeveranceAndOtherEmployeeRelatedCostsMember2025-01-012025-12-310001653477ngvt:OtherChargesIncomeMember2025-01-012025-12-310001653477ngvt:AssetDisposalChargesMember2025-01-012025-12-310001653477ngvt:EmployeeSeveranceAndOtherEmployeeRelatedCostsMember2024-01-012024-12-310001653477ngvt:OtherChargesIncomeMember2024-01-012024-12-310001653477ngvt:AssetDisposalChargesMember2024-01-012024-12-310001653477ngvt:EmployeeSeveranceAndOtherEmployeeRelatedCostsMember2023-01-012023-12-310001653477ngvt:OtherChargesIncomeMember2023-01-012023-12-310001653477ngvt:AssetDisposalChargesMember2023-01-012023-12-310001653477ngvt:MultipleRestructuringChangesMemberngvt:PerformanceChemicalsMember2025-12-310001653477ngvt:RestructuringAssetRelatedMemberngvt:PerformanceChemicalsMember2025-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMemberngvt:PerformanceChemicalsMember2025-12-310001653477us-gaap:OtherRestructuringMemberngvt:PerformanceChemicalsMember2025-12-310001653477srt:MaximumMemberngvt:PerformanceChemicalsMember2025-12-310001653477us-gaap:OtherRestructuringMemberngvt:NorthCharlestonPlantTransitionMember2025-01-012025-12-310001653477us-gaap:OtherRestructuringMemberngvt:NorthCharlestonPlantTransitionMember2024-01-012024-12-310001653477ngvt:AssetDisposalChargesMemberngvt:NorthCharlestonPlantTransitionMember2025-01-012025-12-310001653477ngvt:AssetDisposalChargesMemberngvt:NorthCharlestonPlantTransitionMember2024-01-012024-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2024-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2025-01-012025-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2025-12-310001653477ngvt:OtherChargesIncomeMember2024-12-310001653477ngvt:OtherChargesIncomeMember2025-12-310001653477ngvt:RestructuringMember2024-12-310001653477ngvt:RestructuringMember2025-01-012025-12-310001653477ngvt:RestructuringMember2025-12-310001653477ngvt:OtherIncomeChargesNetMember2024-12-310001653477ngvt:OtherIncomeChargesNetMember2025-01-012025-12-310001653477ngvt:OtherIncomeChargesNetMember2025-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2023-12-310001653477ngvt:RestructuringSeveranceAndOtherEmployeeRelatedCostsMember2024-01-012024-12-310001653477ngvt:OtherChargesIncomeMember2023-12-310001653477ngvt:RestructuringMember2023-12-310001653477ngvt:RestructuringMember2024-01-012024-12-310001653477ngvt:OtherIncomeChargesNetMember2023-12-310001653477ngvt:OtherIncomeChargesNetMember2024-01-012024-12-310001653477country:US2025-01-012025-12-310001653477country:US2024-01-012024-12-310001653477country:US2023-01-012023-12-310001653477country:GB2025-01-012025-12-310001653477country:GB2024-01-012024-12-310001653477country:GB2023-01-012023-12-310001653477country:CN2025-01-012025-12-310001653477country:CN2024-01-012024-12-310001653477country:CN2023-01-012023-12-310001653477country:BE2025-01-012025-12-310001653477country:BE2024-01-012024-12-310001653477country:BE2023-01-012023-12-310001653477us-gaap:ForeignTaxJurisdictionOtherMember2025-01-012025-12-310001653477us-gaap:ForeignTaxJurisdictionOtherMember2024-01-012024-12-310001653477us-gaap:ForeignTaxJurisdictionOtherMember2023-01-012023-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod1Member2025-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod1Member2025-01-012025-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod2Member2025-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod2Member2025-01-012025-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod3Member2025-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod3Member2025-01-012025-12-310001653477ngvt:DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod4Member2025-12-310001653477country:BR2025-01-012025-12-310001653477ngvt:BASFLawsuitMember2019-02-140001653477us-gaap:SettledLitigationMemberngvt:BASFLawsuitMember2021-09-152021-09-1500016534772021-09-152021-09-150001653477us-gaap:SettledLitigationMember2025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2025-01-012025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2024-01-012024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2023-01-012023-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2025-01-012025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2024-01-012024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2023-01-012023-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2025-01-012025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2024-01-012024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2023-01-012023-12-310001653477us-gaap:MaterialReconcilingItemsMember2025-01-012025-12-310001653477us-gaap:MaterialReconcilingItemsMember2024-01-012024-12-310001653477us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-3100016534772022-01-012022-12-310001653477us-gaap:OtherOperatingIncomeExpenseMember2025-01-012025-12-310001653477us-gaap:OtherOperatingIncomeExpenseMember2024-01-012024-12-310001653477us-gaap:OtherOperatingIncomeExpenseMember2023-01-012023-12-310001653477srt:NorthAmericaMember2025-12-310001653477srt:NorthAmericaMember2024-12-310001653477srt:AsiaPacificMember2025-12-310001653477srt:AsiaPacificMember2024-12-310001653477us-gaap:EMEAMember2025-12-310001653477us-gaap:EMEAMember2024-12-310001653477srt:SouthAmericaMember2025-12-310001653477srt:SouthAmericaMember2024-12-310001653477country:US2025-12-310001653477country:US2024-12-310001653477country:GB2025-12-310001653477country:GB2024-12-310001653477country:CN2025-12-310001653477country:CN2024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceMaterialsMember2024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:PerformanceChemicalsMember2024-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2025-12-310001653477us-gaap:OperatingSegmentsMemberngvt:AdvancedPolymerTechnologiesSegmentMember2024-12-310001653477us-gaap:OperatingSegmentsMember2025-12-310001653477us-gaap:OperatingSegmentsMember2024-12-310001653477us-gaap:CorporateNonSegmentMember2025-12-310001653477us-gaap:CorporateNonSegmentMember2024-12-310001653477us-gaap:SubsequentEventMember2026-01-012026-01-010001653477ngvt:GroundLeaseMemberus-gaap:SubsequentEventMember2026-01-012026-01-010001653477ngvt:PlantOperationsMemberus-gaap:SubsequentEventMember2026-01-012026-01-010001653477us-gaap:DiscontinuedOperationsHeldforsaleMemberngvt:PerformanceChemicalsMember2025-01-012025-12-310001653477us-gaap:DiscontinuedOperationsHeldforsaleMemberngvt:PerformanceChemicalsMember2024-01-012024-12-310001653477us-gaap:DiscontinuedOperationsHeldforsaleMemberngvt:PerformanceChemicalsMember2023-01-012023-12-310001653477us-gaap:DiscontinuedOperationsHeldforsaleMemberngvt:PerformanceChemicalsMember2025-12-310001653477us-gaap:DiscontinuedOperationsHeldforsaleMemberngvt:PerformanceChemicalsMember2024-12-310001653477us-gaap:AllowanceForCreditLossMember2024-12-310001653477us-gaap:AllowanceForCreditLossMember2025-01-012025-12-310001653477us-gaap:AllowanceForCreditLossMember2025-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2024-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2025-01-012025-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2025-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2025-01-012025-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2025-12-310001653477us-gaap:AllowanceForCreditLossMember2023-12-310001653477us-gaap:AllowanceForCreditLossMember2024-01-012024-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2023-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2024-01-012024-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-01-012024-12-310001653477us-gaap:AllowanceForCreditLossMember2022-12-310001653477us-gaap:AllowanceForCreditLossMember2023-01-012023-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2022-12-310001653477ngvt:SECSchedule1209AllowanceHeldToMaturityDebtSecuritiesCreditLossAllowanceMember2023-01-012023-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001653477us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-3100016534772025-10-012025-12-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________________________________________

FORM 10-K

______________________________________________________________________________________________________


☒			ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, ~~2024~~2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-37586

__________________________________________________________________________

INGEVITY CORPORATION

(Exact name of registrant as specified in its charter)

_________________________________________________________________________


Delaware		47-4027764
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4920 O'Hear Avenue Suite 400	North Charleston	South Carolina	29405
(Address of principal executive offices)			(Zip code)

843-740-2300

(Registrant’'s telephone number)

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class:	Trading Symbol(s)	Name of Each Exchange on Which Registered:
Common Stock ($0.01 par value)	NGVT	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes x No o

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes o No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of ~~“large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):~~

"large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer	x	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	o
		Emerging growth company	o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’'s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o

Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No x

At June 30, ~~2024~~2025, the aggregate market value of common stock held by non-affiliates of the Registrant was $1,~~582~~567,~~951~~103,~~662~~311. The market value held by non-affiliates excludes the value of those shares held by executive officers and directors of the Registrant.

The Registrant had 3635,~~351~~291,~~236~~884 shares of common stock, $0.01 par value, outstanding at February 1418, ~~2025~~2026.


Documents Incorporated by Reference
Portions of the Company's definitive 2025 Annual Meeting Proxy Statement are incorporated by reference into Part III of this report.

Ingevity Corporation

Form 10-K

INDEX

Page No.

Forward-Looking Statements

PART I

Item 1. Business

Item 1A. Risk Factors

Item 1B. Unresolved Staff Comments

Item 1C. Cybersecurity

2322

Item 2. Properties

2423

Item 3. Legal Proceedings

2423

Item 4. Mine Safety Disclosures

2423

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

2524

PART II

2625

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

2625

Item 6. [RESERVED]

2726

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

2726

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

4647

Item 8. Financial Statements and Supplementary Data

4849

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

~~107~~113

Item 9A. Controls and Procedures

~~107~~113

Item 9B. Other Information

~~107~~113

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

~~107~~113

PART III

~~108~~114

Item 10. Directors, Executive Officers and Corporate Governance

~~108~~114

Item 11. Executive Compensation

~~108~~114

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

~~108~~114

Item 13. Certain Relationships and Related Transactions, and Director Independence

~~109~~115

Item 14. Principal Accounting Fees and Services

~~109~~115

PART IV

~~110~~116

Item 15. Exhibits and Financial Statement Schedules

~~110~~116

Item 16. Form 10-K Summary

~~117~~125

SIGNATURES

~~118~~126

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that reflect our current expectations, beliefs, plans, or forecasts with respect to, among other things, future events and financial performance. Forward-looking statements are often characterized by words or phrases such as “"may,”" “"will,”" “"could,”" “"should,”" “"would,”" “"anticipate,”" “"estimate,”" “"expect,”" “"project,”" “"intend,”" “"plan,”" “"believe,”" “"target,”" “"prospects,”" “"potential,”" “"outlook,”" “"guidance,”" and “"forecast,”" and other words, terms and phrases of similar meaning.

These statements, by their nature, involve certain estimates, expectations, projections, forecasts and assumptions, and are subject to various risks and uncertainties that are difficult to predict and often beyond our control. These risks and uncertainties may, and often do, cause actual results to differ materially from those contained in a forward-looking statement. Accordingly, readers are cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement is based on information currently available to us and speaks only as of the date that it is made. We have no duty, and undertake no obligation, to update any forward-looking statement to reflect developments occurring after the statement is made.

The risks and uncertainties that may cause actual results to differ materially from those indicated in any forward-looking may be included with the forward-looking statement itself. Other such risks and uncertainties include, but are not limited to, those discussed in Item 1A. Risk Factors in this report, as well as the following:

•~~the~~our ~~anticipated~~review ~~timing,~~of ~~charges,~~strategic ~~costs~~alternatives ~~and~~for ~~results~~the ofAdvanced ~~any~~Polymer ~~current~~Technologies or("APT") ~~future~~segment ~~repositioning~~and ~~of our~~ Performance Chemicals ~~segment,~~road ~~including~~markings ~~the oleo-based~~ product ~~refining~~line ~~transition~~may ~~and~~not ~~the~~result ~~closure of our plants~~ in ~~DeRidder,~~a ~~Louisiana~~transaction ~~and Crossett, Arkansas may differ materially from our estimates due~~ to ~~events~~sell ~~that~~one ~~may occur as a result of,~~ or ~~in connection with, such repositioning efforts~~both;

•~~our~~any ~~announced~~transaction ~~review~~we ofenter ~~strategic~~into, ~~alternatives~~including ~~for~~ the ~~industrial~~sale ~~specialties~~of ~~product~~our ~~line and~~ North Charleston, ~~South Carolina~~ crude tall oil (“"CTO”") refinery ~~may~~assets ~~not~~and ~~result~~the inmajority aof ~~transaction~~the ~~and~~Performance ~~any~~Chemicals ~~transaction~~industrial ~~entered~~specialties ~~into~~product line, may not yield the expected results or benefits;

•if the review of strategic alternatives for APT and road markings results in transactions, we may be adversely impacted if we are unable to adjust our costs and operating structure to reflect the requirements of the business after giving effect to such transactions;

•we may be adversely affected by general global economic, geopolitical, and financial conditions beyond our control, including inflation, the Russia-Ukraine war, and the conflict in the Middle East;

•leadership transitions within our organization;

•we are exposed to risks related to our international sales and operations, including ~~potential~~recent changes in tariffs and trade policies;

•adverse conditions in the automotive market have and may continue to negatively impact demand for our automotive carbon products;

•if more stringent air quality standards worldwide are not adopted, our growth could be impacted;

•we face competition from substitute products, new technologies, and new or emerging competitors;

•we may be adversely affected by a decrease in government infrastructure spending;

•adverse conditions in cyclical end markets may continue to adversely affect demand for our products;

•lack of access to raw materials upon which we depend would impact our ability to produce our products;

•the inability to make or effectively integrate future acquisitions and other investments may negatively affect our results;

•we are dependent upon third parties for the provision of certain critical operating services at several of our ~~facilities~~plants;

•we may be adversely affected by disruptions in our supply chain;

•the occurrence of natural disasters and extreme weather or other unanticipated problem such as labor difficulties (including work stoppages), equipment failure, or unscheduled maintenance and repair, which could result in operational disruptions of varied duration;

•we are dependent upon attracting and retaining key personnel;

•we are dependent on certain large customers;

•from time to time, we are and may be engaged in legal actions associated with our intellectual property rights;

•if we are unable to protect our intellectual property and other proprietary information, we may lose significant competitive advantage;

•information technology security breaches and other disruptions;

•government policies and regulations, including, but not limited to, those affecting the environment, climate change, tax policies, tariffs, the chemicals industry and subsidies or incentives that may impact key raw materials or products may adversely affect financial results; and

•losses due to lawsuits arising out of environmental damage or personal injuries associated with chemical or other manufacturing processes.

PART I

ITEM 1. BUSINESS

General

Ingevity Corporation provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable. Our products are used in a variety of demanding applications, including ~~adhesives~~automotive gasoline vapor emissions control systems, ~~agrochemicals~~food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers, ~~lubricants,~~and paint for road markings~~, oil drilling, and automotive components~~. We operate in three reportable segments: Performance Materials, Performance Chemicals and Advanced Polymer Technologies.

Throughout this Annual Report on Form 10-K, except where otherwise stated or indicated by the context, "Ingevity," the "Company," "we," "us," or "our" means Ingevity Corporation and its consolidated subsidiaries and their predecessors.

Our business originated as part of the operations of our former parent company, Westvaco Corporation, in 1964, and we operated as a division of Westvaco Corporation and its corporate successors, including MeadWestvaco Corporation and WestRock Company (“"WestRock”"), until our separation from WestRock in May 2016. Our common stock began "regular-way" trading on the New York Stock Exchange in May 2016 under the symbol "NGVT."

Our principal executive offices are located at 4920 O'Hear Avenue, Suite 400, North Charleston, South Carolina 29405. Ingevity maintains a website at www.ingevity.com. We make available, free of charge through our website, our filings with the Securities and Exchange Commission (the “"SEC”"), including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports, as soon as reasonably practicable after such items are filed with, or furnished to, the SEC. We also use our website to publish additional information that may be important to investors, such as presentations to analysts. Information contained in or connected to our website is not incorporated by reference into this Annual Report on Form 10-K. Reports we file with the SEC may also be viewed at www.sec.gov.

~~The~~Finalized ~~table below illustrates~~ our ~~product~~Strategic ~~lines~~Portfolio ~~and~~Review ~~the primary end-use markets for our products by segment, as well as our net sales by segment for the fiscal year 2024. For more information on our U.S.~~ and ~~foreign~~Announced ~~operations,~~New ~~see Notes 4 and 19, to the Consolidated Financial Statements included within Part II. Item 8 of this Form 10-K.~~Ingevity

Performance Materials

Performance Chemicals

Advanced Polymer Technologies

Product Lines

Road Technologies

Industrial Specialties

End-Use Markets

AutomotivePurification: Food, Chemicals, and Water

Pavement ConstructionPavement PreservationPavement Reconstruction and Recycling Pavement Markings

Agricultural ChemicalsLubricantsRubberIndustrial Intermediates AdhesivesOilfield

Automotive & TransportationIndustrial EquipmentFootwear & ApparelBioplasticsConsumer PackagingMedical & Health

2024 Revenue

$609.6 million

$608.2 million

$188.6 million

On October 29, 2024, we announced our intention to comprehensively review Ingevity's asset and product portfolios, referred to as our Strategic Portfolio Review. On January 16, 2025, we announced the exploration of strategic alternatives for our Performance Chemicals industrial specialties product line, including a potential divestiture of portions of the North Charleston site. On September 4, 2025, we announced the agreement to sell the North Charleston crude tall oil refinery and the majority of the industrial specialties product line, and on January 1, 2026, the announced sale was completed.

On December 8, 2025, we announced the completion of our Strategic Portfolio Review. We labeled the state of the Company following the actions contemplated by the Strategic Portfolio Review, New Ingevity. To become New Ingevity, we announced the simplification of our businesses including the exploration of strategic alternatives for our Advanced Polymer Technologies ("APT") reportable segment and the Performance Chemicals road markings product line, which we expect to complete by the end of 2026. New Ingevity will be comprised of two attractive businesses aligned around strong core competencies, with superior and consistent profitability: Performance Materials and Pavement Technologies. New Ingevity's businesses will be focused on high-value, mission-critical applications that benefit from durable, long-term demand and will allow Ingevity to retain our global scale, maintain a strong pro forma financial profile, and provide a more stable, simplified specialty materials portfolio poised to deliver profitable growth with best-in-class earnings before interest, taxes, depreciation, and amortization ("EBITDA") margins. We believe our two business segments are unified by very strong core competencies, including unique technologies that incorporate deep technical expertise on highly engineered materials, leading market positions, and intellectual property, all of which creates a sustainable competitive advantage for Ingevity.

Industrial Specialties Divestiture

On September 3, 2025, Ingevity entered into an Asset Purchase Agreement (the "Purchase Agreement") with Mainstream Pine Products, LLC, a Delaware limited liability company ("Purchaser"), pursuant to which Purchaser agreed to purchase substantially all of the assets and assume and acquire certain of the rights and liabilities of Ingevity or its applicable affiliates that relate to or are used in connection with (a) Ingevity's industrial specialties product line (other than Ingevity's lignin dispersant and alternative fatty acid based products, pavement technologies product line and other businesses and products more fully described in the Purchase Agreement) and (b) Ingevity's North Charleston, South Carolina crude tall oil refinery (the "CTO Refinery") and Ingevity's and its affiliates' operations thereof (collectively, the "Divestiture"). We determined that, upon execution of the Purchase Agreement, the industrial specialties product line and CTO Refinery included within the Divestiture met the criteria to be classified as held for sale and that the sale represents a strategic shift that will have a major effect on Ingevity's operations and results. As such, the results of operations of the Divestiture have been reclassified and presented as discontinued operations for all periods presented. The Divestiture was completed on January 1, 2026.

Unless otherwise noted, discussion within Part II relates to continuing operations. Refer to Note 20 of the Notes to the Consolidated Financial Statements included in Part II. Item 8 within this Form 10-K for further information regarding discontinued operations.

Ingevity as of December 31, 2025

The table below illustrates our primary end-use markets for our products by segment, as well as our net sales by segment for the fiscal year 2025. For more information on our U.S. and foreign operations, see Notes 4 and 18, to the Consolidated Financial Statements included within Part II. Item 8 of this Form 10-K.

Performance Materials

Performance Chemicals

Advanced Polymer Technologies

End-Use Markets

Automotive

Filtration: Chemicals, Food, and Water

Asphalt Pavement Construction

Asphalt Pavement Preservation

Asphalt Pavement Reconstruction and Recycling

Road Markings

Agrochemical Dispersants

Automotive & Transportation

Industrial Equipment

Footwear & Apparel

Bioplastics

Consumer Packaging

Medical & Health

2025 Revenue

$606.9 million

$400.5 million

$160.2 million

Seasonality

There are a variety of seasonal dynamics, including global climate and weather conditions, that impact our businesses, though none have currently materially affected our financial results, except in the case of the ~~road~~pavement technologies and road markings product ~~line~~lines, where roughly 70 to 75 percent of revenue is generated between April and September. Furthermore, our Performance Chemicals pavement technologies and road markings product lines financial results can be sensitive to weather conditions, particularly prolonged or severe wet weather, which can disrupt operations, delay projects, and reduce customer demand across certain markets. From a supply perspective, this seasonality is effectively managed through pre-season inventory build and active inventory management throughout the year.

Energy

Our manufacturing processes require a significant amount of energy. We ~~are~~depend ~~dependent~~ on natural gas to ~~fuel~~power the processes in our ~~chemical~~activated ~~refineries~~carbon plants and ~~activated~~chemical ~~carbon~~manufacturing ~~plants~~operations. Although we believe that we currently have a stable natural gas supply and infrastructure for our operations, we are subject to volatility in the market price of natural gas. We enter into certain derivative financial instruments to mitigate expected fluctuations in market prices and the resulting volatility of earnings and cash flow. All of our manufacturing processes also consume a significant amount of electricity and are located in regulated service areas that have stable electricity rate structures with reliable supply.

gas supply and infrastructure for our operations, we are subject to volatility in the market price of natural gas. We enter into certain derivative financial instruments to mitigate expected fluctuations in market prices and the resulting volatility of earnings and cash flow. All of our manufacturing processes also consume a significant amount of electricity and are located in regulated service areas that have stable electricity rate structures with reliable supply.

Leveraging Sustainability

Throughout our Performance Materials, Performance Chemicals, and Advanced Polymer Technologies reportable segments, we are a leader in adding value to products made from renewable materials and in derivatizing technologies that impart desirable environmental benefits in their use. ToOur ~~create~~mission ato ~~majority of our chemistries~~purify, weprotect ~~take~~and ~~CTO~~enhance ~~from~~is ~~pine~~reflected ~~trees,~~in ~~hardwood~~our ~~sawdust (both co~~bio-~~products~~based ofand ~~the~~certified ~~lumber,~~biodegradable ~~paper~~products, ~~and~~which ~~furniture-making~~help industries), ~~and~~like ~~plant based oils and convert them into products that benefit customers~~automotive, ~~the~~asphalt ~~environment~~paving, packaging and ~~society.~~agriculture ~~For~~create ~~the~~sustainable ~~caprolactone-based products in our Advanced Polymer Technologies segment – although derived from non-oleo feedstocks – these products provide~~ solutions that ~~enable~~benefit ~~performance~~both ~~attributes in~~ end-~~use~~users ~~markets that directly help customers~~ and ~~consumers~~the ~~meet sustainability goals~~environment.

Put simply: Ingevity’'s products help customers reduce their ecological impact. Our asphalt emulsifiers enable pavement recycling that reuses up to 100 percent of existing materials to create longer-lasting roads. Our automotive activated carbon products improve the air we breathe by recovering 8 million gallons of gasoline daily. Our agriculture adjuvants provide enhanced performance in crop protection. ~~Our alternative-fuel vehicle technology enables the use of renewable natural gas as fuel for pickup trucks and buses.~~ The superior durability of caprolactone-based polyurethane technologies extends product life, and the biodegradable performance of our thermoplastic polycaprolactones ~~offer~~offers compostable end -of-life solutions.

Our business is built on our ability to maximize the value and utility of materials over their lifecycle, and we will continue to enhance this value proposition through ~~future acquisitions and new~~ product development.

Strategic Portfolio Review

On October 29, 2024, we announced our intention to comprehensively review Ingevity’s asset and product portfolios. On January 16, 2025, we announced the exploration of strategic alternatives for our Performance Chemicals industrial specialties product line, including a potential divestiture of portions of the North Charleston site. This process includes all industrial specialties pine chemicals based chemistries that serve the paper chemical, rubber, adhesive, oilfield, lubricants and industrial intermediate end-use markets, and the North Charleston, South Carolina, CTO refinery. This process will not include the Performance Chemicals road technologies product line, nor certain lignin-based products that are currently reported in the Performance Chemicals industrial specialties product line.

We will continue to evaluate the rest of our portfolio and remain committed to taking appropriate actions to ensure our cost structure is aligned with our objective of being a specialty chemicals leader. We cannot assure this strategic review will result in a transaction and will update investors when appropriate.

Human Capital Management

Core Values

Developed collaboratively by Ingevity employees, the IngeviWay is the cultural framework that shapes Ingevity’'s future and enables our success. It describes who we are, what we want to be, and what’'s important to us as we work together to fulfill our purpose to purify, protect and enhance the world around us.

Reinforcing our IngeviWay foundation we launched “The IngeviWay in Action,” an initiative that raises the bar on expectations to build, inspire and lead, and better aligns how we work as a team to create the Ingevity of the future. By focusing on making a positive impact through everyday actions, “The IngeviWay in Action” bolsters the way we live our core values of safety and sustainability, maximize value for our people and our customers, commitment to excellence, integrity and ethical behavior, and drive to create innovative solutions.6

~~Talent~~Reinforcing our IngeviWay foundation is the "The IngeviWay in Action," an initiative that raises the bar on expectations to build, inspire and lead, and better aligns how we work as a team to create the Ingevity of the future. By focusing on making a positive impact through everyday actions, "The IngeviWay in Action" bolsters the way we live our core values of safety and sustainability, maximize value for our people and our customers, commitment to excellence, integrity and ethical behavior, and drive to create innovative solutions.

Talent & Culture

Our employees are critical to our success, and we strive to provide a safe, rewarding, and respectful workplace where our people have opportunities to pursue career paths based on skills, performance, and potential. Our success depends, in part, on our ability to attract, retain and motivate critical resources across production, technical, engineering, sales, and various functional disciplines.

5Our success is fueled by a vibrant, team-oriented culture where people understand that our individual differences make a greater collective impact in every interaction, from peer-to-peer collaboration across regions to customer engagements. At the heart of our efforts, we aim to strengthen empathetic and inclusive leadership, cultivate a sense of safety and belonging, and structure our systems, policies and processes to enable employee success. Working as one team, we are building a workplace where everyone has the opportunity to thrive.

~~Labor~~We ~~Relations~~believe that the diversity of our leadership continues to positively impact our growth and ~~Collective~~success. ~~Bargaining~~Today, our board of directors is 27 percent women and 27 percent racially and ethnically diverse, and our executive team is 25 percent women-led and 38 percent racially and ethnically diverse.

We currently employ approximately 1,600 employees, of whom approximately 73 percent are employed in the U.S. Approximately 51 percent of our production employees are represented by labor unions under various collective bargaining agreements ("CBA"). We engage in negotiations with labor unions for new CBAs from time to time based on expiration dates of agreements and statutory requirements. We consider our relationships with all salaried, union-hourly, and non-hourly employees to be positive and collaborative.

In 2024, the International Association of Machinists and Aerospace Workers, on behalf of its affiliated Local Union 1362 at our Crossett, Arkansas manufacturing plant ratified a one year extension agreement which expires March 1, 2025. The parties will begin contract renewal negotiations during the first quarter of 2025. The Advanced Polymer Technologies manufacturing plant in Warrington, United Kingdom negotiates pay and conditions annually with the GMB Trade Union. In addition, the CBA at our Covington, Virginia Performance Materials plant with the International Brotherhood of Electrical Workers on behalf of its affiliated Local Union 464 expired January 15, 2025. The parties began negotiations in the fourth quarter of 2024 and will continue to operate under the same terms and conditions while negotiations are pending. Also, the CBA at our Covington, Virginia Plant with the Covington Paperworkers Union Local 675, affiliated with the Association of Western Pulp and Paper Workers expires December 1, 2025. It is anticipated that the parties will begin contract renewal negotiations in the fourth quarter of 2025.

Diversity, Equity, Inclusion and Belonging

We are committed to fostering Diversity, Equity, Inclusion and Belonging. Our success is fueled by a vibrant, team-oriented culture where people understand that our individual differences make a greater collective impact in every interaction, from peer-to-peer collaboration across regions to customer engagements. At the heart of our efforts, we aim to strengthen empathetic and inclusive leadership, cultivate a sense of safety and belonging, and structure our systems, policies and processes to enable employee success. Working as one team, we are building a diverse, equitable and inclusive workplace where everyone has the opportunity to thrive.

We believe that the diversity of our leadership continues to positively impact our growth and success. Today, our board of directors is 33 percent women and 22 percent racially and ethnically diverse, and our executive team is 14 percent women-led and 29 percent racially and ethnically diverse.

Performance Management

We assess employee performance comprehensively, taking into account behaviors and direct input from the employee, feedback, the individual's progress toward goals, and their level of business impact. Achievements that bolster the team, our business, and our clients—internal and external—and our fundamental values are all included in the performance evaluation process. Our method involves keeping a codified record of employee performance at mid-year and end-of-year. ~~It also includes a requirement for all Ingevity employees to ask for feedback from those who are aware of their performance and contributions.~~ We encourage managers and their employees to have regular discussions to boost productivity, provide positive business outcomes, and raise employee engagement. With our all-encompassing strategy, Ingevity is able to gain a comprehensive understanding of each worker's strengths and identify opportunities for growth and development.

Labor Relations and Collective Bargaining

We currently employ approximately 1,500 employees, of whom approximately 74 percent are employed in the U.S. Approximately 52 percent of our production employees are represented by labor unions under various collective bargaining agreements ("CBA"). We engage in negotiations with labor unions for new CBAs from time to time based on expiration dates of agreements and statutory requirements. We consider our relationships with all salaried, union-hourly, and non-hourly employees to be positive and collaborative.

The CBA at our Warrington, United Kingdom Advanced Polymer Technologies manufacturing plant with GMB Union is negotiated annually and the parties operate under the prior CBA until new terms are agreed. The CBA at our Covington, Virginia Performance Materials plant with the International Brotherhood of Electrical Workers ("IBEW") on behalf of its affiliated Local Union 464 expired on January 15, 2025. A new CBA with IBEW was ratified on June 24, 2025. The CBA at our Covington, Virginia plant with the Covington Paperworkers Union Local 675, affiliated with the Association of Western Pulp and Paper Workers expired on December 1, 2025. The parties began contract renewal negotiations during the fourth quarter of 2025 and negotiations are in process. The parties will continue to operate under the same terms and conditions while negotiations are pending.

Health & Safety

Ingevity ~~has~~is acommitted to maintaining world-‑class health and safety ~~program~~performance ~~and~~as a ~~strong~~core ~~safety culture~~value. Personal, process, and public safety are ~~core~~foundational ~~values~~to athow ~~Ingevity.~~we Weoperate ~~work~~and ~~hard~~essential to ~~protect~~protecting ~~employees~~our workforce, our contractors, and the communities where we ~~operate~~do ~~from~~business. ~~injuries,~~Our ~~illnesses~~approach ~~and~~includes ~~incidents through~~ the design and ~~delivery~~maintenance of safe operations, continuous improvement of ~~personal and process~~ safety performance, robust management systems, ~~and programs, a~~ strong ~~culture of~~ compliance culture, and a long‑term commitment to ~~strive~~achieving ~~for~~ zero harm to people and the environment.

In 2024, we continued our efforts to increase reporting of and response to near miss incidents to prevent more serious injuries before they occur. This included efforts to increase the number of near misses reported and an increase in reporting by a broader number of employees. We also continued to improve safety training, further expanded the use of leading indicators to ensure effective initiatives are proactively implemented, and improved incident investigation quality to ensure contributing factors are appropriately identified and addressed. Employees were trained on the importance of our Life-Saving Rules, put in place to prevent fatalities and serious injuries through leadership videos, monthly interactive training packages, and upgraded procedures, checklists, work permits, and audits. Additionally, in North America where the majority of our bulk shipments are 7

6In 2025, we advanced our safety performance through increased reporting and response to near‑miss incidents and hazardous conditions, enabling us to address risks before they resulted in injuries. We expanded the use of leading indicators and enhanced incident investigations to ensure contributing factors were accurately identified and resolved. These efforts contributed to a 29% reduction in personal and process safety incidents compared to 2024.

~~executed,~~We wealso ~~abide~~completed byimplementation ~~the~~of ~~American~~our ~~Chemistry~~Zero ~~Council’s~~Harm ~~Responsible~~Behaviors ~~Care~~program ~~practices~~across ~~for~~all ~~transporting~~operating sites. This initiative strengthens our ~~chemicals~~safety ~~safely.~~culture Weby ~~strategically~~defining ~~utilize~~the ~~logistics~~behaviors ~~providers~~essential ~~that~~for ~~have~~safe ~~committed~~work, empowering employees to ~~these~~voice ~~higher~~concerns, ~~standards~~propose improvements, and take ownership of safety, ~~security,~~performance. ~~stewardship,~~The program reinforces what excellence in safety behavior looks like at all levels of the organization and ~~sustainability.~~supports a more engaged and proactive safety environment.

For 2026, we have prioritized reducing injuries related to slips, trips, and falls (which accounted for half of all injuries in 2025) while also maintaining a strong focus on preventing significant injuries and process safety incidents.

Our focus on safety extends beyond manufacturing to the safe transport of our products. All operating locations, third‑party warehouses, and distribution centers follow rigorous training, inspection, and auditing protocols to ensure responsible handling of materials. Because we work with third‑party transportation providers, we maintain 24/7/365 global incident support for immediate notification and expert guidance. In the United States, we utilize CHEMTREC for real‑time incident reporting and coordination; internationally, we partner with Ricardo, a trusted emergency response service that provides experienced support for incidents outside the U.S.

Governmental Regulations

Our manufacturing operations are subject to regulation by governmental and other regulatory authorities with jurisdiction over our operations. These regulations include the discharge of materials into the environment, the handling, storage, transportation, disposal, and clean-up of chemicals and waste materials, and otherwise relating to the protection of the environment, as well as other operational regulations, such as the Occupational Safety and Health Act ("OSHA") and the Toxic Substances Control Act ("TSCA") in the U.S., and the Registration, Evaluation and Authorization of Chemicals ("REACH") directives in the European Union, the United Kingdom, and other countries. It is not possible to quantify with certainty the material effects that compliance with these regulations may have ~~upon~~on ~~the~~Ingevity's capital expenditures, earnings, or competitive position ~~of Ingevity~~, but we currently anticipate that such compliance will not have a material adverse effect on any of the foregoing. Environmental and other regulations and related legal proceedings have the potential to involve significant costs and liability for Ingevity.

Intellectual Property

Protection of intellectual property, including patents, closely guarded trade secrets, and highly proprietary manufacturing know-how, as well as other proprietary rights, is critical to maintaining our technology leadership and competitive edge. Our business strategy includes filing patent and trademark applications where appropriate for proprietary developments, as well as protecting our trade secrets. We actively create, protect, and enforce our intellectual property rights. We are filing for and being granted patents for product and process developments for our Performance Materials business that we believe are both novel and consistent with trends in the technological development of engines. Our Evotherm® Warm Mix Asphalt technology is supported by numerous global patents and trademarks. Additionally, our caprolactone and related technologies are supported by numerous global patents and trademarks, as well as proprietary manufacturing and technical know-how. The protection afforded by our patents and trademarks varies based on country, scope, and coverage, as well as the availability of legal remedies. Although our intellectual property taken as a whole is material to the business, there is no individual patent or trademark the loss of which could have a material adverse effect on the business.

On July 19, 2018, we filed suit against BASF Corporation (“"BASF”") in the U.S. District Court for the District of Delaware (the “"Delaware Proceeding”") alleging BASF infringed Ingevity’'s patent covering canister systems used in the control of automotive gasoline vapor emissions (U.S. Patent No. RE38,844) (the “"844 Patent”"). On February 14, 2019, BASF asserted counterclaims against us in the Delaware Proceeding, alleging two claims for violations of U.S. antitrust law (one for exclusive dealing and the other for tying) as well as a claim for tortious interference with an alleged prospective business relationship between BASF and a BASF customer (the “"BASF Counterclaims”"). The BASF Counterclaims relate to our enforcement of the 844 Patent and our entry into several supply agreements with customers of our fuel vapor canister honeycombs. The U.S. District Court dismissed our patent infringement claims on November 18, 2020, and the case proceeded to trial on the BASF Counterclaims in September 2021.

On September 15, 2021, a jury in the Delaware Proceeding issued a verdict in favor of BASF on the BASF Counterclaims and awarded BASF damages of approximately $28.3 million, which will be trebled under U.S. antitrust law to approximately $85.0 million. On May 18, 2023, the court in the Delaware Proceeding entered judgment on the jury’s verdict, which commenced the post-trial briefing stage. On February 13, 2024, the court in the Delaware Proceeding denied BASF’s motion for pre-judgment interest on its tortious interference claim as well as our motion seeking judgment as a matter of law, or a new trial in the alternative. In addition, BASF has indicated it will seek attorneys’ fees and costs in amounts that they will allege and have to demonstrate at a future date. Unless the judgment is set aside, BASF will be entitled to post-judgment interest pursuant to the rate provided under federal law. 8

WeOn ~~disagree~~September ~~with~~15, ~~the verdict~~2021, ~~including~~a jury in the ~~court’s~~Delaware ~~application~~Proceeding ofissued ~~the~~a ~~law~~verdict ~~and~~in ~~entry~~favor of ~~judgment.~~BASF ~~Therefore,~~ on ~~March~~the ~~13,~~BASF ~~2024,~~Counterclaims weand ~~appealed~~awarded ~~the~~BASF ~~verdict~~damages asof ~~well~~approximately as$28.3 million, ~~the~~which will be trebled under U.S. ~~District~~antitrust ~~Court’s~~law ~~November~~to ~~2020~~approximately ~~dismissal~~$85.0 million. ofOn ~~our~~May ~~patent~~18, ~~infringement~~2023, ~~claims~~the ~~against~~court ~~BASF. Ingevity believes~~ in the ~~strength~~Delaware ofProceeding ~~its~~entered ~~intellectual~~judgment ~~property~~on ~~and~~ the ~~merits~~jury's ofverdict, ~~its~~which ~~position~~commenced ~~and~~the ~~intends~~post-trial tobriefing ~~pursue~~stage. ~~all~~On ~~legal~~February ~~relief~~13, ~~available~~2024, tothe ~~challenge~~court ~~these outcomes~~ in the Delaware Proceeding. ~~Final~~denied ~~resolution~~BASF's ofmotion ~~these~~for ~~matters~~pre-judgment ~~could~~interest ~~take~~on upits totortious 15interference ~~months~~claim ~~from~~as ~~the~~well ~~date~~as our motion seeking judgment as a matter of ~~this~~law, ~~Annual~~or ~~Report~~a onnew ~~Form~~trial ~~10-K~~in the alternative.

7On March 13, 2024, we appealed the verdict as well as the U.S. District Court's November 2020 dismissal of our patent infringement claims against BASF to the U.S. Federal Circuit Court of Appeals. On February 11, 2026, the U.S. Federal Circuit Court of Appeals ruled against Ingevity on our appeal and we have decided to no longer pursue any further appeals. We expect payment of the judgment, plus post-judgment interest, to be made in the second quarter of 2026. BASF has indicated it will seek attorneys' fees and costs in amounts that they will allege and have to demonstrate at a future date. See Note 17 to the Consolidated Financial Statements included within Part II. Item 8 of this Form 10-K.

Segments

Performance Materials

We engineer, manufacture, and sell hardwood-based, chemically activated carbon products which are produced through a highly technical and specialized process primarily for use in gasoline vapor emission control systems in internal combustion engines and hybrid electric vehicles including cars, trucks, motorcycles, and boats. ToOur ~~maximize~~activated ~~the~~carbon ~~productivity~~products ofare further used in filtration applications for food and beverage, water, and chemical purification. We believe our ~~manufacturing~~technical ~~assets~~expertise in activated carbon can benefit various applications and expand our markets beyond our core automotive business, wesuch ~~also~~as ~~produce~~energy ~~several~~storage. ~~other~~We are using our engineering and manufacturing expertise in activated carbon ~~products~~to ~~for~~explore ~~food~~opportunities in nanotubes, ~~water~~scaffolding, ~~beverage~~and hard carbon that improve battery life and performance, increase storage capacity, and ~~chemical~~shorten charging times. We continue to explore solutions in renewable natural gas as well as filtration and purification ~~applications~~markets.

Our automotive activated carbon products primarily take the form of granules, pellets, and honeycomb "scrubbers," which are primarily utilized in vehicle-based gasoline vapor emission control systems to capture gasoline vapors that would otherwise be released into the atmosphere as volatile organic compounds. The captured gasoline vapors are largely purged from the activated carbon and re-directed to the engine where they are used as supplemental power for the vehicle. In this way, our automotive activated carbon products are part of a system that improves the environment and fuel efficiency. Performance Materials' net sales for ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023 were $~~609~~606.69 million, $~~586~~609.06 million, and $~~548~~586.50 million, respectively. The chart below reflects our ~~2024~~2025 Performance Materials' net sales by geography. Sales are assigned to geographic areas based on the location of the party to which the product was shipped.

The majority of Performance Materials' EBITDA is derived from activated carbon sales used in newly produced hybrid and non-hybrid vehicles with powertrains utilizing gasoline internal combustion engines. The segment results are influenced by two primary mix factors: the type of vehicles produced globally and the emissions‑control standards in each region. These variables directly influence the demand for the segment's activated carbon products. With respect to vehicle type mix, the segment benefits from larger vehicles, such as trucks and sport utility vehicles, whether hybrid or non-hybrid, as these vehicles contain either more volume of our activated carbon content or higher demanding carbon technologies to maintain regulatory requirements.

Regional mix is also central to the segment performance. North America, which represents approximately half of total Performance Materials net sales, is the segment's most profitable region. This is driven by both the prevalence of larger vehicles and the region's world leading emissions control standards, which require more advanced activated carbon products. The Asia Pacific region accounts for roughly 40 percent of total Performance Materials' net sales. Within Asia Pacific, about half of our net sales are in China, with South Korea and Japan comprising most of the remaining balance. These markets either enforce strict emissions requirements or manufacture vehicles for export to regions with strict emissions requirements, supporting steady demand for activated carbon. Europe is our least impactful region due to the region's regulatory landscape, which heavily favors the accelerated adoption of electric vehicles. Europe's emissions control standards also lag those of North America and Asia Pacific.

Raw Materials and Production

Our Performance Materials segment serves customers globally from three manufacturing locations in the U.S. and two in China. The primary raw material (by volume) used in the manufacture of our activated carbon is hardwood sawdust. Sawdust is readily available and is sourced through multiple suppliers to protect against supply disruptions and to maintain competitive pricing.

We also utilize phosphoric acid to chemically activate the hardwood sawdust. This phosphoric acid is sourced through multiple suppliers to protect against supply disruptions and to maintain competitive pricing. The market price of phosphoric acid is affected by the global agriculture market as the majority of global phosphate rock production is used for fertilizer production and only a portion of that production is used to manufacture purified phosphoric acid.

Customers

We sell our automotive ~~technologies~~technology products to approximately 6065 customers around the globe. In ~~2024~~2025, our ten largest customers accounted for approximately 8590 percent of sales. We are the trusted source of these products for many of the world’'s largest automotive parts manufacturers, including PHINIA Inc. (previously part of BorgWarner Inc.), A. Kayser Automotive System GmbH, Korea Fuel-Tech Corporation, MAHLE GmbH, and many other large and small component manufacturers throughout the global automotive supply chain. Our food, water, beverage, and chemical purification products are sold to approximately 70 customers globally. We primarily sell our products ~~primarily~~ through our own direct sales force in North America, Europe, South America, and Asia.

Europe, South America, Asia, and a smaller, focused network of third-party distributors that have established a strong direct sales and marketing presence in North America and China.

Competition

Our competitors include Norit, Kuraray Co., Ltd., ~~and several~~ domestic U.S. manufacturers and distributors of imported products, and Chinese manufacturers. Ingevity has a decades-long track record of providing activated carbon that achieves life-of-vehicle emission standards. Given the imperative for automotive manufacturers to produce vehicles for the U.S., Canada, and China markets capable of meeting life-of-vehicle emission standards, or potentially face expensive recalls and unfavorable publicity, our automotive activated carbon products provide our customers with the low-risk choice for this high-performance application. Additionally, we are well-positioned to meet ~~increasing~~increasingly stringent emissions standards ~~around the world~~worldwide.

Performance Chemicals

Our Performance Chemicals segment is comprised of two product lines: ~~road~~pavement technologies and ~~industrial~~road ~~specialties~~markings. Our Performance Chemicals products are utilized in ~~road~~asphalt pavement construction, ~~preservation,~~ reconstruction and recycling, road markings, ~~agrochemical dispersants, lubricants, certain adhesives, rubber,~~ and ~~other~~agrochemical ~~diverse industrial uses~~dispersants. Our application expertise is often called upon by our customers to provide unique solutions that maximize resource efficiency. We have a broad and diverse customer base in this segment. In ~~2024~~2025, our top ten customers accounted for approximately 2632 percent of our segment revenue, with the next 100 customers making up approximately 4746 percent of our segment revenue. Performance Chemicals' net sales for ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023 were $~~608~~400.25 million, $~~902~~401.19 million, and $~~875~~425.15 million, respectively. The chart below reflects our ~~2024~~2025 Performance Chemicals' net sales by geography. Sales are assigned to geographic areas based on the location of the party to which the product was shipped.

In 2023, Ingevity began a transformation of the Performance Chemicals’ industrial specialties product line. During the fourth quarter of 2023, Ingevity announced the planned closure of the DeRidder, Louisiana (the “DeRidder Plant”) CTO refinery and derivatives operations. All production at the DeRidder Plant ceased in the first quarter of 2024. Additionally, in July 2024, we announced plans to transition the refining of oleo-based products from our Crossett, Arkansas manufacturing plant (the “Crossett Facility”) to our North Charleston, South Carolina manufacturing plant. We ceased production at the Crossett Facility in the third quarter of 2024 and materially completed the transition in the fourth quarter of 2024. With the majority of this transformation complete, Ingevity’s participation in the rosin-based adhesive and publication printing ink markets along with emulsifiers for drilling into the oilfield markets has been significantly reduced.

On January 16, 2025, we announced the exploration of strategic alternatives for our Performance Chemicals industrial specialties product line, including a potential divestiture of portions of the North Charleston site. This process includes all industrial specialties' pine chemicals based chemistries that serve the paper chemical, rubber, adhesive, oilfield, lubricants and industrial intermediate end-use markets, and the North Charleston, South Carolina, crude tall oil refinery. This process will not include the Performance Chemicals road technologies product line, nor certain lignin-based products that are currently reported in Ingevity’s industrial specialties product line.

Raw Materials and Production

Our Performance Chemicals segment serves customers globally from five manufacturing locations in the U.S. ~~Most~~Our ~~of our industrial specialties~~ products ~~and some of our road technologies products~~ are derived from ~~CTO,~~ a ~~co-product~~variety ~~produced~~of byraw ~~softwood~~materials, ~~kraft~~including ~~pulp~~maleic ~~processors.~~anhydride, Weethoxylates, ~~also~~amines, ~~produce~~and ~~products~~acrylic ~~derived~~emulsions. ~~from~~These ~~kraft~~are ~~lignin,~~sourced ~~which~~where ispossible ~~extracted~~through ~~from~~multiple ~~black~~suppliers ~~liquor,~~to ~~another~~protect ~~co-product~~against ofsupply ~~softwood~~disruptions ~~kraft~~and ~~pulp~~to ~~processing~~maintain competitive pricing.

Historically, we have sourced the majority of our CTO needs through long-term supply contracts. However, CTO pricing volatility in recent years has made it difficult to manage long-term pricing mechanisms, and as a result, during 2024 we exited all material long-term contracts. We now procure our supply of CTO through shorter-duration contracts. Shorter-term contracts of 12 to 15 months enable more flexibility and transparency on pricing. On July 1, 2024, we terminated our last material long-term CTO supply contract. As consideration for the termination, we made cash payments totaling $100.0 million during 2024.

The supply of CTO is generally inelastic and governed by the volume of softwood kraft pulp processing around the world. Also, there are regulatory pressures that may incentivize suppliers of CTO to sell CTO into alternative fuel markets (e.g., biofuels) rather than to historical end users such as Ingevity. CTO-based biofuel has been deemed to meet the EU’s Renewable Energy Directive, second phase (“RED II”) biofuel sustainability criteria. As a result of RED II and related government incentives, there has been a significant increase in demand for CTO and its derivatives over the past several years. The increased demand, combined with the rationalization of softwood kraft pulp processing, has created pressure on CTO pricing and driven the cost of CTO to unprecedented levels, higher by as much as 300 percent in some cases.

During 2024, we sourced approximately 81 percent of our CTO from two primary parties: Smurfit WestRock and Georgia-Pacific. CTO accounted for approximately 14 percent of our consolidated cost of sales and 38 percent of our consolidated raw materials purchases in 2024.

In addition to these developments in the EU, various pieces of legislation regarding the use of alternative fuels have been introduced in the U.S. at both the federal and state level. Currently, none of the U.S. legislation mandates or provides incentives for the use of CTO or its derivatives as a biofuel. Future legislation in the U.S. and elsewhere may promote the use of CTO or its derivatives as a feedstock for the production of biofuels, further constraining supply.

The other key raw materials used in the Performance Chemicals business are maleic anhydride, ethoxylates, amines, and acrylic emulsions. These are sourced where possible through multiple suppliers to protect against supply disruptions and to maintain competitive pricing.

Markets Served

~~Road~~Pavement Technologies

Our ~~road~~pavement technologies product line produces a broad line of innovative additives and technologies utilized globally in ~~road~~asphalt ~~construction and~~ pavement construction, preservation, ~~including pavement~~ reconstruction and recycling~~. With the 2022 acquisition of Ozark Materials~~, ~~LLC~~and ~~(“Ozark~~agrochemical ~~Materials”), we added road markings technologies to the portfolio~~dispersants.

~~Road~~Asphalt Pavement Construction. Evotherm®, our premier ~~road~~line of pavement construction ~~additive~~additives, is a warm mix asphalt technology that ~~acts~~allows asproduction ~~both~~temperatures ato ~~liquid~~be ~~antistrip~~significantly ~~and~~lowered acompared ~~warm~~to conventional hot mix asphalt. Lower ~~Once~~production ~~Evotherm®~~temperatures isallow ~~mixed~~customers ~~into~~to extend the ~~binder~~paving ~~utilized~~season, ~~for~~increase ~~road~~recycled ~~layer~~asphalt ~~construction~~content, ~~production~~and ~~temperatures~~reduces ~~can~~emissions. beEvotherm ~~significantly~~improves ~~lowered~~the ~~compared~~quality toof ~~conventional~~the ~~hot~~asphalt mix, ~~asphalt.~~improves ~~Lower~~road ~~production~~density ~~temperatures reduces our customers' emissions~~ and ~~fuel~~extends ~~use during~~ road ~~construction~~life asby ~~well as making roads last~~ up to ~~20 percent longer~~30%.

Asphalt Pavement Preservation. We provide an array of pavement preservation products ~~that~~used ~~eliminate~~to ~~many~~create ~~traditional~~ asphalt ~~heating,~~emulsions ~~mixing,~~for ~~and~~road ~~transportation~~maintenance ~~demands – saving our customers time, energy, and money~~projects. Our technical team matches the right emulsifier and design to our customers’' materials and conditions to create high-performing emulsions. We offer a full range of specialized cationic, anionic, and amphoteric emulsifiers with additional, custom-formulated specialty additives.

Asphalt Pavement Reconstruction and Recycling. We provide an array of pavement reconstruction and recycling emulsifiers and additives that reduce the life cycle cost of pavement by enabling the milling and reuse of existing roadways. Our cold in-place recycling additives allow our customers to reopen existing roadways faster, while also lowering overall costs and jobsite emissions.

Pavement Markings. We provide thermoplastic and waterborne paint road markings technologies which provide long service life, excellent adhesion, superior color, and higher retro-reflectivity. Based on the customer and/or governmental agency requirements, the markings can be designed for varying levels of initial and retained performance properties.11

Agrochemical Dispersants. We produce dispersants for crop protection products as well as other naturally derived products for agrochemicals. Crop protection formulations are highly engineered, specifically formulated, and cover a range of different formulation types, from liquids to solids. We deliver a wide range of dispersants that are high-performing and consistent. In addition, our crop protection products are approved for use as inert ingredients in agrochemicals by regulatory agencies worldwide.

Customers

We supply our ~~road~~pavement technologies products to approximately ~~750~~600 customers in 60 countries through our own direct sales force, primarily in the Americas and Europe, as well as a network of third-party distributors. In ~~2024~~2025, our ten largest customers accounted for approximately 3738 percent of the product line's sales. Our largest customers include Ergon, Inc., ~~TRP~~Idaho ~~Group,~~Asphalt ~~Frontline~~Supply Inc., The Heritage Group, and ~~Idaho Asphalt Supply Inc~~Syngenta.

Competition

Our primary competitors in ~~road~~pavement technologies are Nouryon Chemicals B.V., Arkema S.A., ~~Kao Specialties Americas LLC, Sherwin-Williams Company,~~ and ~~PPG~~Zydex ~~Industries Traffic Solutions~~Group. We compete based on deep knowledge of our customers’' businesses and extensive insights into road-building technologies and trends globally. We use these strengths to develop consultative relationships with government departments of transportation, facilitating new technology introduction into key markets around the world. Our combined expertise in the disciplines of chemistry and civil engineering provides us with a comprehensive understanding of the relationship between the molecular structure of our products and their impact on the performance of pavement systems. This allows us to develop products customized to local markets and to consistently deliver cost-effective solutions for our customers.

~~Industrial~~Road ~~Specialties~~Markings

Our ~~industrial~~road ~~specialties~~markings product line produces thermoplastic and ~~sells~~waterborne ~~chemicals~~paint ~~utilized~~road inmarkings ~~several~~technologies ~~industrial~~which ~~applications,~~provide ~~including~~long ~~adhesive~~service ~~tackifiers~~life, ~~agrochemical~~excellent ~~dispersants~~adhesion, ~~lubricant~~superior ~~additives~~color, ~~rubber~~and ~~resins,~~higher ~~industrial~~retro-reflectivity. ~~intermediates~~Based on the customer and/or governmental agency requirements, the markings can be designed for varying levels of initial and ~~oilfield.~~retained performance properties.

Agricultural Chemicals. We produce dispersants for crop protection products as well as other naturally derived products for agrochemicals. Crop protection formulations are highly engineered, specifically formulated, and cover a range of different formulation types, from liquids to solids. We deliver a wide range of dispersants that are high performing and consistent. In addition, our crop protection products are approved for use as inert ingredients in agrochemicals by regulatory agencies throughout the world.

Rubber. We are a global supplier of tall oil-based products and we offer a broad range of resins, rosin soaps, mixed acids and fatty acids from renewable resources. We currently supply specialty products to latex manufacturers, compounders and tire producers where our resins help improved fuel efficiency, wear and traction.

Industrial Intermediates. Our functional chemistries are sold across a diverse range of industrial markets including, textile dyes, rubber, cleaners, mining, oilfield and nutraceuticals.

Adhesives, and Lubricants. We are a North American supplier of tackifier resins which provide superior adhesion to difficult-to-bond materials to the adhesives industry. Adhesive applications for our products include construction, product assembly, packaging, pressure-sensitive labels and tapes, hygiene products, and road markings. We supply lubricant additives and corrosion inhibitors for the metalworking and fuel additives markets. Our lubricant products are multi-functional additives that contribute to lubricity, wetting, corrosion inhibition, emulsification, and general performance efficiency.

Customers

We ~~sell~~supply our ~~industrial~~road ~~specialties~~markings products to approximately ~~400~~200 customers ~~around the globe~~ in ~~over~~North 40America ~~countries~~ through our own direct sales ~~representatives and third-party sales representatives and distributors~~force. In ~~2024~~2025, our ten largest customers accounted for approximately 3959 percent of the product line's sales. Our largest customers include ~~Solenis,~~TRP ~~Arboris~~Group, ~~ChampionX,~~ and ~~Syngenta~~Frontline.

Competition

Our primary competitors, ~~which~~in ~~differ~~road ~~depending~~markings onare ~~the~~Sherwin-Williams ~~product~~Company, ~~application,~~ and ~~region,~~PPG ~~include~~Industries ~~Kraton~~Traffic ~~Corp~~Solutions., ~~Forchem,~~We Eastman Chemical Co., Borregaard ASA, Repsol S.A., Lamberti S.p.A., Cargill, Vantage, and PMC, as well as several others. Specific to our industrial specialty products, our customers select the product that provides the best balance of performance, consistency, and price. Reputation and loyalty are ~~also~~a ~~valued~~proven ~~by our customers~~ and ~~allow~~trusted usprovider ~~to win business when other factors are equal. In agrochemicals, the selection~~ of ~~a dispersant is made early in the product development cycle and the formulator has a choice among our sulfonated lignin products, lower~~mission-~~quality~~critical ~~lignosulfonates~~road ~~and~~marking ~~other surfactants such as naphthalene sulfonates. In adhesives~~solutions, ~~our~~relied ~~products~~upon ~~compete~~by ~~against~~leading ~~other~~private ~~tackifiers,~~contractors ~~including other tall oil resin ("TOR") based tackifiers as well as tackifiers produced from gum rosin~~ and ~~hydrocarbon~~government ~~based~~agencies ~~materials.~~across InNorth ~~lubricants, we compete against other producers of distilled tall oil and additives~~America. InWe ~~our~~maintain ~~industrial~~a ~~intermediates business~~strong, ~~our~~defensible ~~tall~~market ~~oil~~position ~~fatty~~reinforced ~~acid~~by ~~("TOFA")~~deep ~~competes~~customer ~~against~~relationships ~~widely~~and ~~available~~a ~~fats~~competitive ~~and~~advantage ~~oils~~built ~~derived~~on ~~from~~exceptional ~~tallow~~service, ~~soy~~reliability, ~~rapeseed, palm,~~ and ~~cotton~~consistent ~~sources.~~product performance.

Advanced Polymer Technologies

Our Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical ~~devices~~. Advanced Polymer Technologies' net sales for ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023 were $~~188~~160.62 million, $~~204~~188.06 million, and $~~244~~204.70 million, respectively. The chart below reflects our ~~2024~~2025 Advanced Polymer Technologies' net sales by geography. Sales are assigned to geographic areas based on the location of the party to which the product was shipped.

Raw Materials and Production

Our Advanced Polymer Technologies segment serves customers globally from one manufacturing location in the U.K. Our Advanced Polymer Technologies' products are caprolactone-based, which is derived from cyclohexanone, a benzene derivative, and hydrogen peroxide, both of which are readily available in the market. We maintain multiple suppliers of cyclohexanone to protect against supply disruptions and to maintain competitive pricing. Our hydrogen peroxide is currently supplied by Solvay Interox Limited ~~under a long-term supply agreement~~.

Customers

We sell our Advanced Polymer Technologies products to approximately ~~250~~200 customers around the globe through our own direct sales representatives and third-party sales representatives and distributors. In ~~2024~~2025, our ten largest customers accounted for approximately 4644 percent of the segment's sales. Our largest customers are active in polyurethane, elastomers, adhesives, coatings, and bioplastics ~~manufacturers~~applications.

Competition

Our primary caprolactone competitors are Daicel Corporation, Hunan Juren Chemical Hitechnology, and BASF SE, but we also face competition from other competing materials. Our value proposition is focused on sustainability elements, either through the high durability performance our Capa polyols impart to polyurethane articles or via the biodegradability characteristics of our Capa thermoplastics which now hold certification in multiple environments. We also add value through customer intimacy, a high focus on environmental, health, safety and quality performance and our supply chain capabilities.

ITEM 1A. RISK FACTORS

Based on the information currently known to us, we believe that the following information identifies the most significant risk factors affecting the Company. However, the risks and uncertainties we face are not limited to those set forth in the risk factors described below. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. In addition, past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods.

If any of the following risks and uncertainties develop into actual events, these events could have a material adverse effect on our business, financial condition. or results of operations. In such case, the trading price of our Common Stock could decline.

Operational Risks

~~The~~Our ~~repositioning~~review of ~~our~~strategic alternatives for the APT reportable segment and Performance Chemicals ~~business~~road ~~has~~markings ~~reduced~~product ~~our~~line ~~net~~may ~~sales~~not result in a transaction and ~~may~~any ~~otherwise~~transaction ~~adversely~~we ~~affect~~enter into, including the completed sale of our ~~financial~~North ~~condition~~Charleston CTO refinery assets and ~~results~~the majority of ~~operations~~the ~~during~~Performance ~~this~~Chemicals ~~transition~~industrial ~~period.~~specialties product line, may not yield the expected results or benefits.

On ~~November~~December 18, ~~2023 and July 31~~2025, ~~2024,~~ we announced aplans ~~number~~to ofexplore strategic ~~actions~~alternatives ~~designed~~for ~~to further reposition~~ our ~~Performance~~APT ~~Chemicals~~ reportable segment ~~to improve the profitability~~ and ~~reduce~~Performance ~~the~~Chemicals ~~cyclicality~~road ofmarkings ~~the~~product ~~Company as a whole~~line. ~~These~~While ~~initiatives,~~it ~~including~~is ~~the closure of~~ our ~~plants~~intent into ~~DeRidder,~~identify ~~Louisiana~~ and ~~Crossett,~~pursue ~~Arkansas~~a ~~(the~~transaction ~~“Plant~~for ~~Closures”),~~each ~~focus~~of onAPT ~~reducing~~and ~~exposure~~the toroad ~~lower~~markings ~~margin end-use markets of our industrial specialties~~ product line~~. The anticipated timing~~, ~~charges~~that, ~~costs~~in ~~and~~each ~~results~~case ofwill ~~the~~improve ~~closure of~~ the ~~Plant~~Company's ~~Closures~~financial performance and ~~other~~benefit ~~current~~our orstockholders ~~future~~by ~~repositioning~~enabling ~~activities~~us ~~are subject~~ to afocus ~~number~~on ofhigher ~~assumptions~~margin ~~and~~opportunities, ~~risks~~there ~~and~~can ~~the~~be ~~actual~~no ~~results~~guarantee ~~could~~that ~~materially~~this ~~differ~~strategic ~~from~~review ~~our~~will ~~estimates if such actions~~ result in ~~adverse~~such ~~legal~~transactions or ~~regulatory~~achieve ~~actions,~~such ifexpected ~~personnel~~results ~~required to effect the shutdown become unavailable,~~ or ~~we are affected by other factors not currently contemplated~~benefits. ~~These actions have, and may continue to, adversely affect the Company’s financial condition and results of operations.~~

~~Our~~We ~~review~~are ofdependent ~~strategic~~upon ~~alternatives~~third parties for the ~~industrial~~provision ~~specialties~~of ~~product~~certain ~~line~~critical ~~and~~operating ~~North~~services ~~Charleston,~~at ~~South~~several ~~Carolina~~of ~~crude~~our ~~tall oil (“CTO”) refinery may not result in a transaction and any transaction entered into may not yield the expected results or benefits~~plants.

OnWe ~~January~~are 16dependent upon third parties for the provision of certain critical operating services, ~~2025~~primarily utilities and related services (depending on the site, wee.g., ~~announced~~compressed ~~plans~~air, toenergy, ~~explore~~water, ~~strategic~~wastewater ~~alternatives~~treatment, ~~for~~hydrogen peroxide), at our ~~industrial~~plants ~~specialties~~in ~~product~~Covington, ~~line~~Virginia, and ~~North Charleston~~Warrington, ~~South~~United ~~Carolina~~Kingdom. ~~CTO~~We ~~refinery,~~are ~~including~~co-located awith ~~potential~~third ~~divestiture~~parties ofat ~~portions~~each of the ~~North~~foregoing ~~Charleston~~plants, ~~site.~~and ~~While~~we itface isrelated ~~our~~risks ~~intent~~of disruptions to ~~identify~~our ~~and~~operations ~~pursue~~arising aout ~~transaction~~of ~~that~~the ~~will~~acts ~~strengthen~~or ~~the~~omissions ~~Performance~~of ~~Chemicals~~such ~~segment~~third ~~and~~parties. ~~improve~~We ~~the~~are ~~Company’s~~also ~~financial~~co-located ~~performance~~with, and ~~benefit~~provide ~~our~~certain ~~stockholders~~critical byoperating ~~enabling~~services us to, ~~focus~~a onthird ~~higher~~party ~~growth~~at ~~and~~our ~~higher~~North ~~margin opportunities~~Charleston, ~~there~~South ~~can~~Carolina beplant. noIf ~~guarantee~~we ~~that~~are ~~this~~unable ~~strategic~~to ~~review~~provide ~~will~~such ~~result~~services, inwe ~~such~~could aface ~~transaction~~liability orfor ~~achieve~~disrupting such ~~expected~~third ~~results~~party's ~~or benefits~~operations.

WeThe ~~are~~services ~~dependent~~provided ~~upon~~by third parties ~~for~~would be at risk if any of the ~~provision~~counterparties were to idle or permanently shut down the associated mill or plant, or if operations at the associated mill or plant were disrupted due to natural or other disaster, or by reason of ~~certain~~strikes or other labor disruptions, or if there were a significant contractual dispute between the parties. The third party provider of critical ~~operating~~and non-critical services at ~~several~~our location in Warrington, United Kingdom has discontinued most of its operations at its Warrington, United Kingdom plant, but continues to provide services to us. In the event that the applicable counterparty were to fail to provide the contracted services, we would be required to obtain these services from other third parties, most likely at an increased cost, or to expend capital to provide these services ourselves. The expenses associated with obtaining or providing these services, as well as any interruption in our ~~facilities~~operations as a result of the failure of the counterparty to provide these services, may be significant and may adversely affect our financial condition and results of operations.

WeFurthermore, ~~are~~in ~~dependent~~the ~~upon~~event ~~third~~that ~~parties~~Smurfit ~~for~~WestRock's ~~the~~Covington, ~~provision~~VA ofpaper ~~certain~~mill's ~~critical~~wastewater ~~operating~~treatment ~~services,~~operations ~~primarily~~do ~~utilities~~not comply with permits or applicable law and ~~related~~Smurfit ~~services~~WestRock ~~(depending~~is onunable to determine the ~~site,~~cause ~~e.g.,~~of ~~steam~~such non-compliance, ~~compressed~~then ~~air,~~we ~~energy,~~will ~~water,~~be ~~wastewater~~responsible ~~treatment,~~for ~~hydrogen~~between ~~peroxide~~10 percent and 50 percent of the costs and expenses of such noncompliance (increasing in 10 percent increments per violation during each twelve-month period), atdespite ~~our~~representing ~~Covington,~~less ~~Virginia~~than ~~Performance~~3 ~~Materials~~percent ~~facility~~of the total wastewater volume. These costs and atexpenses ~~our~~may ~~Warrington,~~be ~~United~~significant ~~Kingdom~~and ~~Advanced~~may ~~Polymer~~adversely ~~Technologies~~impact ~~facility~~our financial condition and results of operations.

~~The~~Additionally, ~~services~~several ~~provided by third parties would be at risk if any~~ of ~~the~~our ~~counterparties~~manufacturing ~~were~~plants toare ~~idle~~leased. orIn ~~permanently shut down~~ the ~~associated~~event ~~mill~~we ~~or plant, or if operations at the associated mill or plant~~ were ~~disrupted due~~ to ~~natural~~have ~~or other disaster, or by reason of strikes or other labor disruptions, or if there were~~ a ~~significant contractual~~ dispute ~~between~~with the ~~parties.~~landlord ~~The~~regarding ~~third~~the ~~party~~terms ~~provider~~ of ~~critical~~the ~~and~~relevant ~~non-critical~~lease ~~services at our location in Warrington~~agreements, ~~United~~or ~~Kingdom~~we ~~has announced plans to discontinue operations at its Warrington, United Kingdom plant, but continues to provide services to us. In the event that the applicable counterparty~~ were tootherwise ~~fail~~unable to ~~provide~~fully ~~the~~access ~~contracted services, we would be required to obtain these services from other third parties, most likely at an increased cost,~~ or toutilize ~~expend~~the ~~capital~~leased ~~to provide these services ourselves. The expenses associated with obtaining or providing these services~~property, ~~as well as any interruption in our operations as a result of~~ the ~~failure~~associated ofbusiness ~~the~~disruption ~~counterparty to provide these services,~~ may be significant and may adversely affect our financial condition and results of operations.

~~Furthermore,~~Disruptions inat ~~the~~any ~~event~~of ~~that~~our ~~Smurfit~~plants ~~WestRock’s~~could ~~Covington,~~negatively VAimpact ~~paper~~our ~~mill’s~~production, ~~wastewater~~financial ~~treatment~~condition ~~operations do not comply with permits or applicable law~~ and ~~Smurfit~~results ~~WestRock is unable to determine the cause~~ of ~~such~~operations. ~~non-compliance,~~

Disruptions to any of our manufacturing operations or other plants due to natural disasters and extreme weather, such as a hurricane, tropical storm, earthquake, tornado, severe weather, flood or fire, or other unanticipated problems such as labor

~~then~~difficulties, wepandemics, ~~will~~equipment befailure, ~~responsible~~cyberattacks ~~for~~or ~~between~~other 10cybersecurity ~~percent~~incidents, capacity expansion difficulties or unscheduled maintenance, and 50planned ~~percent~~or ofunplanned ~~the~~production ~~costs~~slowdowns and ~~expenses~~shutdowns, turnarounds and outages, could cause operational disruptions of ~~such~~varied ~~noncompliance~~duration. ~~(increasing~~Also, inmany 10of ~~percent~~our ~~increments~~production ~~per~~employees ~~violation~~are ~~during~~governed ~~each~~by ~~twelve-month~~collective ~~period)~~bargaining ~~despite~~agreements. ~~representing~~The ~~less~~CBA ~~than~~at 3our ~~percent~~Warrington, ofUnited Kingdom APT manufacturing plant with GMB Union is negotiated annually and the ~~total~~parties ~~wastewater~~operate ~~volume~~under the prior CBA until new terms are agreed. ~~These~~The ~~costs~~CBA ~~and~~at ~~expenses~~our ~~may~~Covington, beVirginia ~~significant~~Performance ~~and~~Materials ~~may~~plant ~~adversely~~with ~~impact~~the International Brotherhood of Electrical Workers ("IBEW") on behalf of its affiliated Local Union 464 expired on January 15, 2025. A new CBA with IBEW was ratified on June 24, 2025. The CBA at our ~~financial~~Covington, ~~condition~~Virginia Plant with the Covington Paperworkers Union Local 675, affiliated with the Association of Western Pulp and ~~results~~Paper Workers expired on December 1, 2025. The parties began contract renewal negotiations during the fourth quarter of ~~operations~~2025 and negotiations are in process. The parties will continue to operate under the same terms and conditions while negotiations are pending.

Additionally, several of our manufacturing facilities are leased. In the event we were to have a dispute with the landlord regarding the terms of the relevant lease agreements, or we were otherwise unable to fully access or utilize the leased property, the associated business disruption may be significant and may adversely affect our financial condition and results of operations.

Disruptions at any of our facilities could negatively impact our production, financial condition and results of operations.

Disruptions to any of our manufacturing operations or other facilities due to natural disasters and extreme weather, such as a hurricane, tropical storm, earthquake, tornado, severe weather, flood or fire, or other unanticipated problems such as labor difficulties, pandemics, equipment failure, cyberattacks or other cybersecurity incidents, capacity expansion difficulties or unscheduled maintenance, could cause operational disruptions of varied duration. Also, many of our production employees are governed by collective bargaining agreements (“CBAs”). The CBA at our Warrington, United Kingdom Advanced Polymer Technologies manufacturing facility with GMB Union is negotiated annually and the parties operate under the prior CBA until new terms are agreed. The CBA at our Covington, Virginia Performance Materials plant with the International Brotherhood of Electrical Workers on behalf of its affiliated Local Union 464 expired on January 15, 2025. The parties began negotiations in the fourth quarter of 2024 and will continue to operate under the same terms and conditions while negotiations are pending. The CBA at our Crossett, Arkansas Performance Chemicals manufacturing facility with the International Association of Machinists and Aerospace Workers Union ("IAM") expires on March 1, 2025. The parties will begin contract renewal negotiations during the first quarter of 2025. Further, the CBA at our Covington, Virginia Plant with the Covington Paperworkers Union Local 675, affiliated with the Association of Western Pulp and Paper Workers will expire on December 1, 2025. It is anticipated that the parties will begin contract renewal negotiations during the fourth quarter of 2025.

While the Company has generally positive relations with its labor unions, there is no guarantee the Company will be able to successfully negotiate new union contracts without work stoppages, labor difficulties or unfavorable terms. In addition, existing CBAs may not prevent a strike or work stoppage at the applicable plant.

These types of disruptions could materially adversely affect our financial condition and results of operations to varying degrees depending upon the ~~facility~~plant, the duration of the disruption, and our ability to shift business to another ~~facility~~plant or find alternative sources of manufacturing capacity. Any losses due to these events may not be covered by our existing insurance policies or may be subject to certain deductibles. In certain cases, we have products, such as our extruded honeycomb, caprolactone, pavement preservation products, road construction products, pavement reconstruction and recycling products, ~~and industrial specialties products,~~ that are only made at a single site, such as our ~~Covington~~Waynesboro, ~~Virginia~~Georgia Performance Materials plant, North Charleston Performance Chemicals plant and Warrington, U.K. APT plant. While we have some redundancies within the ~~facilities~~plants that are the sole manufacturer of certain products, we have limited ability to make these products at other ~~facilities~~plants.

Supply Chain Risks

We purchase a variety of raw materials, which are subject to pricing pressures and limited availability; inability to procure these raw materials or to pass on price increases could negatively impact our operations or financial results.

The Company purchases a variety of raw materials from third parties for its manufacturing operations, including, but not limited to, ~~CTO,~~ hardwood sawdust, phosphoric acid, ethylene amines, ~~black~~tall ~~liquor~~oil fatty acid ("TOFA"), lignin, maleic/fumaric acid, hydrogen peroxide, cyclohexanone, and ethoxylates. Each raw material is subject to its own supply and demand dynamics which may, at times, limit availability and/or cause price volatility. The Company may be unable to procure the quantities of raw materials it needs which could negatively impact our operations or we may be unable to pass through price increases to our customers which could negatively impact our financial results. For example, ~~our Performance Chemicals segment produces many products derived from CTO and~~ lignin, ~~which are co-products of the kraft pulping process. While we have taken aggressive action to limit the Company’s exposure to the volatility of the CTO market, its limited availability~~ and ~~competing~~TOFA ~~demands for its use could again impact our financial results and results of operations if we~~ are ~~unable to source a sufficient supply at a reasonable cost. Lignin is also~~ in limited supply and if we are unable to secure a sufficient amount of lignin or TOFA on a cost-effective basis we could suffer disruption to our ~~road~~pavement technologies product line, which could negatively impact our financial results and our results of operations.

Disruptions within our supply chain could negatively impact, our production, financial condition and results of operations.

We could be adversely affected by disruptions within our supply chain and transportation network. Our products are transported by truck, rail, barge or ship primarily by third-party providers. The costs of transporting our products could be negatively affected by factors outside of our control, including rail service interruptions or rate increases, extreme weather events, local hostilities, tariffs, rising fuel costs, and capacity constraints. For example, port strikes within the U.S. have adversely impacted, and could continue to adversely impact, the reliability and cost of our export shipments to customers. Significant delays or increased costs relating to transportation could materially affect our financial condition and results of operations. Disruptions at our suppliers could lead to volatility or increases in raw material or energy costs and/or reduced availability of materials or energy, potentially affecting our financial condition and results of operations.

International Operations Risks

We are exposed to the risks inherent in international sales and operations.

In 2025, sales to customers outside of the U.S. made up approximately 43 percent of our total sales, and we sell our products to customers in approximately 70 countries. We have exposure to risks of operating outside the U.S., including: fluctuations in foreign currency exchange rates, including the euro, pound sterling, Japanese yen, Brazilian Real, and Chinese renminbi; restrictions on, or difficulties and costs associated with, the repatriation of cash from foreign countries to the U.S.; difficulties and costs associated with complying with a wide variety of complex laws, treaties and regulations, which may carry

significant penalties for non-compliance including reputational harm, fines or shutdowns; unexpected changes in political or regulatory environments; earnings and cash flows that may be subject to tax withholding requirements or the imposition of tariffs, exchange controls or other restrictions; geopolitical and economic instability, including the wars in Ukraine and the Middle East and the potential escalation of these conflicts; general country strikes or work stoppages; unforeseen public health crises, such as pandemic and epidemic diseases; import and export restrictions; difficulties in maintaining overseas subsidiaries and international operations; difficulties in obtaining approval for significant transactions; government limitations on foreign ownership; government takeover or nationalization of business; and government mandated price controls.

Changes in tariff regimes could negatively impact our business.

The U.S. government has imposed new global tariffs, and is considering the imposition of additional tariffs. These new tariffs have resulted in (or could result in) retaliatory measures imposed, announced or under consideration by certain U.S. trading partners, most notably China. These changes to trade policy are expected to make it more difficult or costly for us to export our products and import raw materials. This in turn could require us to increase prices to our customers, which may reduce demand. Such demand reduction or inability to increase customer prices may negatively impact our profitability. The retaliatory tariff measures imposed by China, if not unwound, may significantly lower our margin on Performance Materials and Performance Chemicals products sold from the United States into China if we are unable to pass these costs onto our customers. These tariff measures may also result in decreased demand for our customers' products that incorporate our products, and adversely affect our financial condition and results of operations. Reciprocal tariffs from China and other trading partners could impact our competitive position compared to local competitors and other companies not subject to the same restrictions. As such, we could lose market position and our business, operating results, and financial condition would be adversely impacted.

Market Risks

Adverse conditions in the automotive market may negatively impact demand for our automotive carbon products.

Sales of our automotive activated carbon products are tied to global internal- combustion- engine (“"ICE”") and hybrid electric vehicle automobile (“"HEV”") production levels. ICE and HEV automotive production in the markets we serve can be affected by macro-economic and other outside factors such as interest rates, fuel prices, shifts in vehicle mix (including shifts toward alternative energy vehicles), consumer confidence, employment trends, regulatory and legislative oversight requirements, ~~and~~tariffs, trade agreements, microchip shortages, and disruptions to the operations of suppliers within the automotive original equipment manufacturer ("OEM") supply chain.

The Company’'s ~~road~~pavement technologies product line is heavily dependent on government infrastructure spending.

A significant portion of our customers’' revenues in our ~~road~~pavement technologies ~~business~~ is derived from contracts with various foreign and U.S. governmental agencies, and therefore, when government spending is reduced, our customers’' demand for our products is similarly reduced. While we do not do business directly with governmental agencies in our pavement technologies product line, our customers provide paving services to the governments of various jurisdictions within North America, South America, Europe, China, Brazil and India, and revenue either directly or indirectly attributable to such government spending continues to remain a significant portion of our revenues. Government business is, in general, subject to special risks and challenges, including: delays in funding and uncertainty regarding the allocation of funds to federal, state and local agencies; delays in spending or reductions in other state and local funding dedicated for transportation projects; other government budgetary constraints, cutbacks, delays or reallocation of government funding; long purchase cycles or approval processes; our customers’' competitive bidding and qualification requirements; changes in government policies and political agendas; and international conflicts or other military operations that could cause the temporary or permanent diversion of government funding from transportation or other infrastructure projects.

Certain of the Company’s products are sold into cyclical end-markets, such as the automotive market and the apparel market, which are impacted by changes in consumer and industrial demand.

Certain of our products are sold into end-markets that are cyclical and subject to frequent and rapid technology changes, changes in consumer preferences, evolving standards, and changes in product supply and demand. For example, demand for our Advanced Polymer Technologies products in the automotive market, where our products are formulated into automotive resins and coatings and various components, may be affected by technological advances, changing automotive original equipment manufacturer ("OEM") specifications, and global automobile production levels. Demand for our Advanced Polymer Technologies products which are sold into automotive applications, footwear adhesives and structural support, may be affected by consumer discretionary spending and changes in consumer preferences. Additionally, sales of our industrial specialties and Advanced Polymer Technologies products have, and may continue to be, negatively impacted due to reduced global industrial demand. The impact of these changes may lead to increased competition from competing and substitute products and downward pricing pressures on our customers, and therefore, on our Advanced Polymer Technologies and industrial specialties product offerings.

We face competition from new technologies and new or emerging competitors.

Our industries and the end-use markets into which we sell our products experience periodic technological change and product innovation. Our future growth depends on our ability to gauge the direction of commercial and technological progress in key end-use markets, to swiftly identify and respond to disruptive technologies, and to fund and successfully develop, manufacture, and market products in such changing end-use markets. If we fail to keep pace with the evolving or disruptive technological innovations in our end-use markets on a competitive basis, our financial condition and results of operations could be adversely affected.

~~technological~~In ~~innovations~~the inPerformance Materials segment, there is competition from other activated carbon and honeycomb manufacturers. These competitors are trying to develop more advanced and alternative activated carbon products that could more effectively compete with our ~~end~~products in automotive applications. There is also competition in automotive applications from non-activated carbon competitors and product offerings. For example, multiple OEMs are using sealed tanks in certain subsets of their vehicles to comply with the strict emission regulations (i.e., Tier 3/LEV III) in the U.S. While sealed tank fuel systems generally require an increased sized pelleted activated carbon canister to deal with refueling emissions, in most cases, they do not use ~~markets~~an onextruded honeycomb to meet current U.S. and California regulations. If a competitor were to succeed in developing products that are better suited than ours for automotive evaporative emissions capture applications and/or a competitive ~~basis~~technology, ~~our~~such ~~financial~~as, ~~condition~~but ~~and~~not ~~results~~limited ofto, ~~operations~~sealed gas tanks, our financial results could be ~~adversely~~negatively ~~affected~~impacted.

In the Performance Materials segment, there is competition from other activated carbon manufacturers. These competitors are trying to develop more advanced and alternative activated carbon products that could more effectively compete with our products in automotive applications. There is also competition in automotive applications from non-activated carbon competitors and product offerings. For example, multiple OEMs are using sealed tanks in certain subsets of their vehicles to comply with the strict emission regulations (i.e., Tier 3/LEV III) in the U.S. While sealed tank fuel systems generally require an increased sized pelleted activated carbon canister to deal with refueling emissions, in most cases, they do not use an extruded honeycomb to meet current U.S. and California regulations. There is also emerging competition in the "honeycomb" space, which may impact sales of the Company's products. If a competitor were to succeed in developing products that are better suited than ours for automotive evaporative emissions capture applications and/or a competitive technology, such as, but not limited to, sealed gas tanks, our financial results could be negatively impacted.

In addition, the adoption of electric and hydrogen fuel cell vehicles is increasing in the U.S. and other parts of the world. Consumer demand for these alternative-fueled vehicles is expected to continue to increase significantly in future years as certain states and international governments implement limits on the sale of vehicles with ICE with various time lines to phase out sales of ICE vehicles. A reduction in the sales of vehicles with internal combustion engines would reduce demand for our activated carbon automotive products. Our long-term strategy is to grow our sales of products for applications in all-electric and hydrogen fuel cell vehicles to off-set the expected decline in activated carbon sales for ICE. If we are unable to develop products for all-electric and hydrogen fuel cell vehicles or grow sales fast enough, our business and results of operations could be adversely impacted. The process of designing and developing new technology and related products is complex, costly, and uncertain and may require us to retain and recruit talent in areas of expertise outside of our current core competencies. There can be no assurance that such advances in technology will be feasible or successful, or will occur in a timely and efficient manner.

In the Advanced Polymer Technologies segment, there is competition from other caprolactone manufacturers, including new market entrants. IfThis weincreased ~~are~~competition ~~unable to successfully compete~~ in our end-use markets, has impacted and may continue to impact, our financial condition and results of operations ~~could be adversely affected~~.

Certain of our products face competition from substitute products where the costs of different raw material inputs can impact the price competitiveness of our products and negatively impact our sales and/or profits as we respond to substitute product competition.

The price of gum rosin has a significant impact on the market price for TOR and rosin derivatives and is driven by labor rates for harvesting, land leasing costs, and various other factors that are not within our control. Hydrocarbon resins, for example, C5 resins, are co-products from the manufacture of isoprene (synthetic rubber). Availability and pricing are determined by the supply/demand dynamics for synthetic rubber as well as the price of crude oil as the feedstock for isoprene and various other factors that are not within our control. Animal and plant based fatty acids compete with TOFA products in industrial specialties. The market price for our TOFA and oleochemical products are impacted by the prices of other fats and oils, and the prices for other fats and oils are driven by actual and expected harvest rates, petroleum oil prices, and the biofuel market. Other monomers, thermoplastics, and polyols compete with our caprolactone-based products. The price for our products is impacted by the prices of competitive substitutes which are influenced by oil prices as well as other supply and demand factors. We may not be able to pass through raw material cost increases, or we may lose market share if we do not effectively manage our pricing, which in either case could negatively impact our financial results.

~~Additionally,~~Certain ~~the price~~ of ~~energy~~the ~~may~~Company's ~~directly or indirectly impact demand, pricing or profitability for certain of our~~ products. Asare ~~petroleum~~sold ~~oil~~into ~~prices~~cyclical ~~can change rapidly~~end-markets, ~~Performance~~such ~~Chemical~~as ~~segment~~the ~~products~~automotive ~~may~~market beand ~~disadvantaged due to~~ the ~~fact~~apparel ~~that CTO is a thinly traded commodity with pricing commonly established for periods ranging from one quarter to one-year periods of time. Due to this~~market, ~~alternative technologies~~ which ~~compete~~are ~~with~~impacted ~~product offerings provided~~ by ~~Ingevity~~changes ~~may be advantaged from time to time~~ in ~~the~~consumer ~~marketplace.~~and ~~Protracted~~industrial ~~periods of high volatility or sustained oversupply of petroleum oil may also translate into increased competition from petroleum-based alternatives~~demand. ~~In addition, pricing for competing oleochemicals such as palm or soybean is likely to put further pressure on pricing of the Company’s products during periods of depressed petroleum prices.~~

17Certain of our products are sold into end-markets that are cyclical and subject to frequent and rapid technology changes, changes in consumer preferences, evolving standards, and changes in product supply and demand. For example, demand for our Advanced Polymer Technologies products in the automotive market, where our products are formulated into automotive resins and coatings and various components, may be affected by technological advances, changing OEM specifications, and global automobile production levels. Demand for our Advanced Polymer Technologies products which are sold into automotive applications, footwear adhesives and structural support, may be affected by consumer discretionary spending and changes in consumer preferences. Additionally, sales of our Advanced Polymer Technologies products have, and may continue to be, negatively impacted due to reduced global industrial demand. The impact of these changes may lead to increased competition from competing and substitute products and downward pricing pressures on our customers, and therefore, on our Advanced Polymer Technologies product offerings.

We are dependent on certain large customers.

We have certain large customers in particular businesses, the loss of which could have a material adverse effect on the applicable segment’'s sales and, depending on the significance of the loss, our results of operations, financial condition or cash flows. Sales to the Company’'s ten largest customers (across all three segments) accounted for 3841 percent of total sales for ~~2024~~2025. No customer accounted for more than 10 percent of total sales for ~~2024~~2025. With some exceptions, our business with those large customers is based primarily upon individual purchase orders. As such, our customers could cease buying our products from us at any time, for any reason, with little or no recourse. If a major customer or multiple smaller customers elected not to purchase products from us, our financial condition and results of operations could be materially adversely affected.

at any time, for any reason, with little or no recourse. If a major customer or multiple smaller customers elected not to purchase products from us, our financial condition and results of operations could be materially adversely affected.

We are dependent on attracting and retaining key personnel.

We are dependent upon our production workers, as well as upon engineering, technical, sales, and application specialists, together with experienced industry professionals and senior management. Our success depends, in part, on our ability to attract, retain and motivate key talent. Our failure to attract and retain individuals making significant contributions to our business could adversely affect our financial condition and results of operations.

The inability to make or effectively integrate future acquisitions may negatively affect our results.

As part of our growth strategy, we may pursue acquisitions of businesses and product lines or invest in joint ventures. The ability to grow through acquisitions or other investments depends upon our ability to identify, negotiate, finance, complete, and integrate suitable acquisitions or joint venture arrangements. There can be no assurances that we will be able to integrate these acquisitions in an efficient and cost-effective manner or that these acquisitions or joint ventures will generate the expected value.

Acquisitions and other investments may expose us to liability from the target company and/or joint venture partner. Acquisition and investment target companies may be or may become involved in disputes regarding intellectual property and other aspects of their businesses or may be subject to liabilities that are unknown at the time of the transaction, including liabilities under environmental or tax laws. Depending on the nature of our investment and/or structure of an acquisition, we may take on or be exposed to such liability, which could materially impact our business, financial condition, or results of operations.

As we rely on information technologies to conduct our business, cyber-attacks, data and privacy breaches, or a failure of information technology systems could disrupt our operations and expose us to liability, which could cause our business and reputation to suffer.

We rely on our information technology systems, some of which are managed by third parties, to support, manage and maintain the day-to-day operations and activities of our business, including our manufacturing ~~facilities~~plants, customer and vendor transactions, and financial, accounting, and business records. In addition, we collect and store certain data, including proprietary business information, and may have access to confidential or personal information that is subject to privacy and security laws and regulations.

The secure processing, storage, and transmission of sensitive, confidential, and personal data is critical to our operations and business strategy. We have instituted a system of security policies, procedures, capabilities, internal controls and audits aligned with our ISO 27001 certification, designed to protect this information. Additionally, we engage third-party threat detection, penetration testing, and monitoring services which includes a global cybersecurity incident response team. Despite our security architecture and controls, and those of our third-party providers, we may be vulnerable to cyber-attacks, computer viruses, security breaches, ransomware attacks, inadvertent or intentional employee actions, system failures, and other risks that could potentially lead to the compromising of sensitive, confidential or personal data, improper use of our, or our third-party provider systems, solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, and operational disruptions. Further, the widespread availability, adoption and rapid evolution of artificial intelligence ("AI") technologies may increase our cybersecurity risk, including the use of generative artificial intelligence to augment existing or to create new malware, and additional vulnerabilities may be introduced from the use of artificial intelligence by our customers or third parties. We also maintain an information security risk insurance policy to help mitigate the financial consequences of these risks, however, there is no guarantee that such a policy will be sufficient to address such costs. In addition, the global regulatory environment pertaining to information security and privacy is increasingly complex, with new and changing requirements, such as the European Union’'s General Data Protection Regulation (“"GDPR”"), California Consumer Privacy Act (“"CCPA”"), and the China Cybersecurity Law and Personal Information Protection Law. GDPR, which applies to the collection, use, retention, security, processing, and transfer of personally identifiable information of residents of EU countries, mandates new compliance obligations and imposes significant fines and sanctions for violations. CCPA requires companies to provide new data disclosure, access, deletion, and opt-out rights to consumers in California. Implementing and complying with these laws and regulations may be more costly or take longer than we anticipate, or could otherwise affect our business operations. Information security breaches, cyber incidents, and disruptions, or failure to comply with laws and regulations related to information security or privacy, could result in legal claims or proceedings against us by governmental entities or individuals, significant fines, penalties or judgements, disruption of our operations, remediation requirements, changes to our business practices, and damage to our reputation, which could adversely affect our business, financial condition or results of operations.

companies to provide new data disclosure, access, deletion, and opt-out rights to consumers in California. Implementing and complying with these laws and regulations may be more costly or take longer than we anticipate, or could otherwise affect our business operations. Information security breaches, cyber incidents, and disruptions, or failure to comply with laws and regulations related to information security or privacy, could result in legal claims or proceedings against us by governmental entities or individuals, significant fines, penalties or judgements, disruption of our operations, remediation requirements, changes to our business practices, and damage to our reputation, which could adversely affect our business, financial condition or results of operations.

International Operations Risks

We are exposed to the risks inherent in international sales and operations.

In 2024, sales to customers outside of the U.S. made up approximately 42 percent of our total sales, and we sell our products to customers in approximately 70 countries. We have exposure to risks of operating outside the U.S., including: fluctuations in foreign currency exchange rates, including the euro, pound sterling, Japanese yen, Brazilian Real, and Chinese renminbi; restrictions on, or difficulties and costs associated with, the repatriation of cash from foreign countries to the U.S.; difficulties and costs associated with complying with a wide variety of complex laws, treaties and regulations, which may carry significant penalties for non-compliance; unexpected changes in political or regulatory environments; earnings and cash flows that may be subject to tax withholding requirements or the imposition of tariffs, exchange controls or other restrictions; geopolitical and economic instability, including the wars in Ukraine and the Middle East; general country strikes or work stoppages; unforeseen public health crises, such as pandemic and epidemic diseases; import and export restrictions; difficulties in maintaining overseas subsidiaries and international operations; difficulties in obtaining approval for significant transactions; government limitations on foreign ownership; government takeover or nationalization of business; and government mandated price controls.

Tariffs and other trade barriers or retaliatory actions could also negatively impact our business. For example, the new U.S. administration has increased the tariff on Chinese products to 10 percent and has imposed, or is considering imposing, tariffs on products from other countries. Whether and to what extent these tariffs will be imposed is presently unknown, however such tariffs (and any retaliatory action taken as a result) could lead to increased costs, which could cause decreased customer demand for our products as well as our customers’ products that incorporate our products due to increased pricing, and adversely affect our financial condition and results of operations.

Any one or more of the above factors could adversely affect our international operations and could significantly affect our financial condition and results of operations. For example, Chinese government agencies have in the past required companies to reduce or suspend manufacturing operations from time to time, with little or no notice, for reasons such as energy restrictions and air quality concerns. The timing and length of these suspensions, which are expected to continue occurring, are difficult to predict. These unpredictable events could negatively impact our results of operations and cash flows. Further, any of these factors may impact our customers’ non-U.S. operations, which could reduce demand for our products. As our international operations and activities expand, we inevitably have greater exposure to the risks associated with operating in many foreign countries.

Legal and Regulatory Risks

From time to time, we may be engaged in legal actions associated with our intellectual property rights; if we are unsuccessful, these could potentially result in an adverse effect on our financial condition and results of operations.

Intellectual property rights, including patents, trade secrets, confidential information, trademarks, trade names, and trade dress, are important to our business. See “"Intellectual Property”" included within Part I. Item 1 of this Form 10-K for more information on the 844 Patent. We endeavor to protect our intellectual property rights in key jurisdictions in which our products are produced or used, in jurisdictions into which our products are imported, and in jurisdictions where our competitors have significant manufacturing capabilities. Our success will depend to a significant degree upon our ability to protect and preserve our intellectual property rights. However, we may be unable to obtain or maintain protection for our intellectual property in key jurisdictions and the Company’'s patents and other intellectual property may not prevent competitors from independently developing or selling similar or duplicative products and services. Although we own and have applied for numerous patents and trademarks throughout the world, we may have to rely on judicial enforcement of our patents and other proprietary rights. Our patents and other intellectual property rights may be challenged, invalidated, circumvented, and rendered unenforceable or otherwise compromised. We are currently involved in ~~several~~a legal ~~actions~~action related to the intellectual property associated with the 844 Patent. On September 15, 2021, a jury in the lawsuit filed by the Company against BASF Corporation for patent infringement in the U.S. District Court for the District of Delaware (the "Delaware Proceeding") issued a verdict in favor of BASF on certain counterclaims filed by BASF in the Delaware Proceeding. The jury awarded BASF damages of approximately $28.3 million, which will be trebled under U.S. antitrust law to approximately $85.0 million when the court enters judgment. On May 18, 2023, the court in the Delaware Proceeding entered judgment on the jury's verdict, which commenced the post-trial briefing stage. On February 13, 2024, the court in the Delaware Proceeding denied BASF's motion for pre-judgment interest on its tortious interference claim as well as our motion seeking judgment as a matter of law, or a new trial in the alternative. Earlier in the Delaware Proceeding, the U.S. District Court dismissed the Company's patent infringement claims against BASF alleging BASF infringed the 844 Patent and invalidated some, but not all, of the claims in our 844 patent, which expired in March 2022.

On March 13, 2024, we appealed the verdict as well as the U.S. District Court's November 2020 dismissal of our patent infringement claims against BASF to the U.S. Federal Circuit Court of Appeals. On February 11, 2026, the U.S. Federal Circuit Court of Appeals ruled against Ingevity on our appeal and we have decided to no longer pursue any further appeals. We expect payment of the judgment, plus post-judgment interest, to be made in the second quarter of 2026. The Company continues to accrue a total of $85.0 million, the full amount of the jury's verdict (including treble damages). The amount accrued for this matter is included within Accrued expenses on the consolidated balance sheets as of December 31, 2025, and the charge was included within Other (income) expense, net on the consolidated statement of operations for the twelve months ended December 31, 2021. In addition, as a result of the judgment being officially entered on May 18, 2023, we have started accruing for post-judgment interest at the legally mandated interest rate. As of December 31, 2025 and 2024, the total amount accrued, inclusive of post-judgement interest, was $95.4 million and $91.4 million, respectively. The amount of any liability the Company may ultimately incur related to the Delaware Proceeding could be more or less than the amount accrued. BASF has indicated it will seek attorneys' fees and costs in amounts that they will allege and have to demonstrate at a future date. The Company has and may continue to incur additional fees, costs and expenses for as long as the post-trial motions are ongoing. If the Company is required to pay any associated fees, costs, and expenses, such outcomes could have an adverse effect on the Company's business, financial condition, and operating results.

The Delaware Proceeding and other legal actions to protect, defend or enforce our intellectual property rights could result in significant costs and diversion of our resources and our management's attention, and we may not prevail in any such other actions, which could have an adverse effect on our financial condition and results of operations. Similarly, third parties may assert claims against us and our customers and distributors alleging our products infringe upon third-party intellectual property rights. If the Company is found to infringe any third-party rights, it could be required to pay substantial damages, or it could be enjoined from offering some of its products and services.

We also rely heavily upon unpatented proprietary technology, know-how, and other trade secrets to maintain our competitive position. While we maintain policies to enter into confidentiality agreements with our employees and third parties to protect our proprietary expertise and other trade secrets, these agreements may not be enforceable or, even if legally enforceable, we may not have adequate remedies for breaches of such agreements. We also may not be able to readily detect breaches of such agreements. For instance, we manufacture some of our products in China where we may be at a greater risk of a third party misappropriating our intellectual property despite the foregoing policies, procedures and agreements. The failure of

~~the~~our ~~844~~patents ~~Patent.~~or Onconfidentiality ~~September~~agreements 15, 2021, a jury in the lawsuit filed by the Company against BASF Corporation for patent infringement in the U.S. District Court for the District of Delaware (the “Delaware Proceeding”) issued a verdict in favor of BASF on certain counterclaims filed by BASF in the Delaware Proceeding. The jury awarded BASF damages of approximately $28.3 million, which will be trebled under U.S. antitrust law to ~~approximately~~protect ~~$85.0~~our ~~million~~proprietary ~~when the court enters judgment. On May 18~~technology, ~~2023, the court in the Delaware Proceeding entered judgment on the jury’s verdict, which commenced the post~~know-~~trial~~how briefing stage. On February 13, 2024, the court in the Delaware Proceeding denied BASF’s motion for pre-judgment interest on its tortious interference claim as well as our motion seeking judgment as a matter of law, or atrade ~~new~~secrets ~~trial~~could inresult ~~the alternative. In addition, BASF may seek post-judgment interest and attorneys’ fees and costs~~ in ~~amounts~~significantly ~~that~~lower ~~they will have to prove at a future date. Earlier in the Delaware Proceeding~~revenues, ~~the~~reduced ~~U.S.~~profit ~~District Court dismissed the Company’s patent infringement claims against BASF alleging BASF infringed the 844 Patent and invalidated some~~margins, ~~but~~or ~~not~~loss ~~all,~~ of ~~the~~market ~~claims in our 844 patent, which expired in March 2022~~share.

The Company disagrees with the verdict, including the court’s application of the law and entry of judgment. Therefore, on March 13, 2024, we appealed the verdict as well as the U.S. District Court’s November 2020 dismissal of our patent infringement claims against BASF. As of December 31, 2024, the final resolution of these matters could take up to 15 months and there can be no assurance that the Company will prevail in its attempts to challenge the verdict. Because the outcome of the Company’s post-trial motions and possible appeal is difficult to predict, as of December 31, 2024, the Company has accrued a total of $85.0 million, the full amount of the jury’s verdict (including treble damages). The amount accrued for this matter is included within Other liabilities on the consolidated balance sheet as of December 31, 2024, and the charge is included within Other (income) expense, net on the consolidated statement of operations for the twelve months ended December 31, 2021. In addition, as a result of the judgment being officially entered on May 18, 2023, we have started accruing for post-judgment interest at the legally mandated interest rate. As of December 31, 2024 and 2023, the total amount accrued, inclusive of post-judgement interest, was $91.4 million and $87.4 million, respectively. The amount of any liability the Company may ultimately incur related to the Delaware Proceeding could be more or less than the amount accrued. The Company has and may continue to incur additional fees, costs and expenses for as long as the post-trial motions and possible appeal are ongoing. If the Company is required to pay the entire jury verdict (together with any associated fees, costs, and expenses), or the Company must make certain changes to its business when the matters associated with the Delaware Proceeding are eventually resolved, such outcomes could have an adverse effect on the Company’s business, financial condition, and operating results.

The Delaware Proceeding and other legal actions to protect, defend or enforce our intellectual property rights could result in significant costs and diversion of our resources and our management’s attention, and we may not prevail in any such suits or proceedings, which could have an adverse effect on our financial condition and results of operations. Similarly, third parties may assert claims against us and our customers and distributors alleging our products infringe upon third-party intellectual property rights. If the Company is found to infringe any third-party rights, it could be required to pay substantial damages, or it could be enjoined from offering some of its products and services.

Environmental and Sustainability Risks

Certain elements of our strategic growth are dependent on the adoption of more stringent air quality standards around the world.

Environmental standards drive the implementation of gasoline vapor emission control systems by automotive manufacturers. Given increasing societal concern over global warming and health hazards associated with poor air quality, there is growing pressure on regulators across the globe to take meaningful action. For those countries that have not significantly regulated gasoline vapor emissions, enacting more stringent regulations governing gasoline vapor emissions represents a significant upside to our Performance Materials’' automotive carbon business. However, regulators may react to a variety of considerations, including economic and political, that may result in any such more stringent regulations being delayed or shelved entirely, in one or more countries or regions. As the adoption of more stringent regulations governing gasoline vapor emissions is expected to drive significant growth in our automotive carbon applications, the failure to enact such regulations would have a negative impact on the growth prospects for these products.

shelved entirely, in one or more countries or regions. As the adoption of more stringent regulations governing gasoline vapor emissions is expected to drive significant growth in our automotive carbon applications, the failure to enact such regulations would have a negative impact on the growth prospects for these products.

Our business involves hazards associated with chemical manufacturing, storage, transportation and disposal; the legal and regulatory environment related to such chemicals could require expenditures or changes to our product formulations and operations.

There are hazards associated with the chemicals we manufacture and the related storage and transportation of our raw materials, including common solvents, such as toluene and methanol, and reactive chemicals, such as acrylic acid, all of which fall under the OSHA Process Safety Management Code. These hazards could lead to an interruption or suspension of operations and have an adverse effect on the productivity and profitability of a particular manufacturing ~~facility~~plant or on us as a whole. While we endeavor to provide adequate protection for the safe handling of these materials, issues could be created by various events, including natural disasters, severe weather events, acts of sabotage and performance by third parties, and as a result we could face potential hazards, including the following: piping and storage tank leaks and ruptures; mechanical failure; employee exposure to hazardous substances; and chemical spills and other discharges or releases of toxic or hazardous substances or gases. These hazards may cause personal injury and loss of life, damage to property, and contamination of the environment, which could lead to government fines, work stoppage injunctions, lawsuits by injured persons, damage to our public reputation and brand, and diminished product acceptance. While we have insurance coverage intended to assist with any financial impacts, the financial resources of the Company could be impacted. If such actions are determined adversely to us, or there is an associated economic impact on our business, we may have inadequate insurance or cash flow to offset any associated costs.

Our operations are subject to a wide range of general and industry-specific environmental laws and regulations; changes to this legal and regulatory landscape could limit our business activities and increase our operating costs.

Our operations are subject to a wide range of general and industry-specific environmental laws and regulations. Certain regulations applicable to our operations, including the OSHA and the TSCA in the U.S. and the REACH directive in Europe, the United Kingdom and other countries, prescribe limits restricting exposure to several chemicals used in our operations, including certain forms of formaldehyde, a raw material used in the manufacture of some lignin-based dispersants. Future studies on the health effects of chemicals used in our operations may result in additional regulation or new requirements, which might further restrict or prohibit the use of, and exposure to, these chemicals. Additional regulation of or requirements for such chemicals could require us to change our operations, and these changes could affect the quality or types of products we manufacture and/or materially increase our costs.

Increased focus by governmental entities on environmental issues and sustainability have resulted in a complex landscape of new or increased regulations. Changes in environmental laws and regulations, or their application, could subject Ingevity to significant additional capital expenditures and operating expenses. Additionally, changes in the regulation of greenhouse gases, as well as future climate change laws and regulations, depending on their nature and scope, could subject our operations to significant additional costs or limits on operations. Our manufacturing ~~facilities~~plants use energy, including electricity and natural gas and some of our plants emit amounts of greenhouse gasses that may in the future be affected by legislative and regulatory efforts to limit greenhouse gas emissions. Potential consequences could include increased energy, transportation, and raw material costs and may require us to make additional investments in ~~facilities~~plants and equipment or limit our ability to grow. Any such changes are uncertain and, therefore, it is not possible for Ingevity to predict with certainty the amount of additional capital expenditures or operating expenses that could be necessary for compliance with respect to any such changes.

such changes are uncertain and, therefore, it is not possible for Ingevity to predict with certainty the amount of additional capital expenditures or operating expenses that could be necessary for compliance with respect to any such changes.

Independent of any such regulation, increased public awareness and adverse publicity about potential impacts on climate change or environmental harm from us or our industry could harm our reputation or otherwise impact Ingevity adversely. In recent years, some investors have also begun to show increased interest about sustainability and climate change as it relates to their investment decisions. We have set targets for greenhouse gas emissions and related sustainability goals. There can be no assurance that we will meet these targets and goals. If we fail to achieve our sustainability goals or reduce our impact on the environment or if we are unable to respond or are perceived to be inadequately responding to sustainability concerns, we may receive adverse publicity, and certain investors may divert from, or avoid investing in, our securities, which could have a negative impact on our business and reputation.

Adverse weather conditions and other environmental impacts (such as climate change and extreme weather) may impact our operations and the demand for some of our products, which could negatively affect our financial condition and results of operations.

Our ~~road~~pavement technologies and road markings product ~~line~~lines isare seasonal in nature, with roughly 70 to 75 percent of revenue generated between April and September each year. Adverse weather conditions, which directly affect the ability to engage in paving and/or road marking activity, have had, and going forward may have, an adverse effect on sales in the ~~road~~pavement technologies and road markings product ~~line~~lines if such conditions result in lower customer demand due to a shortened season.

Increasing weather-related impacts on our operations and plant sites may impact the cost or availability of insurance. Furthermore, the potential impact of climate change and related regulations on our suppliers and customers is highly uncertain and there can be no assurance that it will not have an adverse effect on the availability over time of our suppliers’' and customers’' businesses, and on our financial condition and results of operations.

Financial and Economic Risks

We may be adversely affected by general global economic and financial conditions beyond our control.

Our businesses may be affected by a number of factors that are beyond our control such as general economic and business conditions, changes in tax laws, or tax rates and conditions in the financial services markets including counterparty risk, insurance carrier risk, rising interest rates, inflation, deflation, fluctuations in currencies, which factors may negatively impact our ability to compete. Macroeconomic challenges, including conditions in financial and capital markets and levels of unemployment, and the ability of the U.S. and other countries to deal with their rising debt levels, may continue to put pressure on the economy or lead to changes in tax laws or tax rates. There can be no assurance that changes in tax laws or tax rates will not have a material impact on our future cash taxes, effective tax rate, or deferred tax assets and liabilities. Adverse developments in global or regional economies could drive an increase or decrease in the demand for our products that could increase or decrease our revenues, increase or decrease our manufacturing costs, and ultimately increase or decrease our results of operations, financial condition and cash flows. As a result of negative changes in the economy, customers, vendors, or counterparties may experience significant cash flow problems or cause consumers of our products to postpone or refrain from spending in response to adverse economic events or conditions. If customers are not successful in generating sufficient revenue or cash flows or are precluded from securing financing, they may not be able to pay or may delay payment of accounts receivable that are owed to us or we may experience lower sales volumes. Our financial condition and results of operations could be materially and adversely affected by any of the foregoing.

Inflation could result in an adverse impact on our results of operations.

We are affected by general global economic and financial conditions that are beyond our control, including inflation and significant spikes in energy costs. We attempt to reduce our inflation risk and mitigate the effects of other adverse economic and financial conditions by passing on price increases where appropriate to our customers. A significant portion of our business with our customers is purchase order based, which allows us to increase prices in response to inflation and other market conditions. However, to the extent our customers are under fixed-price contracts with limited or no price adjustment mechanisms, we are unable to mitigate the impact of inflation by passing on price increases through to our customers, and we could experience an adverse impact on our results of operations as a result.

~~Challenges in the commercial and credit environment may materially adversely affect Ingevity’s future access to capital.~~21

Challenges in the commercial and credit environment may materially adversely affect Ingevity's future access to capital.

We have, at times, relied on various forms of credit to satisfy working capital needs. Our ability to issue debt or enter into other financing arrangements on acceptable terms could be materially adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers or if other significantly unfavorable changes in economic conditions occur. Volatility in the world financial markets could increase borrowing costs or affect our ability to gain access to the capital markets, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and cash flows.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

At Ingevity, we ~~recognize~~understand ~~the~~that ~~paramount~~strong ~~importance~~cybersecurity ofis ~~cybersecurity~~essential into ~~safeguarding~~protecting sensitive information and maintaining trust. WeOur ~~align~~program ~~with~~is grounded in industry-recognized standards, including the ISO  27001 information security framework, for which we ~~became~~achieved ~~certified~~certification in 2024. Our ~~comprehensive~~diverse cybersecurity ~~program is led by a~~ team ofuses ~~diverse,~~advanced ~~highly skilled professionals, and we invest in modern~~ technologies, including ~~artificial~~AI ~~intelligence~~ and machine learning, to ~~fortify~~enhance and continuously refine our defenses. We ~~actively~~also collaborate closely with local, state, and federal agencies, as well as peers inacross the chemical manufacturing ~~industry~~sector, to ~~identify~~stay ~~the~~ahead ~~latest~~of emerging threats and implement effective ~~defenses~~measures that safeguard our employees, customers, and ~~customers~~operations.

Key Components of Our Cybersecurity Program:

Leadership and Governance. We ~~have~~maintain a highly skilled team of ~~skilled~~ internal and external cybersecurity professionals, led by our Vice President of Information Technology, Chief Information Officer, and Chief Information Security Officer ("~~CIO~~VP of IT"), who ~~has~~brings ~~over~~more than three decades of experience in information security and information technology ~~infrastructure~~. Our cybersecurity team ~~has~~holds ~~experience~~deep inexpertise ~~information~~across the security domain and ~~information~~maintains ~~technology~~a ~~infrastructure~~range ~~and~~of ~~holds several~~ advanced ~~and~~industry ~~expert licenses and~~ certifications, including ~~International~~ISA/IEC ~~Society of Automation~~ 62443, Cybersecurity Expert, ~~and International Information System Security Certification Consortium~~ (~~ISC2~~"ISC")² certifications, Certified Information Security Manager ("CISM"), and Certified Information Systems Security Professional ("CISSP"). Beginning in 2025, the Sustainability & Safety Committee of our Board of Directors (“the Board”) has oversight of our cybersecurity and risk management programs. Prior to that, the full Board exercised oversight of cybersecurity risk management. The Board moved oversight of cybersecurity risk management into the Sustainability & Safety Committee to allow for more in-depth reviews. The Sustainability & Safety Committee receives at least quarterly updates from the CIO on cybersecurity matters and our related risk management program, and periodic updates from external cybersecurity experts on the overall risk landscape. Our full Board of Directors also receives an update at least once a year on these matters in addition to regular reporting from the Sustainability & Safety Committee on matters reviewed. We have implemented processes for continual monitoring of our information systems, including the deployment of advanced security measures and system audits to identify potential vulnerabilities. If a cybersecurity incident were to occur, we have developed and documented an incident response plan that includes immediate actions to mitigate the impact and long-term strategies for remediation and prevention of future incidents. Additionally, our CIO regularly meets with our executive management leadership team to provide updates on our cybersecurity risks and incidents ensuring management is keenly aware of any potential threat.

~~Protection~~Beginning in 2025, the Sustainability & Safety Committee of ~~Sensitive~~our ~~Information.~~Board Weof ~~enforce~~Directors ~~collection,~~assumed ~~storage~~oversight of our cybersecurity and risk management programs, a responsibility previously held by the full Board. This shift enables more focused and ~~access~~in‑depth ~~controls~~review of ~~personal,~~cybersecurity ~~proprietary,~~matters. The Committee receives quarterly updates from the VP of IT and ~~confidential~~periodic ~~information~~briefings from external cybersecurity experts, ~~focusing~~while onthe ~~protecting~~full ~~trade~~Board ~~secrets,~~receives ~~intellectual~~at ~~property,~~least ~~clinical~~one ~~trial~~formal ~~data,~~update ~~third-party~~each ~~information,~~year ~~and~~supported ~~employee~~by ~~data~~regular Committee reporting.

~~Industry-Standard~~We ~~Frameworks~~continuously monitor our information systems with advanced security controls and ~~Policies~~routine audits to identify and address vulnerabilities. WeOur ~~incorporate~~incident ~~industry-standard~~response ~~frameworks~~plan provides immediate mitigation steps, ~~policies~~long‑term remediation, and ~~practices~~measures ~~such~~to asprevent ~~ISO~~recurrence. ~~27001~~The ~~which~~VP ~~are~~of ~~designed~~IT regularly briefs the executive leadership team to ~~protect~~ensure senior management stays informed of cybersecurity risks, incidents, and emerging threats. We also maintain strict controls over the ~~confidentiality~~collection, storage, and ~~privacy~~access of personal, proprietary, and confidential information, with a focus on protecting trade secrets, intellectual property, third‑party data, and employee information.

Industry-Standard Frameworks, Policies, and Protection ~~Mechanisms~~Measures. We ~~currently~~follow ~~adhere~~industry‑recognized topractices, including the ISO  27001 information security ~~framework~~standard, ~~and~~for ~~are~~which ~~advancing~~we ~~our~~earned ~~program having achieved ISO 27001~~ certification in 2024. WeOur ~~continuously~~program ~~monitor~~includes ~~our~~continuous ~~enterprise~~ network ~~and~~monitoring, ~~have~~preventive ~~deployed~~and detective ~~and preventative~~ controls., ~~In-depth~~and ~~third-party~~annual independent security assessments ~~are~~to ~~conducted~~help ~~annually.~~safeguard sensitive information.

Incident Response and Testing. We maintain a ~~robust~~comprehensive ~~cybersecurity~~ incident response plan ~~that~~supported ~~incorporates~~by regular simulations, ~~drills,~~ vulnerability scans, penetration ~~testing~~tests, and ~~third-party~~independent assessments to ~~evaluate~~continually ~~and~~strengthen ~~enhance~~ our cybersecurity controls and resilience.

Third-‑Party Monitoring. WeA ~~partner with a~~ managed security services provider ~~for~~monitors ~~24/7 monitoring of~~ our enterprise network 24/7. We also require third-‑party ~~service~~ providers with access to personal, confidential, or proprietary information to ~~implement and~~ maintain ~~comprehensive~~strong cybersecurity measures aligned with ~~applicable~~ legal ~~standards~~requirements and industry best practices.

Our proactive approach to cybersecurity involves the integration of leading technologies and collaboration with third-party experts to ensure alignment with industry standards. We believe these measures contribute to the protection of both our organization's and our clients' sensitive information.22

~~During~~Our proactive cybersecurity approach combines advanced technologies with collaboration from third‑party experts to maintain alignment with industry standards and strengthen the protection of sensitive information for both our organization and our customers. Over the past three years, ~~there~~we have ~~been~~not noexperienced ~~material~~any ~~impacts from~~ cybersecurity threats or ~~cybersecurity~~ incidents that have ~~materially~~had, ~~affected~~ or are reasonably likely to ~~materially~~have, ~~affect~~a ~~the~~material ~~Company’s~~effect on our business strategy, results of operations, or financial condition.

23However, despite our security architecture, controls, and those of our third‑party providers, we remain exposed to risks such as cyberattacks, ransomware, security breaches, system failures, the rapid evolution and increased adoption of AI and inadvertent or malicious employee actions. Any such event could materially impact our operations or financial performance.

or financial condition. Despite our security architecture and controls, and those of our third-party providers, we may be vulnerable to cyber-attacks, computer viruses, security breaches, ransomware attacks, inadvertent or intentional employee actions, system failures, and other risks that could materially impact our financial results and our results of operations.

ITEM 2. PROPERTIES

We are headquartered in North Charleston, South Carolina and operate manufacturing facilities in the U.S., United Kingdom, and the People's Republic of China and have business offices and warehouse and distribution facilities globally. The following locations represent the principal properties of Ingevity. We believe these facilities are adequate and suitable for our current operations, and that the production capacity of our facilities is sufficient to meet current demand. In the case of the properties identified as “"Leased,”" we nevertheless own the manufacturing facilities and equipment.

Location

Own / Lease

Functional Use

North Charleston, South Carolina

Own / Lease (1)

Corporate Headquarters;Application Labs;Performance Chemicals: Manufacturing

Covington, Virginia

Lease

Performance Materials: Manufacturing

Crossett, Arkansas

Lease (2)

Performance Chemicals: Manufacturing

Waynesboro, Georgia

Own (2)

Performance Materials: Manufacturing

DeRidder, Louisiana

Own (2)

Performance Chemicals: Manufacturing

Waynesboro, Georgia

Own (3)

Performance Materials: Manufacturing

Shanghai, People's Republic of China

Lease

Regional Headquarters; Application Lab

Wickliffe, Kentucky

Own (43)

Performance Materials: Manufacturing

Changshu, People’s Republic of China

Lease

Performance Materials: Manufacturing

Changshu, People's Republic of China

Lease

Performance Materials: Manufacturing

Warrington, United Kingdom

Lease

Advanced Polymer Technologies: Manufacturing, Application Lab

Zhuhai, People’s Republic of China

Lease

Performance Materials: Manufacturing, Application Lab

Zhuhai, People's Republic of China

Lease

Performance Materials: Manufacturing, Application Lab

Greenville, Alabama

Lease

Performance Chemicals: Manufacturing

Dayton, Nevada

Own

Performance Chemicals: Manufacturing

Childress, Texas

Own (54)

Performance Chemicals: Manufacturing

Marion, Indiana

Own

Performance Chemicals: Manufacturing

________________________

(1) Portions of the manufacturing operations are on leased land and our corporate headquarters building is leased.

(2) ~~All~~Certain ~~production~~manufacturing atassets ~~our~~are ~~DeRidder~~subject ~~and~~to ~~Crossett~~a ~~Plants~~finance ~~ceased~~lease ~~during~~with ~~2024.~~the WeDevelopment ~~continue~~Authority toof ~~lease~~Burke County (the ~~Crossett,~~county ~~Arkansas~~in ~~site~~which ~~and own the DeRidder~~Waynesboro, ~~Louisiana~~Georgia ~~site.~~is located).

(3) Certain manufacturing assets are subject to a finance lease ~~with the Development Authority of Burke County (the county in which Waynesboro, Georgia is located)~~.

(4) ~~Certain~~Portions of the manufacturing ~~assets~~operations are ~~subject~~on toleased ~~a finance lease~~land.

(5) Portions of the manufacturing operations are on leased land.

ITEM 3. LEGAL PROCEEDINGS

Information regarding certain of these matters is set forth in Note 1817 – Commitments and Contingencies to the Consolidated Financial Statements included within Part II. Item 8 of this Form 10-K.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

2423

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The executive officers of Ingevity Corporation, the offices they currently hold, their business experience over the past five years and their ages are as follows:

Name

Age (1)

Present Position and Business Experience

Luis Fernandez-Moreno

Interim President and Chief Executive Officer (2024-present); Senior Vice President of Ashland Inc. (2012-2017); President, Ashland Inc. Chemicals Group (2015-2017); President, Ashland Inc. Specialty Ingredients (2013-2015); and President, Ashland Water Technologies (2012-2013). Prior to that role, he held various senior-level positions of increasing responsibility with Rohm & Haas Company for 27 years.

David H. Li

Chief Executive Officer and President (2025-present); Chief Executive Officer, President of CMC Materials (formerly Cabot Microelectronics) (2015-2022); Vice President Asia Pacific Region at CMC Materials (2006-2015); Prior to that role, he held various senior-level positions of increasing responsibility with CMC Materials from 1997 through 2006.

Mary Dean Hall

6768

Executive Vice President and Chief Financial Officer (2021-present); Senior Vice President, Chief Financial Officer and Treasurer at Quaker Houghton (2015-2021); Vice President and Treasurer at Eastman Chemical Company (2009-2015); Prior to that role, she held various senior-level financial positions of increasing responsibility with Eastman from 1995 through 2009, including Treasurer, Vice President and Controller, and Vice President, Finance.

S. Edward Woodcock

Executive Vice President & President of Performance Materials (2015-present); Vice President of MeadWestvaco's Carbon Technologies business (2010-2015)

Ruth Castillo

Senior Vice President and President, Performance Materials (2025-present), Vice President, Global Chemicals at Avantor (2025); Vice President, Business Transformation at Avantor (2023-2025); Vice President, Supply Chain and Engineering at Avantor (2020-2023); Vice President Global Product Management at Avantor (2018-2020); Prior to that role, she held various senior-level positions of increasing responsibility with Celanese from 2009 through 2018.

Rich White

6263

Senior Vice President & President of Performance Chemicals (2022-present); Vice President, Industrial Specialties (2019-2022); Vice President, Global Sales at DuPont Nutrition & Biosciences (2017-2019); Prior to that role, he held various senior-level positions of increasing responsibility with FMC from 1998 through 2017.

Steve Hulme

Senior Vice President & President of Advanced Polymer Technologies (2022-present); Vice President, Engineered Polymers (2020-2022); General Manager at Maysta International Ltd (2018-2020); Prior to that role, he held various senior-level positions of increasing responsibility with Evonik and Air Products and Chemicals from 2010 through 2018.

Michael Shukov

Senior Vice President and President, Advanced Polymer Technologies (2025-present); Managing Director, Industrial Coatings EMEA at PPG (2020-2023); Managing Director, PPG Industries at PPG (2017-2020); Regional Business Director at PPG (2014-2017); Managing Director at Solvay (2012-2014); Business Director at Dow Chemical (2009-2011); Prior to that role, he held various senior-level positions of increasing responsibility with Rohm and Haas from 2001 through 2011.

Ryan Fisher

4950

Senior Vice President, General Counsel & Secretary (2024-present); Vice President, Deputy General Counsel, Chief Compliance Officer and Assistance Secretary (2021-2024); Deputy General Counsel, Chief Legal Officer - Performance Chemicals and Assistant Secretary (2016-2020); Senior Counsel, WestRock Company (2015-2015); Associate General Counsel, WestRock Company (2014-2015); Assistant General Counsel, WestRock Company (2006-2013).

Terry Dyer

5859

Senior Vice President & Chief Human Resources Officer (2024-present); Senior Vice President Human Resources and Communications, Billerud (2020-2024); Chief Human Resource Officer, Worthington Industries (2012-2016); Prior to that role, he held various senior-level positions of increasing responsibility with Armstrong World Industries and Burlington Industries from 1998 through 2012.

Reid Clontz

Senior Vice President, Operations (2025-Present); Vice President, Global Operations (2025-2025), Vice President Operations, Performance Materials (2022-2025); Plant Manager (2018-2022); Production Manager (2014-2018); Prior to that role, he held various senior-level positions of increasing responsibility with MeadWestvaco from 2002 through 2014.

_______________

(1) As of December 31, ~~2024~~2025.

All officers are elected to hold office for one year or until their successors are elected and qualified. No family relationships exist among any of our executive officers or directors, and there are no arrangements or understandings between any of the above-listed officers and any other person pursuant to which they serve as an officer.

2524

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDERS MATTER AND ISSUER PURCHASES OF EQUITY SECURITIES

Market for Registrant's Common Equity and Related Stockholder Matters

Ingevity's common stock ($0.01 par value) is listed on the New York Stock Exchange, Inc. ("NYSE") under the symbol "NGVT." There were approximately 4,200 record holders of our common stock as of February 1418, ~~2025~~2026.

Unregistered Sales of Equity Securities

Not Applicable.

Issuer Purchases of Equity Securities

The following table summarizes information with respect to the repurchase of our common stock during the three months ended December 31, ~~2024~~2025.

Period	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
October 1-31, 2024	—	$	—	—	$	353,384,633
October 1-31, 2025	121,977	$	54.34	121,977	$	321,756,728
November 1-30, 2024	—	$	—	—	$	353,384,633
November 1-30, 2025	493,759	$	49.13	493,759	$	297,498,482
December 1-31, 2024	—	$	—	—	$	353,384,633
December 1-31, 2025	—	$	—	—	$	297,498,482
Total	—615,736			—615,736

_______________

(1) On July 25, 2022, our Board of Directors authorized the repurchase of up to $500.0 million of our common stock (the "2022 Authorization"), and rescinded the prior outstanding repurchase authorization with respect to the shares that remained unused under the prior authorization. Shares under the 2022 Authorization may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market prevailing conditions and other factors, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act.

Stock Performance Graph

The following table and graph present the cumulative total stockholder return for Ingevity's common stock compared with the Standard & Poor's ("S&P") SmallCap 600 Index, S&P MidCap 400 Index, the S&P Chemicals 600 Index, and the Dow Jones ("DJ") U.S. Specialty Chemicals Index for the five-year period ended December 31, ~~2024~~2025.

The graph assumes the investment of $100 in each of Ingevity's common stock, the S&P SmallCap 600 Index, S&P MidCap 400 Index, the S&P Chemicals 600 Index, and the DJ U.S. Specialty Chemicals Index, respectively, as of market close on December 31, 2019, and that all dividends, if any, were reinvested. Previously, Ingevity was included in the S&P MidCap 400 Index and was moved to the S&P SmallCap 600 Index on June 16, 2023. We updated our comparative broad market index accordingly for the fiscal year ended December 31, ~~2024~~2025. In light of our market capitalization, the S&P SmallCap 600 Index is a more comparable broad market index with which to compare Ingevity's common stock.

2625

	December 31,
	2019		2020		2021		2022		2023		2024
	2020		2021		2022		2023		2024		2025
Ingevity Corporation	$	100.00	$	8682.6706	$	8280.0661	$	8054.6104	$	5446.0464	$	4667.6473
S&P Small Cap 600 Index	$	100.00	$	~~111~~140.2498	$	~~140~~118.9822	$	~~118~~137.2207	$	~~137~~148.0791	$	~~148~~157.9183
S&P MidCap 400 Index	$	100.00	$	~~113~~141.6576	$	~~141~~123.7616	$	~~123~~143.1934	$	~~143~~163.3826	$	~~163~~175.3048
S&P Chemicals 600 Index	$	100.00	$	~~118~~148.6068	$	~~148~~127.6825	$	~~127~~135.2524	$	~~135~~128.2411	$	~~128~~107.1123
Dow Jones U.S. Specialty Chemicals Index	$	100.00	$	~~115~~142.2161	$	~~142~~123.6118	$	~~123~~124.1891	$	~~124~~118.9183	$	~~118~~121.8382

The graph and related information set forth above are not deemed to be "filed" with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any future filing made by us with the SEC, except to the extent that we specifically incorporate it by reference into any such filing. The stock price performance included in the graph above is not necessarily indicative of future stock performance.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Management’'s discussion and analysis of Ingevity’'s financial condition and results of operations (“"MD&A”") should be read in conjunction with Item 8. Financial Statements and Supplementary Data. Investors are cautioned that the forward-looking statements contained in this section and other parts of this Annual Report on Form 10-K involve both risk and

2726

uncertainty. Several important factors could cause actual results to differ materially from those anticipated by these statements. Many of these statements are macroeconomic in nature and are, therefore, beyond the control of management. See "Cautionary Statements about Forward-Looking Statements" at the beginning of this Annual Report on Form 10-K for further discussion.

All references to notes (herein referred to as "Note") in this section refer to the notes accompanying the Consolidated Financial Statements included in Part II. Item 8 within this Form 10-K.

Overview

Ingevity Corporation ("Ingevity," "the "Company," "we," "us," or "our") provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable. Our products are used in a variety of demanding applications, including ~~adhesives~~automotive gasoline vapor emissions control systems, ~~agrochemicals~~food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers, ~~lubricants,~~and paint for road markings~~, oil drilling, and automotive components~~. We operate in three reportable segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.

Recent Developments

~~Interest~~Performance ~~Rate~~Chemicals ~~Risk~~Repositioning ~~Management~~and Industrial Specialties Divestiture

~~During~~Beginning ~~the~~in ~~third quarter of 2024~~2023, wefollowing ~~entered into~~ a ~~floating-to-fixed~~sharp ~~interest~~decline ~~rate~~in ~~swap~~volumes ~~with a notional amount of $200.0 million to manage the variability of cash flows~~ in the ~~interest~~industrial ~~rate~~end ~~payments~~markets ~~associated~~served ~~with~~by our ~~existing~~Performance ~~Secured~~Chemicals ~~Overnight~~industrial ~~Financing~~specialties ~~Rate~~product ~~("SOFR") based interest payments~~line, ~~effectively~~we ~~converting~~announced ~~$200.0~~a ~~million~~series of ~~our~~strategic ~~floating~~initiatives ~~rate~~designed ~~debt~~ to aright-size ~~fixed~~our ~~rate.~~cost Instructure, ~~accordance~~streamline ~~with~~our ~~the terms of this instrument~~footprint, ~~we receive floating rate interest payments based upon one-month U.S. dollar SOFR~~ and instrengthen ~~return~~the ~~are~~overall ~~obligated~~resilience ~~to pay interest at a fixed rate~~ of ~~3.84~~the ~~percent until August 2026~~Company. ~~The fair value of outstanding interest rate instruments at December 31~~Collectively, ~~2024~~these ~~and~~initiatives ~~2023~~are ~~was~~referred anto ~~asset~~as ofthe ~~$0.6~~Performance ~~million~~Chemicals ~~and~~("PC") ~~zero,~~Repositioning ~~respectively~~Actions.

~~Measurement~~The ~~Alternative~~PC ~~Investments~~Repositioning Actions were designed to:

~~For~~•Prioritize ~~the~~growth ~~year~~in ~~ended~~our ~~December~~higher-margin ~~31,~~Performance ~~2024,~~Chemicals ~~the~~product ~~Company identified triggering events indicating that investments being accounted for under the measurement alternative may be impaired and recognized impairment charges of $11.5 million~~lines, ~~recorded~~such inas ~~Other~~pavement ~~(income) expense, net on the consolidated statement of operations.~~ technologies;

~~Impairment~~•Improve ~~Assessment(s)~~the ~~and~~financial ~~Goodwill~~performance ~~Impairment~~of ~~Charge~~the industrial specialties product line; and

~~Impairment~~•Reduce ~~Assessment~~exposure to lower-margin, more cyclical end-use markets, including adhesives, publication inks, and oilfield applications, which historically represented approximately 45 percent of our industrial specialties product line's pre-2023 annualized net sales.

~~Our~~The actions completed through fiscal year 2024 ~~annual~~successfully ~~goodwill~~enhanced ~~impairment~~the ~~assessment~~financial ~~was~~performance ~~performed~~of asthe ofindustrial ~~October~~specialties 1product line and positioned that business for strategic alternatives. As a result, ~~2024~~on January 16, 2025, we announced our intention to pursue a potential sale of the product line. WeOn ~~determined~~September ~~that~~3, 2025, Ingevity entered into a sales agreement to sell substantially all of the ~~fair~~assets, ~~value~~rights, and liabilities associated with the industrial specialties product line and the CTO refinery, (collectively, the "Divestiture"). Upon execution of ~~our~~the ~~reporting~~sales ~~units~~agreement, ~~were~~the industrial specialties product line and the CTO refinery included in ~~excess~~the Divestiture met the criteria for classification as discontinued operations. As such, the results of ~~their~~operations ~~carrying~~of ~~value~~the Divestiture have been reclassified and ~~therefore~~presented ~~concluded~~as ~~that~~discontinued nooperations ~~goodwill~~for ~~impairment~~all ~~existed~~periods presented. The sale was completed on January 1, 2026.

~~The~~PC ~~results~~Repositioning ofStatus ~~our October 1st annual review calculated that our APT reporting unit headroom, defined as the percentage difference between the fair value of a reporting unit~~ and ~~its~~Charges ~~carrying~~To value, is 12 percent. Since the fair value of our APT reporting unit is higher than the carrying value, we have concluded that no impairment to goodwill is necessary. Our analysis includes significant assumptions such as revenue growth rate, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margin, and discount rate, which are judgmental, and variations in any assumptions could result in materially different calculations of fair value.Date

We have substantially completed all activities associated with the restructuring program and expect the plan to be completed in 2026. The PC Repositioning Actions restructuring program is expected to result in total charges of approximately $370 million, consisting primarily of:

•~$255 million in non-cash asset-related charges; and

•~$115 million in cash charges, including:

▪~$25 million in severance and other employee-related costs, and

▪~$90 million in other restructuring costs, including decommissioning, dismantling, and removal charges, and contract termination costs.

We expect to incur approximately $10 million of additional cash charges during 2026.

Through December 31, 2025, we have incurred $353.7 million in total charges, including $248.3 million of non-cash asset-related charges and $105.4 million in cash charges. As of December 31, 2025, we have paid $91.3 million of the cash charges.

The charges expected in connection with these actions are subject to several assumptions and risks, and actual results may differ materially. Additional charges may arise from events related to or resulting from these actions.

Savings and Impact

The combined PC Repositioning Actions were expected to generate realized savings of approximately $95 million to $110 million. As of December 31, 2025, we have captured substantially all of the anticipated savings. Inclusive of continuing and discontinued operations, since November of 2023, we have realized approximately $105 million in cash savings. These savings were recognized in the following financial statement captions:

•~75 percent in Cost of sales,

•~20 percent in Selling, general, and administrative expenses, and

•~5 percent in Research and technical expenses

The savings also included approximately $15 million of annualized run-rate savings from corporate and shared service model changes that will continue to benefit New Ingevity, following the Divestiture.

In addition to the cash savings, we realized approximately $12 million in lower full year depreciation and intangible amortization expenses.

Long Lived Asset Impairment Charge - Performance Chemicals' Road Markings Asset Group

We periodically evaluate whether current events or circumstances indicate that the carrying value of our long-lived assets, including intangible assets, to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to carrying value to determine whether impairment exists.

As a result of the advanced diligence completed in the fourth quarter of 2025 as part of our pursuit of a sale of the Performance Chemicals' road markings asset group, we concluded that a triggering event occurred. The triggering event required us to conduct an impairment analysis of the Performance Chemicals road markings long-lived assets, which included significant assumptions such as the revenue growth rates, earnings before interest, taxes, depreciation, and amortization ("EBITDA") margins, and discount rate, which are judgmental. Variations in any assumptions could result in materially different calculations of fair value.

Based on the results of the quantitative analysis, which was based on both quoted market prices in active markets and a discounted value of estimated future cash flows, we concluded that the carrying value of the Performance Chemicals road markings asset group exceeded its fair value. As a result, we recorded a non-cash impairment charge of $109.3 million. The charge is included within "Long lived asset impairment charge" on the consolidated statements of operations for the twelve months ended December 31, 2025, and was allocated between "Property, plant, and equipment, net" and "Other intangibles, net" on the consolidated balance sheets in the amount of $25.2 million, and $84.1 million, respectively.

Interim Goodwill Impairment Charge - Advanced Polymer Technologies

During the second quarter of 2025, the announcements and subsequent modifications of international tariffs escalated global trade tensions and contributed to increased consumer uncertainty, which negatively impacted parts of our businesses, particularly Advanced Polymer Technologies ("APT"). As a result, we conducted an analysis of the APT reporting unit's goodwill and long-lived assets. This analysis incorporated revised expectations regarding the pace and strength of industrial demand recovery in key markets. In addition, the macroeconomic changes experienced during the quarter contributed to unfavorable movements in key valuation inputs, including an increase in the risk-free rate used in calculating the discount rate.

~~There~~Our ~~were~~analysis noincluded ~~events~~significant orassumptions ~~circumstances~~such ~~indicating~~as ~~that~~the ~~goodwill~~revenue ~~might~~growth berates, ~~impaired~~EBITDA asmargins, ~~of December 31~~and discount rate, ~~2024~~which are judgmental. Variations in any assumptions could result in materially different calculations of fair value.

Based on the results of the quantitative analysis, we concluded that the carrying value of the APT reporting unit exceeded its fair value. As a result, we recorded a non-cash goodwill impairment charge of $183.8 million, representing all of the goodwill associated with the APT reporting unit. The charge is included within "Goodwill ~~Impairment~~impairment ~~Charge~~charge" on the consolidated statements of operations for the twelve months ended December 31, 2025. Specific to our long-lived assets, we determined that the undiscounted cash flows were in excess of the carrying values and therefore concluded that no impairment existed. Our analysis included significant assumptions such as the revenue growth rates, EBITDA margins, and EBITDA exit multiple, which are judgmental. Variations in any assumptions could result in materially different calculations of undiscounted cash flows.

~~Beginning~~Strategic in fiscal year 2023, we began to see depressed volumes in our industrial end markets, constraining our ability to offset the continued crude tall oil (“CTO”) price inflation we were experiencing, and negatively impacting earnings and cash flow within our Performance Chemicals reporting unit, particularly in our industrial specialties product line. As a result, we concluded that a triggering event occurred in the third quarter of 2023. Our third quarter 2023 impairment analysis included significant assumptions, such as the execution of several measures in 2023 to pursue greater cost efficiency, including a reorganization to streamline certain functions and reduce ongoing costs, and expectations of decreased CTO costs beginning in the second half of 2024. We concluded that no impairment was necessary as a result of that third quarter 2023 interim analysis or at our annual impairment assessment, dated October 1, 2023.Investments

~~During~~Equity ~~the~~Method second quarter of 2024, our contracted long-term supplier of CTO provided new information regarding the cost of CTO for the second half of 2024, which significantly exceeded our forecasted costs, resulting in a triggering event for our Performance Chemicals reporting unit. We performed an analysis of the reporting unit’s goodwill, intangibles, and long-lived assets. Our analysis included significant assumptions such as: revenue growth rate, EBITDA margin, and discount rate, which are judgmental, and variations in any assumptions could result in materially different calculations of fair value. Investments

~~Our~~During ~~analysis reassessed~~ the ~~expected~~year ~~cash~~ended ~~flows in light of current performance and expected lack of near term recovery in our industrial specialties product line~~December 31, ~~resulting in lower volume and profitability expectations. As a result~~2025, we ~~concluded~~sold ~~that~~a ~~the~~strategic ~~carrying~~equity ~~amount~~method ofinvestment ~~the~~for ~~Performance Chemicals reporting unit exceeded its fair value~~$6.8 million, resulting in a ~~non-cash goodwill impairment charge of~~ $~~349~~7.1 million loss, ~~which~~recorded ~~represented all of the goodwill~~ within ~~the~~"Other ~~Performance~~(income) ~~Chemicals'~~expense, ~~reportable~~net" ~~segment. The charge was is included within Goodwill impairment charge~~ on the consolidated ~~statements~~statement of operations for the ~~year~~twelve months ended December 31, ~~2024~~2025. ~~Specific~~We torecognized ~~our~~an ~~long-lived~~additional ~~assets,~~$0.1 million wegain ~~determined~~associated ~~that~~with ~~the~~an ~~undiscounted~~equity ~~cash~~method ~~flows~~investment ~~were~~sale induring ~~excess of~~ the ~~carrying~~year ~~values~~ended ~~and~~December 31, ~~therefore concluded that no impairment existed~~2025.

~~Performance~~Measurement ~~Chemicals'~~Alternative ~~Repositioning~~Investments

OnDuring ~~November 1, 2023, we announced a number of strategic actions designed to reposition our Performance Chemicals reportable segment to improve profitability and reduce~~ the ~~cyclicality~~year ofended ~~the Company as a whole. These actions increased our focus on growing our most profitable Performance Chemicals product lines~~December 31, ~~such as road technologies~~2025, ~~and~~the ~~diversifying~~Company ~~our~~identified ~~raw~~triggering ~~material~~events ~~stream~~indicating tothat ~~non-CTO~~investments ~~based~~being ~~fatty~~accounted ~~acids.~~for ~~The~~under ~~repositioning~~the ~~focused~~measurement onalternative ~~reducing~~may ~~exposure~~be ~~to lower margin end-use markets of our industrial specialties product line~~impaired, ~~such as adhesives, publication inks,~~ and ~~oilfield,~~recognized ~~representing~~impairment ~~approximately~~charges ~~45 percent~~ of ~~our industrial specialties product line's historical annualized net sales~~$11.9 million, ~~The~~recorded ~~repositioning included the permanent closure of our Performance Chemicals CTO refinery and our manufacturing plant located~~ in ~~DeRidder,~~"Other ~~Louisiana~~ (~~the “DeRidder Plant”~~income) expense, ~~including~~net" ~~the~~on ~~polyol production assets associated with~~ the ~~APT~~consolidated ~~reportable~~statement ~~segment.~~of ~~All~~operations ~~production~~for at the ~~DeRidder~~twelve ~~Plant~~months ~~ceased~~ended inDecember 31, ~~the first quarter of 2024~~2025. ~~The Performance Chemicals’ repositioning initiative included additional corporate and business cost reduction actions executed in November 2023.~~

~~Additionally,~~Proxy in July 2024, we announced plans to transition the refining of oleo-based products manufactured for our Performance Chemicals reportable segment from our Crossett, Arkansas manufacturing plant (the “Crossett Facility”) to our North Charleston, South Carolina manufacturing plant. This action included the closure of the Crossett Facility, as well as additional corporate and business cost reduction actions. We ceased production at the Crossett Facility in the third quarter of 2024. Contest

~~The~~On ~~actions~~March ~~referenced~~30, ~~above~~2025, ~~when~~the ~~combined~~Company entered into a cooperation agreement (the "Cooperation Agreement") with ~~other~~Vision ~~targeted~~One ~~workforce~~Fund, ~~reduction~~L.P. ~~initiatives~~and its affiliates ("Vision One"), ~~during~~a ~~2024~~stockholder ~~and~~of ~~2023~~the ~~resulted~~company. inPursuant to the ~~reduction~~Cooperation Agreement, our Board of ~~Ingevity~~Directors ("Board") agreed to appoint a new member to the Company's ~~global~~Board ~~workforce~~within byone 23day ~~percent.~~of ~~Specific~~the to2025 ~~Performance~~annual ~~Chemicals~~meeting of stockholders ("Annual Meeting"), and Vision One agreed to withdraw its nominees for election at the ~~reduction~~Annual ~~represented~~Meeting ~~approximately~~and 40to ~~percent~~abide by certain customary standstill restrictions, mutual non-disparagement provisions, voting commitments and other obligations until the opening of the ~~reportable~~nomination ~~segment~~window for the company's ~~workforce~~2026 annual meeting of stockholders. In connection with the Cooperation Agreement, Vision One was entitled to the reimbursement of certain of its reasonable and documented out-of-pocket fees and expenses. During the year ended December 31, 2025, we incurred costs of approximately $8.2 million in connection with our response to the proxy contest. These costs, which were included within "Other (income) expense, net" on the consolidated statements of operations, include legal and other professional service fees as well as incremental proxy solicitation costs related to the Annual Meeting.

~~Expected~~2025 ~~Charges~~U.S. Tax Reform

WeOn ~~expect~~July 4, 2025, the United States enacted into law the legislation formally titled "An Act to ~~incur~~provide ~~total~~for ~~charges~~reconciliation pursuant to title II of ~~approximately~~H. ~~$350~~Con.0 ~~million~~Res. 14," ~~excluding~~and ~~CTO~~commonly ~~resale~~referred ~~activity~~to as ~~described~~the ~~below~~One Big Beautiful Bill ("OBBB"), ~~associated~~which ~~with~~provides for the ~~Performance~~permanent ~~Chemicals~~extension ~~repositioning,~~of ~~consisting~~several expiring provisions of ~~approximately~~the ~~$250.0~~2017 ~~million~~Tax inCuts ~~asset-related~~and ~~charges,~~Jobs ~~approximately~~Act ~~$25.0~~and ~~million~~includes ina ~~severance~~comprehensive ~~and~~tax ~~other~~reform ~~employee-related~~package ~~costs,~~that ~~and~~significantly ~~approximately~~modifies ~~$75~~U.0S. ~~million~~federal intax ~~other~~policy ~~restructuring~~and ~~costs~~the ~~including~~international ~~decommissioning,~~tax ~~dismantling~~framework. ~~and~~Based ~~removal~~on ~~charges~~the analysis performed by the Company, ~~and~~the ~~contract~~OBBB ~~termination~~will ~~costs.~~have Wean ~~expect~~impact ~~approximately~~on ~~$250.0~~cash ~~million~~taxes as a result of the ~~total~~ability ~~charges~~to accelerate deductions. This increase to bethe ~~non~~one-~~cash~~time ~~and~~deductibility ~~$100.0~~of ~~million~~previously toamortizable beexpenses ~~settled~~is indriving ~~cash.~~down ~~Through~~our ~~December 31,~~benefit ~~2024,~~from wethe ~~have~~foreign-derived ~~incurred~~intangible ~~$311.8~~income ~~million~~deduction, ~~associated~~thus ~~with~~negatively ~~these~~impacting ~~actions,~~the ~~including~~effective ~~$244.8~~tax ~~million~~rate offor ~~non-cash~~the ~~asset-~~year ended December 31, 2025.

Results of Operations

related charges, excluding $7.4 million related to an asset retirement obligation ("ARO"), and $67.0 million of charges to be settled in cash, which includes the aforementioned ARO. As of December 31, 2024, $54.5 million of the charges to be settled in cash have been paid and all non-cash charges have been incurred. In total, we expect approximately $100 million of cash charges, including approximately $20-$25 million during 2025.


	Years Ended December 31,
In millions	2025		2024		2023
Net sales	$	1,167.6	$	1,200.1	$	1,215.5
Cost of sales	706.1		735.3		770.5
Gross profit	461.5		464.8		445.0
Selling, general, and administrative expenses	171.2		157.8		161.8
Research and technical expenses	28.4		24.5		25.4

Restructuring and other (income) charges, net	12.8		18.1		53.4
Goodwill impairment charge	183.8		306.6		—
Long lived asset impairment charge	109.3		—		—
Acquisition-related costs	—		0.3		3.6
Other (income) expense, net	25.0		7.9		(16.2)
Interest expense	78.3		97.8		93.3
Interest income	(5.2)		(7.7)		(6.3)
Income (loss) from continuing operations before income taxes	(142.1)		(140.5)		130.0
Provision (benefit) for income taxes on continuing operations	8.2		(19.1)		24.2
Net income (loss) from continuing operations	(150.3)		(121.4)		105.8
Income (loss) from discontinued operations, net of income taxes	(16.8)		(308.9)		(111.2)
Net income (loss)	$	(167.1)	$	(430.3)	$	(5.4)

Inventory Charges

The Company believes the collective actions of workforce, operational, and regional business exits will hinder our ability to dispose of the associated inventory on hand. As a result, in the years ended December 31, 2024 and 2023, we recorded $6.3 million and $19.7 million, respectively, of non-cash, lower of cost or market, inventory charges to adjust the carrying value of the impacted inventory to what we will realize upon disposal, less disposal costs. These inventory charges are recorded to Cost of sales on the consolidated statement of operations. Since these inventory charges are directly attributable to the Performance Chemicals’ repositioning, that is, they do not represent normal, recurring expenses necessary to operate our business, we have excluded such impact from the financial results of our Performance Chemicals reportable segment. Refer to Note 19 for more information.

CTO Resale Activity

The DeRidder Plant closure, and the corresponding reduced CTO refining capacity, significantly reduced our CTO volume requirements. However, we were obligated under an existing CTO supply contract to purchase CTO volumes through 2025 at amounts in excess of the CTO volumes needed to support our business operations. To manage this excess inventory, we sold CTO volumes (herein referred to as "CTO resales") in the open market. During the years ended December 31, 2024 and 2023, we incurred $52.7 million and $22.0 million of CTO resale losses, which are recorded as Other (income) expense, net on the consolidated statements of operations. Refer to Note 2, under the section: Non-operating income and expense, for more information.

As of July 1, 2024, we terminated the CTO supply contract that resulted in these excess CTO volumes. As consideration for the early termination of the CTO supply contract, we made cash payments totaling $100.0 million. The total charge was recorded within Other (income) expense, net on the consolidated statements of operations for the year ended December 31, 2024. As a result of the termination, the purchases under the CTO supply contract ended effective June 30, 2024. The CTO resale activity described above ended in 2024 and no excess CTO volumes were on hand at December 31, 2024.

Expected Savings and Impact

The Performance Chemicals' repositioning, which began in November 2023, was focused on reducing exposure to lower margin end-use markets of our industrial specialties product line, such as adhesives, publication inks, and oilfield. Sales into these end-use markets represented approximately 45 percent of our industrial specialties product line historical annualized net sales. As a result of this initiative, we expect to realize savings of approximately $95 million to $110 million. These cash savings are derived from headcount reductions, plant operating efficiencies, and reduced supply chain costs. During the year ended December 31, 2024, we realized cash savings of approximately $84.0 million, including $68.0 million in Cost of sales, $12.0 million in Selling, general, and administrative expenses, and $4.0 million in Research and technical expenses, respectively. Collectively, these savings are realized in the following financial statement captions: 70-80 percent in Cost of sales, 15-25 percent in Selling, general, and administrative expenses, and ~5 percent in Research and technical expenses, all presented on our consolidated statements of operations. We expect to realize the remaining savings in 2025.

In addition to the cash savings, we expect to realize approximately $15 million to $17 million in depreciation and intangible amortization expenses, respectively. During the year ended December 31, 2024, we realized savings of approximately $10 million. We expect to realize the remaining savings in 2025.

The charges we currently expect to incur and the savings we expect to obtain in connection with these actions are subject to a number of assumptions and risks, and actual results may differ materially. We may also incur other material charges not currently contemplated due to events that may occur as a result of, or in connection with, these actions.

	Years Ended December 31,
In millions	2024		2023		2022
Net sales	$	1,406.4	$	1,692.1	$	1,668.3
Cost of sales	951.7		1,220.2		1,098.2
Gross profit	454.7		471.9		570.1
Selling, general, and administrative expenses	166.7		183.7		198.8
Research and technical expenses	28.1		31.8		30.3
Restructuring and other (income) charges, net	186.2		170.2		13.8
Goodwill impairment charge	349.1		—		—
Acquisition-related costs	0.3		3.6		5.0
Other (income) expense, net	169.8		5.7		(1.7)
Interest expense	97.8		93.3		61.8
Interest income	(7.7)		(6.3)		(7.5)
Income (loss) before income taxes	(535.6)		(10.1)		269.6
Provision (benefit) for income taxes	(105.3)		(4.7)		58.0
Net income (loss)	$	(430.3)	$	(5.4)	$	211.6

Net sales

The table below shows ~~2024~~2025 and ~~2023~~2024 Net sales and variances from ~~2023~~2024 and ~~2022~~2023, respectively.

			Change vs. prior year
In millions	Prior year Net sales		Volume	Price/Mix	Currency effect	Current year Net sales
Year Ended December 31, 2024 vs. 2023	$	1,692.1	(274.9)	(1.0)	(9.8)	$	1,406.4
Year Ended December 31, 2025 vs. 2024	$	1,200.1	(41.2)	6.9	1.8	$	1,167.6
Year Ended December 31, 2023 vs. 2022	$	1,668.3	(106.3)	142.3	(12.2)	$	1,692.1
Year Ended December 31, 2024 vs. 2023	$	1,215.5	(8.7)	2.3	(9.0)	$	1,200.1

~~2024~~2025 Performance Summary

The Net sales decrease of $32.5 million was driven primarily by the ~~Performance~~APT ~~Chemicals~~reportable ~~industrial~~segment ~~specialties~~as ~~product~~continued ~~line~~weak ~~due~~industrial todemand, ~~repositioning~~indirect ~~actions~~tariff ~~that~~impacts ~~have~~negatively ~~resulted~~impacted incustomer ~~the reduction of sales to lower margin~~ end~~-use~~ markets, ~~therefore~~demand ~~reducing~~and ~~Net~~increased ~~sales~~China ~~during~~competition ~~the~~pressured ~~year~~sales. byThe ~~approximately~~decrease ~~$210~~was ~~million.~~partially ~~Also~~offset ~~contributing~~by toslight ~~the~~growth ~~lower~~(less ~~sales~~than ~~was~~one ~~unfavorable~~percent) ~~weather~~ in ~~key North American regions impacting~~ the ~~Performance~~pavement ~~Chemicals road~~ technologies product line ~~contributing to the decline in Net sales of $27~~.5 ~~million, continued weakness in certain industrial end markets that negatively impacted sales in the~~ Performance ~~Chemicals~~Materials ~~industrial~~maintained ~~specialties product line that contributed to the reduction in Net~~ sales ofyear ~~$56.4~~over ~~million,~~year ~~and~~despite ~~lower~~supply ~~sales~~chain indisruptions ~~our Advanced Polymer Technologies reportable segment of $15.4 million, partially offset by an increase~~ in ~~our~~the ~~Performance~~automobile ~~Materials reportable segment of $23~~industry.6 ~~million.~~

Year Ended December 31, 2025 vs. 2024

The Net sales decrease in 2025 was driven by a volume decline of $41.2 million (three percent), partially offset by favorable pricing and sales mix of $6.9 million (one percent) and favorable foreign exchange impacts of $1.8 million (zero percent).

Year Ended December 31, 2024 vs. 2023

The Net sales decrease in 2024 was driven by a volume decline of $~~274~~8.97 million (16one percent), and unfavorable foreign exchange impacts of $9.80 million (one percent), ~~and~~partially ~~unfavorable~~offset by favorable pricing and sales mix of $12.03 million (zero percent).

~~Year Ended December 31, 2023 vs. 2022~~30

The Net sales increase in 2023 was driven by favorable pricing and sales mix of $142.3 million (nine percent), primarily attributed to an increase in Performance Chemicals of $93.1 million, partially offset by volume decline of $106.3 million (six percent), and unfavorable foreign exchange impacts of $12.2 million (one percent).

Gross profit

Year Ended December 31, 2025 vs. 2024

Gross profit decrease of $3.3 million was driven by improved operating efficiencies of $23.4 million, favorable pricing and sales mix of $6.8 million, and favorable foreign exchange impacts of $2.8 million, offset by unfavorable sales volume of $20.0 million and LIFO impact of $16.3 million. Refer to the Segment Operating Results section included within this MD&A for more information on the drivers of the changes in gross profit period over period for all segments.

Year Ended December 31, 2024 vs. 2023

Gross profit ~~decrease~~increase of $1719.28 million was driven by ~~unfavorable~~decreased ~~sales~~manufacturing ~~volume~~costs of $3546.86 million, ~~unfavorable pricing~~ and favorable sales ~~mix~~volume of $60.45 million, ~~and~~partially ~~unfavorable~~offset ~~foreign~~by ~~exchange~~LIFO ~~impacts~~impact of $216.94 million, ~~partially~~unfavorable ~~offset~~pricing byand ~~decreased~~sales ~~manufacturing~~mix ~~costs~~ of $273.92 million., ~~Gross~~and ~~profit~~unfavorable ~~includes~~foreign ~~the~~currency ~~realized~~exchange ~~savings~~impacts of $687.07 million ~~from the Performance Chemicals repositioning action initiated in 2023~~. Refer to the Segment Operating Results section included within this MD&A for more information on the drivers ofto the changes in gross profit period over period for all segments.

Year Ended December 31, 2023 vs. 2022

Gross profit decrease of $98.2 million was driven by increased manufacturing costs of $158.6 million primarily due to significant CTO raw material cost pressure within our industrial specialties product line in our Performance Chemicals reportable segment, unfavorable sales volume of $46.9 million, inventory charges of $19.7 million, and unfavorable foreign currency exchange impacts of $0.9 million, partially offset by favorable pricing and sales mix of $127.9 million. Refer to the Segment Operating Results section included within this MD&A for more information on the drivers to the changes in gross profit period over period for all segments.

Selling, general, and administrative expenses

Year Ended December 31, 2025 vs. 2024

Selling, general, and administrative ("SG&A") expenses were $171.2 million (15 percent of Net sales) and $157.8 million (13 percent of Net sales) for the years ended December 31, 2025 and 2024, respectively. Overall, SG&A increased by approximately $13.4 million or eight percent. The higher SG&A was driven by improved business performance that drove increased variable incentive compensation expense of $12.9 million, and increased amortization expense of $0.5 million.

Year Ended December 31, 2024 vs. 2023

~~Selling, general, and administrative ("~~SG&A") expenses were $~~166~~157.78 million (1213 percent of Net sales) and $~~183~~161.78 million (1113 percent of Net sales) for the years ended December 31, 2024 and 2023, respectively. ~~Overall,~~The decrease in SG&A ~~decreased~~expenses byis ~~approximately~~primarily ~~$17.0~~due ~~million~~decreased ortravel ~~nine~~and ~~percent.~~other ~~Our~~miscellaneous ~~Performance~~costs ~~Chemicals'~~of ~~repositioning~~$8.6 ~~actions~~million, ~~resulted~~and indecreased ~~a non-cash reduction of intangible~~ amortization expense of $111.46 million, ~~and $12.0 million in cash savings. These combined savings were~~ partially offset by increased ~~spending~~employee-related oncosts ~~commercial activities~~ of $16.02 million ~~and increased variable incentive compensation of $5~~.~~4 million, driven by adjustments recognized in the year ended December 31, 2023, that did not repeat in 2024.~~

Year Ended December 31, 2023 vs. 2022

SG&A expenses were $183.7 million (11 percent of Net sales) and $198.8 million (12 percent of Net sales) for the years ended December 31, 2023 and 2022, respectively. The decrease in SG&A expenses is primarily due to lower employee-related costs of $18.4 million, and decreased travel and other miscellaneous costs of $6.9 million, partially offset by increased amortization expense of $10.2 million due to the Ozark Materials acquisition.

Research and technical expenses

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

Research and technical expenses as a percentage of Net sales remained relatively consistent period over period, totaling 2.04 percent of sales in the year ended December 31, ~~2024~~2025, compared to 12.90 percent in the year ended December 31, ~~2023~~2024, and 12.81 percent in the year ended December 31, ~~2022~~2023. Research and technical expenses as a percentage of Net sales increased due to lower sales. Overall, Research and technical expense ~~decreased~~increased by $3.79 million in ~~2024~~2025, compared to ~~2023~~2024, ~~which~~primarily ~~included~~driven ~~approximately~~by ~~$4.0~~an ~~million~~increase ~~realized~~within ~~from~~our ~~the~~ Performance ~~Chemicals~~Materials ~~repositioning~~reportable ~~actions initiated in 2023~~segment.

Restructuring and other (income) charges, net

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Work force reductions and other	$	2.3	$	12.5	$	—
Workforce reductions and other	$	10.7	$	2.3	$	11.5
Performance Chemicals' repositioning	~~172~~2.71		~~113~~4.16		—23.7
Restructuring charges	$	~~175~~12.08	$	~~125.~~6.9	$	—35.2
Alternative feedstock transition	—		22.1		—
North Charleston plant transition	—		11.2		10.5
North Charleston plant transition	11.2		14.8		—
Business transformation costs	—		—		7.7
Business transformation costs	—		7.7		13.8
Other (income) charges, net	$	—	$	11.2	$	18.2
Other (income) charges, net	$	11.2	$	44.6	$	13.8
Restructuring and other (income) charges, net (1)	$	12.8	$	18.1	$	53.4
Restructuring and other (income) charges, net (1)	$	186.2	$	170.2	$	13.8

_______________

(1) See Note 15 for more information.

Goodwill impairment charge

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

~~Goodwill~~The goodwill impairment charge of $~~349~~183.18 million for the year ended December 31, 2025 was recognized within our Advanced Polymer Technologies reporting unit. The goodwill impairment charge of $306.6 million for the year ended December 31, 2024 was recognized within our Performance Chemicals reporting unit. See Note 8 for more information.

Long lived asset impairment charge

Years Ended December 31, 2025, 2024, and 2023

The long lived asset impairment charge of $109.3 million for the year ended December 31, 2025 was driven by the road markings asset group within our Performance Chemicals segment. See Note 7 and Note 8 for more information.

Acquisition-related costs

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

Acquisition costs were zero, $0.3 million, and $3.6 million, ~~and $5.0 million~~ for the years ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023, respectively. For the twelve months ended December 31, 2024, ~~2023,~~ and ~~2022~~2023, all charges related to the integration of Ozark Materials into our Performance Chemicals reportable segment. ~~See Note 16 for more information.~~

Other (income) expense, net

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
(Gain) loss on strategic investments (1)	$	1119.46	$	~~(19~~2.3)1	$	—(19.3)
Foreign currency transaction (gain) loss	4(0.26)		34.72		2.3.7
CEO severance charges	~~4.8~~—		—4.8		—
Loss on CTO resales (2)	52.7		22.0		—
Proxy contest charges (2)	8.2		—		—
CTO supply contract termination charges (2)	100.0		—		—
Portfolio realignment costs (2)	3.1		—		—
Other (income) expense, net	(35.3)		(03.72)		(4.0.6)
Total Other (income) expense, net	$	~~169~~25.80	$	5.7.9	$	(116.72)

_______________

(1) See Note 5 for more information.

(2) See Note 1518 for more information.

Interest expense

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Finance lease obligations (1)	$	7.32	$	7.3	$	7.53
Revolving credit facility and term loan (2) (3)	57.2		59.1		21.2
Revolving credit facility and term loan (2)	39.3		57.2		59.1
Senior Notes (3)	22.4		22.4		33.1
Senior Notes (2)	22.4		22.4		22.4
Accounts receivable securitization (3)	5.7		1.5		—
Accounts receivable securitization (2)	4.2		5.7		1.5
Litigation related interest expense (4)	5.2		3.0		—
Litigation related interest expense (3)	4.0		4.0		2.4
Total interest expense	$	97.8	$	93.3	$	61.8
Other	1.2		1.2		0.6
Total Interest expense	$	78.3	$	97.8	$	93.3

_______________

(1) See Note 13 for more information.

(2) ~~The~~See ~~increase~~Note in10 ~~interest~~for ~~expense~~more ~~was driven by higher average debt levels during 2024 and 2023 due to the October 2022, $325~~information.~~0 million acquisition of Ozark Materials, as well as higher average interest rates compared to prior years.~~

(3) See Note 1017 for more information.

~~(4) See Note 18 for more information.q~~32

Interest income

Years Ended December 31 ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Restricted investment (1)	$	2.60	$	2.46	$	2.14
Fixed-to-fixed cross-currency interest rate swap (2)	—		—		1.1
Floating-to-fixed interest rate swaps (2)	0.8		0.8		—
Floating-to-fixed interest rate swaps (2)	0.8		—		1.7
Other (3)	2.4		4.3		3.9
Other (3)	4.3		3.9		2.6
Total Interest income	$	5.2	$	7.7	$	6.3
Total interest income	$	7.7	$	6.3	$	7.5

_______________

(1) See Note 5 for more information.

(2) See Note 9 for more information.

(3) Primarily consists of bank interest.

Provision (benefit) for income taxes

Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

For the years ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023, our effective tax rate was 19(5.7) percent, 4613.56 percent, and 2118.5 percent respectively. AnThe ~~explanation~~decrease ofin our effective tax rate from 2024 to 2025 was mainly driven by the ~~change~~mix inof earnings, with U.K. losses, due to the APT goodwill impairment (see Note 8), driving an overall global loss with net tax expense creating a negative effective tax rate isin ~~presented~~2025. Additionally, the foreign-derived intangible income deduction decreased in ~~Note~~2025 17compared to 2024 as a result of the OBBB signed into law on July 4, 2025, which allowed immediate deductibility of previously amortizable expenses. Additionally, a significant decrease in the Federal Research and Development credit in 2025, further increased total tax expense as compared to 2024.

3433

Segment Operating Results

In addition to the information discussed above, the following sections discuss the results of operations for each of Ingevity's segments. Our segments are (i) Performance Materials, (ii) Performance Chemicals, and (iii) Advanced Polymer Technologies. Segment Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") is the primary measure used by the Company's chief operating decision maker to evaluate the performance of and allocate resources among our operating segments. Segment EBITDA is defined as segment net sales less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense associated with corporate debt facilities, interest income, income taxes, depreciation, amortization, restructuring and other income (charges), net, ~~including~~goodwill ~~inventory~~impairment ~~lower of cost or market~~ charges, ~~associated~~long ~~with~~lived ~~restructuring~~asset ~~actions, goodwill~~ impairment ~~charge~~charges, acquisition and other-related income (costs), ~~litigation verdict charges,~~ gain (loss) on strategic investments, ~~loss~~proxy oncontest ~~CTO resales~~charges, ~~CTO~~portfolio ~~supply~~realignment ~~contract termination charges~~costs, ~~and~~ pension and postretirement settlement and curtailment income (charges), net, indirect costs allocated to Divestiture, and Corporate and other costs. In general, the accounting policies of the segments are the same as those described in the Summary of Significant Accounting Policies in Note 2.

Performance Materials

~~2024~~2025 Performance Summary

~~Performance Materials delivered record Net sales, Segment EBITDA, and Segment EBITDA margins.~~ Sales ~~growth~~ of ~~four percent was driven by higher volume and improved price and mix~~$606.9 ~~There~~million ~~are~~dollars ~~two~~were ~~components~~in toline ~~mix~~with ~~that~~the ~~are~~prior ~~key to understanding this reportable segment. The segment benefits from larger vehicles~~year, ~~such~~which asis ~~trucks~~a ~~and~~strong ~~sport~~result ~~utility~~given ~~vehicles,~~that as2024 ~~well~~was asa ~~more~~record ~~hybrids~~year ~~and~~for ~~internal~~the ~~combustion engine vehicles versus all electric vehicles, as these vehicles contain more of our activated carbon content~~business. ~~Regional~~Throughout ~~mix is also important as North America~~2025, ~~which~~the isautomotive ~~nearly~~industry 50faced ~~percent~~significant ofdisruption ~~Performance~~from ~~Material~~tariff ~~sales~~uncertainty, ~~is our most profitable region due to the typically larger size of vehicles requiring more content~~fires, and ~~this~~chip ~~region~~shortages. ~~also~~Against ~~has~~that ~~the~~backdrop, ~~highest emissions control standards in~~ the ~~world~~resilience ~~requiring more advanced forms~~ of our ~~activated carbon product. Asia Pacific is also an important region, representing about 40 percent of total~~ Performance Materials ~~net~~business ~~sales.~~becomes ~~Within~~more ~~Asia Pacific, about half of our net sales are in China and the remaining are made up primarily of South Korea and Japan~~evident. ~~All~~While of these ~~countries~~dynamics ~~have~~led ~~strict~~to ~~emissions~~slightly ~~control~~lower ~~standards~~volumes, ordisciplined ~~strong~~pricing ~~export~~actions ~~markets~~helped ~~where~~to ~~our~~offset ~~activated~~the ~~carbon~~impact, ~~plays~~allowing anus ~~important~~to ~~role~~hold inyear-over-year ~~meeting~~sales ~~regulations~~essentially flat. ~~Europe~~Segment isEBITDA ~~our~~declined ~~least~~2% ~~impactful~~year ~~region~~over year due to ~~the~~lower ~~regulatory~~volume ~~environment favoring electric vehicles,~~ and ~~also~~higher ~~because European emissions standards lag behind North America and Asia Pacific~~SG&A. ~~Segment~~Despite ~~EBITDA for Performance Materials increased 11 percent to $319.1 million~~this, ~~with~~ Segment EBITDA ~~margins~~margin ~~for~~remained ~~the~~strong ~~year~~at ~~of 52~~53.38 percent. This record result was primarily driven by operational improvements that enabled our production operations to run more efficiently which reduced our input costs by using less natural gas and also improved yields.

In millions	Years Ended December 31,
	2024		2023		2022
	2025		2024		2023
Total Performance Materials - Net sales	$	~~609~~606.69	$	~~586~~609.06	$	~~548~~586.50
Segment EBITDA	$	~~319~~326.13	$	~~286~~333.62	$	~~252~~303.21

Net Sales Comparison of Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

			Change vs. prior year
In millions	Prior year Net sales		Volume	Price/Mix	Currency effect	Current year Net sales
Year Ended December 31, 2025 vs 2024	$	609.6	(3.7)	0.8	0.2	$	606.9
Year Ended December 31, 2024 vs 2023	$	586.0	11.2	17.3	(4.9)	$	609.6
Year Ended December 31, 2023 vs 2022	$	548.5	17.3	32.2	(12.0)	$	586.0

Year Ended December 31, 2025 vs. 2024

Segment net sales. The decrease of $2.7 million in 2025 was driven by a volume decline of $3.7 million (one percent), partially offset by favorable pricing and sales mix of $0.8 million (zero percent), and favorable foreign currency exchange impacts of $0.2 million (zero percent).

Segment EBITDA. The decrease of $6.9 million in 2025 was driven by increased SG&A expenses and research and technical costs of $6.0 million, volume decline of $5.6 million, and LIFO impact of $3.4 million, partially offset by favorable foreign currency exchange and other charges of $3.7 million, decreased manufacturing costs of $3.6 million, and favorable pricing and sales mix of $0.8 million.

Year Ended December 31, 2024 vs. 2023

Segment net sales. The increase of $23.6 million in 2024 was driven by favorable pricing and sales mix of $17.3 million (three percent), and a volume increase of $11.2 million (two percent), partially offset by unfavorable foreign currency exchange impacts of $4.9 million (one percent).

3534

Segment EBITDA. The increase of $3230.51 million in 2024 was driven by decreased manufacturing costs of $2623.~~0 million~~9, favorable pricing and sales mix of $11.9 million, ~~and~~ favorable volume of $6.3 million, and a LIFO impact of $2.1 million. The increase was partially offset by higher SG&A expenses and research and technical costs of $1013.92 million, and unfavorable foreign currency exchange and other charges of $0.89 million.

Year Ended December 31, 2023 vs. 2022

Segment net sales. The increase in 2023 was driven by favorable pricing and sales mix of $32.2 million (six percent), and a volume increase of $17.3 million (three percent), partially offset by unfavorable foreign currency exchange impacts of $12.0 million (two percent).

Segment EBITDA. Segment EBITDA increased by $34.4 million due to pricing and sales mix of $21.1 million, decreased SG&A expenses and research and technical costs of $11.6 million, and favorable volume of $10.9 million. The increase was partially offset by higher manufacturing costs of $8.8 million, and unfavorable foreign currency exchange impacts of $0.4 million.

Performance Chemicals

~~2024~~2025 Performance Summary

Performance Chemicals net sales of $~~608~~400.25 million ~~declined~~were ~~almost~~flat ~~$300 million, a 33 percent decline,~~ versus the prior year. ~~primarily~~Pavement asTechnologies aproduct ~~result~~line of2025 ~~our~~sales ~~repositioning~~remained ~~actions.~~flat ~~Approximately~~to ~~$210~~2024 ~~million~~as ofvolume ~~the~~growth ~~decline~~ in ~~net~~the ~~sales~~NAFTA ~~reflects~~region ~~the~~was ~~exit~~largely ofoffset by lower~~-margin~~ ~~end~~infrastructure ~~markets~~investment in ~~our~~South ~~industrial~~America. ~~specialties~~The product line asalso webenefited ~~continue~~from topricing ~~focus~~and onfavorable ~~maximizing~~mix ~~profitability~~shift. ~~The~~While ~~remaining~~adverse ~~net~~wet ~~sales~~weather ~~decline~~impacted ~~was~~results ~~due~~in ~~primarily~~the tofirst ~~lost~~half ~~sales~~of as2025, ~~customers~~demand ~~sought~~shifted ~~alternative~~into ~~suppliers~~the insecond ~~light~~half, ofand ~~our~~most ~~repositioning~~projects ~~actions~~were ~~and~~ultimately ~~lower~~completed ~~road~~within ~~technologies~~the year. Road Markings product line ~~sales~~continued ~~attributed~~ to ~~adverse~~experience ~~weather~~price inpressure ~~the~~from ~~key~~competition, ~~states~~although ~~within~~volumes ~~the~~grew Uslightly.S. The reportable segment generated Segment EBITDA of $1460.73 million for the year. ~~The year over year decline in Segment EBITDA~~ was ~~driven~~supported by ~~higher~~improved ~~CTO~~pricing, ~~costs~~favorable mix, and lower ~~volumes,~~raw ~~particularly~~material ~~in the road technologies product line~~costs, partially offset by ~~cost~~volume ~~savings~~declines ~~realized~~and ~~due~~higher ~~to the Performance Chemicals repositioning~~SG&A.

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Total Performance Chemicals - Net sales	$	608.2	$	902.1	$	875.1
Performance Chemicals - Net sales	$	400.5	$	401.9	$	425.5
Road Technologies product line	342.3		369.8		241.3
Pavement Technologies product line	302.6		300.9		312.1
Industrial Specialties product line	265.9		532.3		633.8
Road Markings product line	97.9		101.0		113.4
Segment EBITDA	$	1460.73	$	6553.7	$	~~160~~71.41

Net Sales Comparison of Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

			Change vs. prior year
In millions	Prior year Net sales		Volume	Price/Mix	Currency effect	Current year Net sales
Year Ended December 31, 2024 vs 2023	$	902.1	(293.2)	0.5	(1.2)	$	608.2
Year Ended December 31, 2025 vs 2024	$	401.9	(9.1)	7.8	(0.1)	$	400.5
Road Technologies product line	369.8		(30.8)	3.7	(0.4)	342.3
Pavement Technologies product line	300.9		(10.8)	12.6	(0.1)	302.6
Industrial Specialties product line	532.3		(262.4)	(3.2)	(0.8)	265.9
Road Markings product line	101.0		1.7	(4.8)	—	97.9
Year Ended December 31, 2023 vs 2022	$	875.1	(65.3)	93.1	(0.8)	$	902.1
Year Ended December 31, 2024 vs 2023	$	425.5	(26.9)	3.7	(0.4)	$	401.9
Road Technologies product line	241.3		98.4	30.4	(0.3)	369.8
Pavement Technologies product line	312.1		(17.8)	7.0	(0.4)	300.9
Industrial Specialties product line	633.8		(163.7)	62.7	(0.5)	532.3
Road Markings product line	113.4		(9.1)	(3.3)	—	101.0

Year Ended December 31, 2025 vs. 2024

Segment net sales. The decrease of $1.4 million in 2025 was driven by a volume decline of $9.1 million (two percent), as a result of a decrease in pavement technologies ($10.8 million), partially offset by growth in road markings ($1.7 million), and unfavorable foreign currency exchange of $0.1 million (zero percent), partially offset by favorable pricing and sales mix of $7.8 million (two percent), comprised of pavement technologies ($12.6 million), offset by road markings ($4.8 million).

Segment EBITDA. The increase of $6.6 million in 2025 was driven by decreased manufacturing costs of $18.3 million, favorable pricing and sales mix of $7.8 million, primarily due to higher cost CTO in the prior year, and favorable foreign currency exchange and other charges of $1.9 million. The decrease was partially offset by LIFO impact of $12.9 million, higher SG&A expenses of $4.5 million, and a volume decline of $4.0 million.

Year Ended December 31, 2024 vs. 2023

Segment net sales. The decrease of $~~293~~23.96 million in 2024 was driven by a volume ~~decrease~~decline of $~~293~~26.29 million (33six percent), as a result of a decrease in ~~industrial~~pavement ~~specialties~~technologies ($~~262~~17.48 million) and road ~~technologies~~markings ($309.81 million), and unfavorable ~~foreign currency exchange of $1.2 million (zero percent). The decrease was partially offset by favorable pricing~~

3635

foreign currency exchange of $0.4 million (zero percent), partially offset by favorable pricing and sales mix of $03.57 million (~~zero~~one percent), comprised of ~~road~~pavement technologies ($3.7.0 million), offset by ~~industrial~~road ~~specialties~~markings ($3.23 million).

Segment EBITDA. The decrease of $5117.04 million in 2024 was driven by aLIFO ~~volume~~impact ~~decrease~~ of $4518.05 million, ~~higher~~a ~~manufacturing~~volume ~~costs~~decline of $218.47 million, ~~primarily due to higher cost CTO,~~ and unfavorable foreign currency exchange and other charges of $52.1 6 million. The decrease was partially offset by decreased manufacturing costs of $8.5 million, favorable pricing and sales mix of $03.57 million, and ~~lower~~decreased SG&A expenses of $~~20.~~0.2 million~~, which benefited from the Performance Chemicals' repositioning and cost savings initiatives implemented in 2023~~.

Year Ended December 31, 2023 vs. 2022

Segment net sales. The sales increase was driven by favorable pricing and sales mix of $93.1 million (11 percent), comprised of industrial specialties ($62.7 million) and road technologies product lines ($30.4 million), respectively. The increase was partially offset by a volume decline of $65.3 million (seven percent), driven by a decline in industrial specialties ($163.7 million), partially offset by growth in road technologies ($98.4 million). Unfavorable foreign currency exchange also impacted Net sales by $0.8 million (zero percent).

Segment EBITDA. Segment EBITDA decreased $94.7 million, mainly due to higher manufacturing costs of $157.8 million primarily due to increased CTO cost, a volume decline of $34.1 million, and unfavorable foreign currency exchange impacts of $0.1 million, These increases were partially offset by favorable pricing and sales mix of $89.7 million, and decreased SG&A expenses of $7.6 million.

Advanced Polymer Technologies

~~2024~~2025 Performance Summary

Advanced Polymer Technologies ~~generated~~("APT") ~~higher~~sales ~~volumes~~of $160.2 million declined 15 percent year over year. asDuring 2025 APT faced headwinds from the ~~segment~~indirect ~~made~~impact ~~progress~~of intariffs, ~~end~~combined ~~markets~~with ~~such~~the ascontinued ~~elastomers~~weak demand, ~~adhesives~~particularly across the automotive, footwear and ~~coatings;~~industrial ~~however~~end markets. In addition, ~~unfavorable~~competitive ~~overall~~dynamics ~~product~~in ~~mix~~China ~~and~~continued ~~selective~~to ~~price~~pressure ~~concessions~~sales, ~~contributed~~most tonotably ain ~~revenue~~the ~~decline~~paint ofprotective ~~eight~~film ~~percent~~markets. ~~The~~As a result, sales declined 15% and segment ~~benefited~~EBITDA ~~from~~was 18% lower ~~energy~~year ~~costs~~over ~~and~~year andue ~~improvement~~to inlower ~~utilization~~volumes ~~rates~~that asmore athan ~~result~~offset ofimproved ~~higher~~operating ~~volumes~~efficiency. ~~but~~Despite these ~~cost~~pressures, ~~savings~~we ~~were~~held ~~more~~pricing ~~than~~and ~~offset~~maintained bya ~~the~~stable ~~revenue~~mix. ~~decline~~The team remained focused on operational discipline, ~~resulting~~which indrove ~~segment~~more ~~EBITDA~~reliable ofplant ~~$35~~production and reduced operating expenses.2 ~~million~~Favorable ~~and~~foreign aexchange ~~segment~~also supported results, enabling strong EBITDA ~~margin~~margins ofat 1820.~~7 percent~~0%.

In millions	Years Ended December 31,
	2024		2023		2022
	2025		2024		2023
Advanced Polymer Technologies - Net sales	$	~~188~~160.62	$	~~204~~188.06	$	~~244~~204.70
Segment EBITDA	$	3532.21	$	4439.50	$	4049.0

Net Sales Comparison of Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

			Change vs. prior year
In millions	Prior year Net sales		Volume	Price/Mix	Currency effect	Current year Net sales
Year Ended December 31, 2024 vs 2023	$	204.0	7.1	(18.8)	(3.7)	$	188.6
Year Ended December 31, 2025 vs 2024	$	188.6	(28.5)	(1.7)	1.8	$	160.2
Year Ended December 31, 2023 vs 2022	$	244.7	(58.3)	17.0	0.6	$	204.0
Year Ended December 31, 2024 vs 2023	$	204.0	7.0	(18.7)	(3.7)	$	188.6

Year Ended December 31, 2025 vs. 2024

Segment net sales. The decrease of $28.4 million in 2025 was driven by a volume decline of $28.5 million (fifteen percent), and unfavorable pricing and sales mix of $1.7 million (one percent), partially offset by favorable foreign currency exchange and other charges $1.8 million (one percent).

Segment EBITDA. The decrease of $6.9 million in 2025 was driven by a volume decline of $10.4 million, unfavorable pricing and sales mix of $1.8 million, and higher SG&A expenses of $1.5 million. The decrease was partially offset by lower manufacturing costs of $3.7 million, and favorable foreign currency exchange impacts and other charges of $3.1 million.

Year Ended December 31, 2024 vs. 2023

Segment net sales. The decrease of $15.4 million in 2024 was driven by unfavorable pricing and sales mix of $18.87 million (nine percent), and unfavorable foreign currency exchange of $3.7 million (two percent), partially offset by volume growth of $7.10 million (~~three~~3 percent).

Segment EBITDA. The decrease of $910.30 million in 2024, was driven by unfavorable pricing and sales mix of $18.8 million, and unfavorable foreign currency exchange impacts and other charges of $2.89 million. The decrease was partially offset by ~~lower~~decreased manufacturing costs of $8.8 million, and volume growth of $2.9 million~~, and lower SG&A expenses of $0~~.~~6 million.~~

Discontinued Operations


Reconciliation of Net Income (Loss) from discontinued operations to EBITDA from discontinued operations (Non-GAAP)
	Years Ended December 31,
In millions	2025		2024		2023
Net income (loss) from discontinued operations (GAAP)	$	(16.8)	$	(308.9)	$	(111.2)
Provision (benefit) for income taxes on discontinued operations	(2.8)		(86.2)		(28.9)

Depreciation and amortization	1.2		8.7		25.4
Restructuring and other (income) charges, net (2)	42.9		168.1		116.8
Goodwill impairment charge (3)	—		42.5		—

Loss on CTO resales (4)	—		52.7		22.0
CTO supply contract termination charges (5)	—		100.0		—
(Gain) loss on strategic investments (6)	—		9.3		—
Inventory charges (7)	—		6.3		19.7
Indirect costs allocated to Divestiture (8)	(14.5)		(22.1)		(37.9)

EBITDA from discontinued operations (Non-GAAP) (1)(9)	$	10.0	$	(29.6)	$	5.9

_______________

(1) EBITDA from discontinued operations is defined as net sales from discontinued operations less operating expenses from discontinued operations (operating expenses from discontinued operations consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from EBITDA from discontinued operations: income taxes, depreciation, amortization, restructuring and other income (charges), net, inventory lower of cost or market charges associated with restructuring actions, goodwill impairment charges, gain (loss) on sale of strategic investments, loss on CTO resales, CTO supply contract termination charges, indirect costs allocated to Divestiture.

(3) During the second quarter of 2024, the company concluded that the carrying value of the Performance Chemicals reporting unit exceeded its fair value, resulting in a non-cash goodwill impairment charge.

(4) Due to the DeRidder Plant closure and the corresponding reduced CTO refining capacity, we were obligated, under an existing CTO supply contract, to purchase CTO through 2025 at amounts in excess of required CTO volumes. On July 1, 2024, the CTO supply contract that resulted in these excess CTO volumes was terminated. As a result of the termination, the purchases under the CTO supply contract ended effective June 30, 2024. The CTO resale activity described above ended in 2024.

(5) As consideration for the termination of the CTO supply contract, we made a cash payment in the amount of $50.0 million on July 1, 2024 and an additional cash payment in the amount of $50.0 million on October 8, 2024. Since this contract termination is directly attributable to the Performance Chemicals' repositioning, that is, it does not represent normal, recurring expenses necessary to operate our business, we have excluded the CTO supply contract termination charges for the purposes of calculating our non-GAAP financial performance measures.

(6) We exclude gains and losses from strategic investments from our segment results, as well as our non-GAAP financial measures, because we do not consider such gains or losses to be directly associated with the operational performance of the segment. We believe that the inclusion of such gains or losses, would impair the factors and trends affecting the historical financial performance of our reportable segments. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our EBITDA from discontinued operations.

(7) For the twelve months ended December 31, 2024 and 2023, respectively, inventory charges represent lower of cost or market charges associated with the Performance Chemicals' repositioning and restructuring actions. These charges were not allocated in the measurement of profitability used by our CODM and are therefore excluded from EBITDA from discontinued operations. Amounts are included in Cost of sales from discontinued operations. See Note 20 for more information.

(8) EBITDA from discontinued operations includes indirect costs that were previously allocated to the Divestiture but not eligible for discontinued operations accounting treatment.

(9) We believe this non-GAAP financial measure provides management as well as investors, potential investors, securities analysts, and others with useful information to evaluate the performance of the business, because such measure, when viewed together with our financial results computed in accordance with GAAP, provides a more complete understanding of the factors and trends affecting our historical financial performance and projected future results. We believe this measure is useful because it excludes the effects of financing and investment activities as well as non-operating activities.

Year Ended December 31, 2023 vs. 2022


	Years Ended December 31,
In millions	2025		2024		2023
Net sales from discontinued operations	$	121.6	$	206.3	$	476.6
Income (loss) from discontinued operations, net of income taxes	(16.8)		(308.9)		(111.2)



EBITDA from discontinued operations	$	10.0	$	(29.6)	$	5.9

~~Segment~~Net ~~net~~Sales ~~sales.~~Comparison ~~The sales decrease was driven by a volume decline~~ of ~~$58.3~~Years ~~million~~Ended ~~(24~~December ~~percent)~~31, ~~partially~~2025, ~~offset by favorable pricing and sales mix of $17.0 million (seven percent)~~2024, and ~~favorable foreign currency exchange of $0.6 million (zero percent).~~2023

Segment EBITDA. Segment EBITDA increased $4.5 million, mainly due to favorable pricing and sales mix of $17.1 million, decreased manufacturing costs of $9.9 million, and decreased SG&A expenses of $5.9 million. These increases were partially offset by volume declines of $23.7 million, and unfavorable foreign currency exchange impacts and other miscellaneous charges of $4.7 million.


			Change vs. prior year
In millions	Prior year Net sales		Volume	Price/Mix	Currency effect	Current year Net sales
Year Ended December 31, 2025 vs 2024	$	206.3	(81.5)	(3.0)	(0.2)	$	121.6


Year Ended December 31, 2024 vs 2023	$	476.6	(266.3)	(3.2)	(0.8)	$	206.3

Year Ended December 31, 2025 vs. 2024

Net sales from discontinued operations. The decrease of $84.7 million in 2025 was driven by volume decline of $81.5 million (40 percent), unfavorable pricing and sales mix of $3.0 million (one percent), and unfavorable foreign currency exchange of $0.2 million (zero percent).

EBITDA from discontinued operations. The increase of $39.5 million in 2025 was driven by lower manufacturing costs of $25.2 million and LIFO liquidation benefit of $20.7 million, favorable foreign currency exchange and other charges of $4.1 million, which included a one time insurance settlement of $1.0 million in 2025, and lower SG&A costs of $3.7 million. The increase was partially offset by a volume decline of $11.2 million, and unfavorable pricing and sales mix of $3.0 million.

Year Ended December 31, 2024 vs. 2023

Net sales from discontinued operations. The decrease of $270.3 million in 2024 was driven by a volume decline of $266.3 million (56 percent), unfavorable pricing and sales mix of $3.2 million (one percent), and unfavorable foreign currency exchange of $0.8 million (zero percent).

EBITDA from discontinued operation. The decrease of $35.5 million in 2024 was driven by a volume decline of $36.3 million, increased manufacturing costs of $17.8 million, unfavorable price and sales mix of $3.2 million, and unfavorable foreign currency exchange and other charges of $2.7 million. The decrease was partially offset by lower SG&A costs of $18.1 million, and a LIFO liquidation benefit of $6.4 million.

Use of Non-GAAP Financial Measures

Ingevity has presented the financial ~~measure~~measures, Total Adjusted EBITDA, Adjusted EBITDA from continuing operations, and Adjusted EBITDA from discontinued operations, defined below, which ~~has~~have not been prepared in accordance with U.S. generally accepted accounting principles (“"GAAP”") and has provided a reconciliation to net income, the most directly comparable financial measure calculated in accordance with GAAP. ~~Adjusted~~These ~~EBITDA~~measures isare not meant to be considered in isolation nor as a substitute for the most directly comparable financial measure calculated in accordance with GAAP. Total Adjusted EBITDA, isAdjusted EBITDA from continuing operations, and Adjusted EBITDA from discontinued operations are utilized by management as a measure of profitability.

We believe ~~this~~these non-GAAP financial ~~measure~~measures ~~provides~~provide management as well as investors, potential investors, securities analysts, and others with useful information to evaluate the performance of the business, because such measure, when viewed together with our financial results computed in accordance with GAAP, provides a more complete understanding of the factors and trends affecting our historical financial performance and projected future results. We believe ~~Adjusted~~these ~~EBITDA~~measures isare a useful ~~measure~~ because itthey ~~excludes~~exclude the effects of financing and investment activities as well as non-operating activities.

Adjusted EBITDA from continuing operations is defined as net income (loss) from continuing operations plus interest expense, ~~net~~interest income, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, goodwill impairment charges, long lived asset impairment charge, acquisition and other-related (income) costs, ~~goodwill impairment charge,~~ litigation verdict charges, (~~loss~~gain) ~~gain~~loss on strategic investments, ~~loss~~proxy oncontest ~~CTO resales~~charges, ~~CTO~~portfolio ~~supply~~realignment ~~contract termination charges~~costs, and pension and postretirement settlement and curtailment (income) charges, net.

~~This~~Adjusted ~~non-GAAP~~EBITDA ~~measure~~from isdiscontinued ~~not~~operations ~~intended~~is todefined ~~replace~~as ~~the~~net ~~presentation~~income of(loss) ~~financial~~from ~~results~~discontinued inoperations ~~accordance~~plus ~~with~~interest ~~GAAP~~expense, ~~and~~interest ~~investors~~income, ~~should~~provision ~~consider~~(benefit) ~~the~~for ~~limitations~~income ~~associated~~taxes, ~~with~~depreciation, ~~these non-GAAP measures~~amortization, ~~including~~restructuring ~~the~~and ~~potential~~other ~~lack~~(income) ofcharges, ~~comparability~~net, ofgoodwill ~~these~~impairment ~~measures~~charges, ~~from~~acquisition ~~one~~and ~~company~~other-related to(income) ~~another.~~costs, A(gain) ~~reconciliation~~loss ofon ~~Adjusted~~strategic ~~EBITDA~~investments, toloss ~~net~~on ~~income~~CTO isresales, ~~set~~and ~~forth~~CTO ~~within~~supply ~~this~~contract ~~section~~termination charges.

Reconciliation of Net Income (Loss) to Adjusted EBITDA
	Years Ended December 31,
In millions	2024		2023		2022
Net income (loss) (GAAP)	$	(430.3)	$	(5.4)	$	211.6
Interest expense	97.8		93.3		61.8
Interest income	(7.7)		(6.3)		(7.5)
Provision (benefit) for income taxes	(105.3)		(4.7)		58.0
Depreciation and amortization (1)	108.3		122.8		108.8
Restructuring and other (income) charges, net (2)	186.2		170.2		13.8
Goodwill impairment charge (3)	349.1		—		—
Acquisition and other-related costs (4)	0.3		4.5		5.9
Loss on CTO resales (5)	52.7		22.0		—
CTO supply contract termination charges (6)	100.0		—		—
(Gain) loss on strategic investments (7)	11.4		(19.3)		—
Pension and postretirement settlement and curtailment charges (income), net (8)	0.2		—		0.2
Adjusted EBITDA (Non-GAAP)	$	362.7	$	377.1	$	452.6

Total adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations.

~~_______________~~These non-GAAP measures are not intended to replace the presentation of financial results in accordance with GAAP and investors should consider the limitations associated with these non-GAAP measures, including the potential lack of comparability of these measures from one company to another. Reconciliations are set forth within this section.

(1) Refer to Note 19 for more information.

(2) We regularly perform strategic reviews and assess the return on our operations, which sometimes results in a plan to restructure the business. These costs are excluded from our reportable segment results and for the purposes of calculating our non-GAAP financial performance measures. Refer to Note 15 for more information on the charges.

(3) Refer to Note 8 for more information.

(4) Charges represent costs incurred to complete and integrate acquisitions and other strategic investments and include the expensing of the inventory fair value step-up resulting from the application of purchase accounting for acquisitions and certain legal and professional fees associated with the completion of acquisitions and strategic investments. Refer to Note 16 for more information.

(5) Due to the DeRidder Plant closure, and the corresponding reduced CTO refining capacity, we were obligated, under an existing CTO supply contract, to purchase CTO at amounts in excess of required CTO volumes. As of July 1, 2024, we terminated the CTO supply contract that resulted in these excess CTO volumes. As a result of the termination of this contract the purchases under the CTO supply contract ended, effective June 30, 2024, and we ended our CTO resale activity as of December 31, 2024. Since these CTO resale activities

are directly attributable to the Performance Chemicals’ repositioning, that is, they do not represent normal, recurring expenses necessary to operate our business, we have excluded the CTO resale (income) charges for the purposes of calculating our non-GAAP financial performance measures. For the years ended December 31, 2024 and 2023, the loss on CTO resales relates to the Performance Chemicals segment. Refer to Note 2 and Note 15 for more information.


Reconciliation of Net Income (Loss) from Continuing Operations (GAAP) and Net Income (Loss) from Discontinued Operations (GAAP) to Adjusted EBITDA from Continuing Operations (Non-GAAP), Adjusted EBITDA from Discontinued Operations (Non-GAAP), and Total Adjusted EBITDA (Non-GAAP)
	Years Ended December 31,
In millions	2025		2024		2023
Net income (loss) from continuing operations (GAAP)	$	(150.3)	$	(121.4)	$	105.8
Interest expense	78.3		97.8		93.3
Interest income	(5.2)		(7.7)		(6.3)
Provision (benefit) for income taxes on continuing operations	8.2		(19.1)		24.2
Depreciation and amortization (1)	105.2		99.6		97.4

Restructuring and other (income) charges, net (2)	12.8		18.1		53.4
Goodwill impairment charge (3)	183.8		306.6		—
Acquisition and other-related costs (4)	—		0.3		4.5
(Gain) loss on strategic investments (5)	19.6		2.1		(19.3)
Long lived assets impairment charge (6)	109.3		—		—
Proxy contest charges (7)	8.2		—		—
Portfolio realignment costs (8)	3.1		—		—
Pension and postretirement settlement and curtailment charges (income), net (9)	—		0.2		—
Adjusted EBITDA from continuing operations (Non-GAAP)	$	373.0	$	376.5	$	353.0

Net income (loss) from discontinued operations (GAAP)	$	(16.8)	$	(308.9)	$	(111.2)
Provision (benefit) for income taxes on discontinued operations	(2.8)		(86.2)		(28.9)
Interest expense, net	—		—		—
Depreciation and amortization (1)	1.2		8.7		25.4
Restructuring and other (income) charges, net (2)	42.9		168.1		116.8
Goodwill impairment charge (3)	—		42.5		—

Loss on CTO resales (10)	—		52.7		22.0
CTO supply contract termination charges (11)	—		100.0		—
(Gain) loss on strategic investments (5)	—		9.3		—
Adjusted EBITDA from discontinued operations (Non-GAAP)	$	24.5	$	(13.8)	$	24.1

Total Adjusted EBITDA (Non-GAAP)	$	397.5	$	362.7	$	377.1

(6) As consideration for the termination of the CTO supply contract, we made cash payments totaling $100.0 million during 2024. Since this contract termination is directly attributable to the Performance Chemicals’ repositioning, that is, it does not represent normal, recurring expenses necessary to operate our business, we have excluded the CTO supply contract termination charges for the purposes of calculating our non-GAAP financial performance measures. Refer to Note 2 and Note 15 for more information._______________

(71) WeRefer ~~exclude gains and losses from strategic investments from our segment results, as well as our non-GAAP financial measures, because we do not consider such gains or losses~~ to beNote ~~directly~~18 ~~associated with the operational performance of the segment. We believe that the inclusion of such gains or losses, would impair the factors~~ and trends affecting the historical financial performance of our reportable segments. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our reportable segment results. Refer to Note 520 for more information.

(82) ~~Our~~We ~~pension~~regularly ~~and~~perform ~~postretirement~~strategic ~~settlement~~reviews and ~~curtailment~~assess ~~charges (income) are related to~~ the ~~acceleration~~return ofon ~~prior~~our ~~service costs~~operations, aswhich asometimes ~~result~~results ofin a ~~reduction~~plan into ~~the~~restructure ~~number of participants within~~ the ~~Union Hourly defined benefit pension plan~~business. These costs are excluded from our reportable segment results ~~because~~and wefor ~~consider~~the ~~these~~purposes ~~costs~~of tocalculating ~~be outside~~ our ~~operational~~non-GAAP financial performance measures. WeRefer ~~continue~~ to ~~include~~Note ~~the~~15 ~~service cost, amortization of prior service cost, interest costs, expected return on plan assets,~~ and ~~amortized actual gains and losses in our segment EBITDA. Refer to~~ Note 1420 for more information.

~~Revision~~(3) Refer to ~~Previously~~Note ~~Reported~~8 ~~Adjusted~~and ~~EBITDA~~Note ~~(Non-GAAP)~~20 for more information.

We(4) ~~revised~~Charges ~~our~~represent ~~December~~costs ~~31,~~incurred ~~2023~~to ~~non-GAAP~~complete ~~Adjusted~~and ~~EBITDA~~integrate ~~calculation~~acquisitions toand ~~remove~~other ~~previous~~strategic ~~adjustments~~investments, ofand ~~$19.7~~include ~~million~~the ~~related~~expensing ~~to inventory lower~~ of ~~cost or market charges associated with~~ the ~~Company's~~inventory ~~Performance~~fair ~~Chemicals~~value ~~repositioning.~~step-up ~~This~~resulting ~~change was made to address a request~~ from the ~~Securities~~application ~~and~~of ~~Exchange~~purchase ~~Commission~~accounting tofor ~~revise~~acquisitions, ~~future~~and ~~filings~~certain tolegal noand ~~longer~~professional ~~exclude~~fees ~~these~~associated ~~adjustments~~with ~~from non-GAAP performance measures. The following table presents~~ the ~~twelve~~completion ~~months~~of ~~ended~~acquisitions ~~December 31, 2023 as previously reported~~ and asstrategic ~~revised~~investments.

Reconciliation of Net Income (Loss) to Adjusted EBITDA
	Twelve Months Ended December 31, 2023
In millions	As previously reported		As revised
Net income (loss) (GAAP)	$	(5.4)	$	(5.4)
Interest expense	93.3		93.3
Interest income	(6.3)		(6.3)
Provision (benefit) for income taxes	(4.7)		(4.7)
Depreciation and amortization	122.8		122.8
Restructuring and other (income) charges, net	189.9		170.2
Acquisition and other-related costs	4.5		4.5
Loss on CTO resales	22.0		22.0
Gain on sale of strategic investment	(19.3)		(19.3)
Adjusted EBITDA (Non-GAAP)	$	396.8	$	377.1

(5) We exclude gains and losses from strategic investments from our segment results, as well as our non-GAAP financial measures, because we do not consider such gains or losses to be directly associated with the operational performance of the segment. We believe that the inclusion of such gains or losses, would impair the factors and trends affecting the historical financial performance of our reportable segments. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our reportable segment results. Refer to Note 5 for more information.

(6) For the year ended December 31, 2025, charge relates to the Performance Chemicals reportable segment. Refer to Note 7 and Note 8 for more information.

(7) Charges represent legal and other professional service fees as well as incremental proxy solicitation costs related to a proxy contest.

(8) Charges represent professional service fees related to a review of the company's portfolio.

(9) Our pension and postretirement settlement and curtailment charges (income) are related to the acceleration of prior service costs, as a result of a reduction in the number of participants within the Union Hourly defined benefit pension plan. These are excluded from our segment results because we consider these costs to be outside our operational performance. We continue to include the service cost, amortization of prior service cost, interest costs, expected return on plan assets, and amortized actual gains and losses in our segment EBITDA. Refer to Note 14 for more information.

(10) Due to the DeRidder Plant closure, and the corresponding reduced CTO refining capacity, we were obligated, under an existing CTO supply contract, to purchase CTO at amounts in excess of required CTO volumes. As of July 1, 2024, we terminated the CTO supply contract that resulted in these excess CTO volumes. As a result of the termination of this contract the purchases under the CTO supply contract ended, effective June 30, 2024, and we ended our CTO resale activity as of December 31, 2024. Since these CTO resale activities are directly attributable to the Performance Chemicals' repositioning, that is, they do not represent normal, recurring expenses necessary to operate our business, we have excluded the CTO resale (income) charges for the purposes of calculating our non-GAAP financial performance measures. For the years ended December 31, 2024 and 2023, the loss on CTO resales relates to the Performance Chemicals segment. Refer to Note 20 for more information.

(11) As consideration for the termination of the CTO supply contract, we made cash payments totaling $100.0 million during 2024. Since this contract termination is directly attributable to the Performance Chemicals' repositioning, that is, it does not represent normal, recurring expenses necessary to operate our business, we have excluded the CTO supply contract termination charges for the purposes of calculating our non-GAAP financial performance measures. Refer to Note 20 for more information.

Adjusted EBITDA

~~Year~~Years Ended December 31, 2025, 2024, ~~2023~~ and ~~2022~~2023

The factors that impacted Adjusted EBITDA period to period are the same factors that affected earnings discussed in the sections entitled "Results of Operations" and "Segment Operating Results" within MD&A.

Current Full Year Company Outlook vs. Prior Year

~~Net~~Our ~~sales~~outlook ~~are~~includes ~~expected~~a tofull beyear ~~between~~of ~~$1.3~~operating ~~billion~~results ~~and $1.4 billion~~ for ~~2025.~~the WeAdvanced ~~expect~~Polymer ~~growth~~Technologies ~~in our Performance Materials~~ reportable segment ~~due~~and ~~to increased pricing on select products while global automotive production remains flat compared to~~ the ~~prior year. For our~~ Performance Chemicals ~~reportable~~road ~~segment,~~markings ~~we expect the industrial specialties~~ product line. toOur ~~deliver~~outlook ~~Net~~excludes ~~sales between $160 and $200 million, which reflects~~ the ~~impact~~divested ~~of our repositioning actions to improve profitability by focusing on higher margin end markets, as well as continued weak~~ industrial ~~demand.~~specialties ~~Additionally, we expect our road technologies~~ product line, ~~Net sales to improve compared to 2024~~ as ~~adverse weather conditions experienced in key states within~~ the ~~U.S.~~sale ~~negatively~~closed ~~impacted~~on ~~2024.~~January ~~Our Advanced Polymer Technologies reportable segment anticipates modest growth as industrial demand recovery will be tempered by continued competitive dynamics~~1, ~~particularly in Asia~~2026.

~~Adjusted~~Net ~~EBITDA~~sales isare expected to be between $~~400~~1.1 ~~million~~billion and $~~415~~1.2 ~~million~~billion for ~~2025~~2026. We expect ~~modest~~Net ~~improvement~~sales in our Performance Materials reportable segment ~~EBITDA,~~to ~~while~~grow ~~maintaining~~low-single ~~segment~~digits ~~EBITDA~~as ~~margins~~increased ~~around~~pricing 50on ~~percent,~~select asproducts ~~improved~~partially ~~pricing~~offsets ~~and~~forecasted ~~continued~~decline ~~operational~~in ~~efficiencies~~global ~~will~~automotive beproduction ~~muted~~for byICE ~~expected~~powertrains ~~higher~~compared ~~input~~to ~~costs,~~the ~~particularly~~prior ~~energy,~~year. ~~and~~We ~~higher~~expect ~~spend~~Net onsales ~~innovation~~in ~~activities. In~~ our Performance Chemicals reportable segment, weinclusive ~~expect~~of ~~improved~~the ~~segment~~road ~~EBITDA,~~markings ~~with~~product ~~segment~~line, ~~EBITDA~~to ~~margins~~grow ~~in the~~ mid-~~to-high~~ single digits. ~~The~~through ~~segment~~continued ~~will~~adoption ~~benefit~~of ~~from~~our ~~revenue~~warm ~~growth~~mix asphalt products in our ~~road~~pavement technologies product line. ~~and~~For ~~further savings from~~ our ~~repositioning~~Advanced ~~actions.~~Polymer ~~While~~Technologies wereportable ~~expect to benefit from lower CTO costs in the latter part of the year~~segment, we expect ~~these~~Net ~~benefits~~sales to begrow ~~offset~~low-single bydigits, ~~price~~reflecting ~~concessions~~a tomild ~~align~~recovery ~~with~~in ~~market~~industrial ~~pricing.~~end ~~We anticipate that our Advanced Polymer Technologies segment EBITDA will improve versus prior year as our enacted pricing and mix strategies will produce segment EBITDA margins of around 20 percent~~markets.

AAdjusted ~~reconciliation~~EBITDA ofis ~~net~~expected ~~income~~to be between $380 million and $400 million for 2026. We expect our Performance Materials reportable segment to ~~adjusted~~maintain segment EBITDA asmargins ~~projected~~consistent ~~for~~with 2025, as revenue growth is ~~not~~partially ~~provided.~~offset ~~Ingevity~~by ~~does~~selective ~~not~~growth ~~forecast~~opportunities. ~~net~~In ~~income~~our asPerformance itChemicals ~~cannot~~reportable segment, ~~without~~we ~~unreasonable~~expect ~~effort,~~segment ~~estimate~~EBITDA ormargins ~~predict~~in ~~with~~the ~~certainty~~mid-teens. ~~various~~The ~~components~~segment ofis ~~net~~expected ~~income~~to benefit from revenue growth in our pavement technologies product line but will be burdened by stranded costs from the divested industrial specialties product line. ~~These~~We ~~components,~~anticipate ~~net~~that ofour ~~tax,~~Advanced ~~include~~Polymer ~~further~~Technologies ~~restructuring~~segment ~~and~~EBITDA ~~other~~will ~~income~~improve ~~(charges),~~versus ~~net;~~prior ~~additional~~year ~~acquisition~~as ~~and~~volume ~~other-related~~growth ~~income~~is ~~(costs);~~partially ~~additional~~offset ~~pension~~by ~~and~~defensive ~~postretirement~~pricing ~~settlement~~actions ~~and~~to ~~curtailment~~maintain ~~(income)~~segment ~~charges;~~EBITDA margins of around 20 percent. Corporate and ~~revisions~~Other ~~due~~costs toare ~~legislative~~expected ~~tax~~to ~~rate~~be ~~changes~~consistent 2025. Additionally, ~~discrete~~we ~~tax~~expect ~~items~~to ~~could~~fully ~~drive~~eliminate ~~variability~~the in$15 ~~our~~million ~~projected~~of ~~effective~~stranded ~~tax~~costs, ~~rate.~~resulting ~~All~~from ofthe ~~these~~divested ~~components~~industrial ~~could~~specialties ~~significantly~~product ~~impact~~line ~~such~~over ~~financial~~the ~~measures~~course of 2026. ~~Further,~~As inwe accumulate the ~~future~~savings, ~~other~~we ~~items~~expect ~~with~~around ~~similar~~$8 ~~characteristics~~million to ~~those~~$12 ~~currently~~million ~~included~~to inburden ~~adjusted~~the ~~EBITDA~~Company in 2026, ~~that~~the ~~have~~majority aof ~~similar~~which ~~impact~~will onbe ~~comparability~~absorbed ofby ~~periods,~~our ~~and~~Performance ~~which~~Chemicals ~~are~~reportable ~~not~~segment. ~~known~~We atexpect ~~this~~that ~~time,~~the ~~may~~full ~~exist~~run ~~and~~rate ~~impact~~from ~~adjusted~~these ~~EBITDA~~savings will be achieved in 2027.

Our effective tax rate is expected to be between 22 to 24 percent. Adjusted Earnings Per Share is expected to be between $4.80 and $5.20.

A reconciliation of net income from continuing operations, to adjusted EBITDA from continuing operations, as projected for 2026 is not provided. Ingevity does not forecast net income as it cannot, without unreasonable effort, estimate or predict with certainty various components of net income. These components, net of tax, include further restructuring and other

income (charges), net; additional acquisition and other-related income (costs); additional pension and postretirement settlement and curtailment (income) charges; and revisions due to legislative tax rate changes. Additionally, discrete tax items could drive variability in our projected effective tax rate. All of these components could significantly impact such financial measures. Further, in the future, other items with similar characteristics to those currently included in adjusted EBITDA from continuing operations, that have a similar impact on comparability of periods, and which are not known at this time, may exist and impact adjusted EBITDA from continuing operations.

Liquidity and Capital Resources

The primary source of liquidity for our business is the cash flow provided by operating activities. We expect our cash flow provided by operations combined with cash on hand and available capacity under our revolving credit facility and revolving accounts receivable securitization to be sufficient to fund our planned operations and meet our interest and other contractual obligations for at least the next twelve months. As of December 31, ~~2024~~2025, our undrawn capacity under our revolving credit facility was $~~302~~474.40 million. Over the next twelve months, we expect to fund the following: ~~debt principal repayments,~~ interest payments, capital expenditures, income tax payments, ~~additional~~purchases ~~spending~~pursuant ~~associated~~to ~~with~~ our ~~Performance~~stock ~~Materials'~~repurchase ~~intellectual~~program ~~property~~(and ~~litigation~~related excise tax payments), ~~and~~BASF ~~restructuring~~litigation ~~activities~~verdict, ~~such~~including aspost-judgment ~~the~~interest ~~repositioning~~and ofpotentially ~~our~~legal ~~Performance~~fees ~~Chemicals~~and ~~reportable~~costs, ~~segment~~and restructuring activities as further described within Note 15. In addition, we may also evaluate and consider ~~purchases~~strategic ~~pursuant to our stock repurchase program (and related excise tax payments)~~investments, ~~strategic acquisitions~~divestitures, joint ventures, or other transactions to create stockholder value and enhance financial performance. In connection with such transactions, or to fund other anticipated uses of cash, we may modify our existing revolving credit facility, redeem all or part of our outstanding senior notes, seek additional debt financing, issue equity securities, or some combination thereof.

Cash and cash equivalents totaled $6878.01 million at December 31, ~~2024~~2025. We continuously monitor deposit concentrations and the credit quality of the financial institutions that hold our cash and cash equivalents, as well as the credit quality of our insurance providers, customers, and key suppliers.

Due to the global nature of our operations, a portion of our cash is held outside the U.S. The cash and cash equivalents balance at December 31, ~~2024~~2025, included $6374.92 million held by our foreign subsidiaries. Cash and earnings of our foreign subsidiaries are generally used to finance our foreign operations and their capital expenditures. As of December 31, 2025, we determined that the earnings of some of our subsidiaries are no longer permanently reinvested due to global volatility. We believe that our foreign holdings of cash will not have a material adverse impact on our U.S. liquidity. If these earnings were distributed, such amounts ~~would~~could be subject to U.S. federal income tax at the statutory rate less the available foreign tax credits, if any, and ~~would~~could potentially be subject to withholding taxes in the various jurisdictions. The potential tax implications of the repatriation of unremitted earnings are driven by facts at the time of distribution, therefore, it is not practicable to estimate the income tax liabilities that might be incurred if such cash and earnings were repatriated to the U.S. ~~Management~~Refer ~~does not currently expect~~ to ~~repatriate~~Note ~~cash~~16 ~~earnings~~for ~~from~~more ~~our foreign operations in order to fund U~~information.S. ~~operations.~~

Debt and Finance Lease Obligations

Refer to Note 10 for a summary of our outstanding debt obligations and revolving credit facility, and Note 13 for details of our lease obligations.

We are in the beginning stages of amending and extending our existing revolving credit facility, which we expect to execute before the end of the second quarter of 2026. The amendment and extension is expected to have materially consistent provisions to that of the existing credit agreement but with an extended maturity beyond June 23, 2027.

Other Potential Liquidity Needs

Share Repurchases

On July 25, 2022, our Board of Directors authorized the repurchase of up to $500.0 million of our common stock (the "2022 Authorization"), and rescinded the prior outstanding repurchase authorization with respect to the shares that remained unused under the prior authorization. Shares under the 2022 Authorization may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market prevailing conditions and other factors, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the year ended December 31, ~~2024~~2025, we repurchased no$56.3 million (inclusive of $0.4 million in excise tax) common stock, representing 1,061,460 shares of our common stock at a weighted average cost per share of $52.67. At December 31, ~~2024~~2025, $~~353~~297.45 million remained ~~available~~unused ~~for purchase~~ under our Board-authorized repurchase program.

Capital Expenditures

Projected ~~2025~~2026 capital expenditures are expected to be $5040 million to $7060 million, the majority of which will be spent on maintenance and safety, health and environment projects. We have no material commitments associated with these projected capital expenditures as of December 31, ~~2024~~2025.

4243

Cash flow comparison of Years Ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Net cash provided by (used in) operating activities	$	~~128~~331.62	$	~~205~~128.16	$	~~313~~205.41
Net cash provided by (used in) investing activities	(7957.5)		(7779.35)		(~~551~~77.93)
Net cash provided by (used in) financing activities	(70252.2)		(9970.92)		48(99.19)

Cash flows provided by (used in) operating activities

Cash provided by operating activities, ~~which~~inclusive of continuing and discontinued operations, consists of net income (loss) adjusted for non-cash items including the cash impact from changes in operating assets and liabilities (i.e., working capital), totaled $~~128~~331.62 million for the year ended December 31, ~~2024~~2025.

Cash provided by operating activities for ~~2024~~2025, when compared to ~~2023~~2024, ~~decreased~~increased by $76202.56 million. This ~~decrease~~increase was driven by a ~~payment~~decrease toin ~~terminate~~CTO asupply ~~Performance~~contract ~~Chemicals~~termination ~~CTO~~cash ~~contract~~outflows of $100.0 million, reduced ~~cash earnings of $75.8 million,~~ CTO resale cash outflows of $3552.53 million, ~~increased~~a ~~spending~~reduction onin ~~restructuring~~tax ~~initiatives~~payments of $1518.32 million, ~~and~~a andecrease ~~increase~~ in cash interest paid of $215.71 million due primarily to ~~rising~~lower interest rates and debt levels when compared to ~~2023.~~2024, ~~Partially~~reduced ~~offsetting~~spending ~~these~~on restructuring initiatives of $13.2 million, increased cash ~~outflows~~earnings ~~was~~of a$3.2 ~~net~~million, ~~reduction~~and an increase in trade working capital (accounts receivable, inventory, and accounts payable) of $~~108~~1.57 million,. ~~reduced~~Partially ~~employee~~offsetting ~~variable~~these ~~compensation~~cash ofinflows ~~$41.5~~was ~~million,~~increased ~~and~~employee avariable ~~reduction~~compensation ~~in tax payments~~ of $21.81 million.

Cash provided by operating activities for ~~2023~~2024, when compared to ~~2022~~2023, decreased by $~~108~~76.35 million. This decrease was driven by ~~lower~~a ~~cash~~payment ~~earnings~~to terminate a Performance Chemicals CTO contract of $41100.40 million, ~~increased~~CTO ~~employee~~resale ~~compensation~~cash ~~payments~~outflows of $3835.95 million, increased spending on restructuring initiatives of $3015.23 million, ana ~~increase~~net reduction in ~~cash~~trade ~~interest~~working ~~paid~~capital of(accounts ~~$27.9~~receivable, ~~million~~inventory, ~~due~~and toaccounts ~~higher~~payable) ~~average~~of ~~debt~~$5.8 ~~levels~~million, ~~resulting~~and ~~from~~an ~~the~~increase ~~October~~in ~~2022~~cash ~~acquisition~~interest paid of ~~Ozark~~$2.7 ~~Materials~~million ~~and~~due primarily to rising interest rates ~~during~~when compared to 2023,. ~~and~~Partially ~~CTO~~offsetting ~~resale~~these cash outflows was increased cash earnings of $1038.65 million., ~~This~~reduced ~~was~~employee ~~partially~~variable ~~offset~~compensation ~~by a reduction in tax payments~~ of $2541.15 million, and a ~~decrease~~reduction in ~~trade~~tax ~~working~~payments ~~capital (accounts receivable, inventory, and accounts payable)~~ of $152.68 million.

Cash flows provided by (used in) investing activities

Cash used in investing activities for ~~2024~~2025 was primarily driven by capital spending and strategic investment charges (refer to Note 5 for more information). Capital spending included the base maintenance capital supporting ongoing operations and cost improvement and growth spending.

Cash used in investing activities for ~~2023~~2024 was driven by capital spending~~, offset partially by the proceeds from the sale of a strategic investment (refer to Note 5 for more information)~~. Capital spending included the base maintenance capital supporting ongoing operations and cost improvement and growth spending in our Advanced Polymer Technologies segment.

Capital expenditure categories	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Maintenance	$	5034.8	$	6548.53	$	5760.49
Safety, health and environment	412.17		114.30		1911.73
Growth and cost improvement	229.79		3318.09		6517.42
Total capital expenditures	$	7757.64	$	~~109~~71.82	$	~~142~~89.54

Cash flows provided by (used in) financing activities

Cash used in financing activities for the year ended December 31, 2025, was $252.2 million and was primarily driven by net payments on the revolving credit facility and other borrowings of $192.3 million, and share repurchases of $56.3 million.

Cash used in financing activities for the year ended December 31, 2024, was $70.2 million and was primarily driven by net payments on the revolving credit facility and other borrowings of $66.1 million.

Cash used in financing activities for the year ended December 31, 2023, was $99.9 million and was driven by share repurchases of $92.1 million, and net payments on the revolving credit facility and other borrowings of $87.9 million, offset by proceeds from our accounts receivable securitization facility of $81.3 million. 44

New Accounting Guidance

Refer to Note 3 for a full description of recent accounting pronouncements including the respective expected dates of adoption and expected effects on our Consolidated Financial Statements.

Critical Accounting Policies and Estimates

Our principal accounting policies are described in Note 2. Our Consolidated Financial Statements are prepared in conformity with GAAP. The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. We have reviewed these accounting policies, identifying those that we believe to be critical to the preparation and understanding of our financial statements. Critical accounting policies are central to our presentation of results of operations and financial condition and require management to make estimates and judgments on certain matters. We base our estimates and judgments on historical experience, current conditions, and other reasonable factors.

The following is a list of those accounting policies that we have deemed most critical to the presentation and understanding of our results of operations and financial condition:

Revenue recognition

Our revenue is derived from contracts with customers, and substantially all our revenue is recognized when products are either shipped from our manufacturing and warehousing facilities or delivered to the customer. Revenue, net of returns and customer incentives, is based on the sale of manufactured products. Revenues are recognized when performance obligations under the terms of a contract with our customer are satisfied; generally, this occurs with the transfer of control of our products. For certain limited contracts, where we are producing goods with no alternative use and for which we have an enforceable right to payment for performance completed to date, we are recognizing revenue as goods are manufactured, rather than when they are shipped. Revenues are presented as Net sales on the consolidated statements of operations.

Since Net sales are derived from product sales only, we have disaggregated our Net sales by our product lines within each reportable segment. Net sales are measured as the amount of consideration we expect to receive in exchange for transferring goods. Sales, value add, and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Sales returns and allowances are not a normal practice in the industry and are not significant. Certain customers may receive cash-based incentives, including discounts and volume rebates, which are accounted for as variable consideration and included within Net sales. Shipping and handling fees billed to customers are included in Net sales. If we pay for the freight and shipping, we recognize the cost when control of the product has transferred to the customer as an expense within Cost of sales on the consolidated statements of operations. Payment terms with our customers are typically in the range of zero to sixty days. Because the period between when we transfer a promised good to a customer and when the customer pays for that good will be one year or less, we elect not to adjust the promised amount of consideration for the effects of any financing component, as it is not significant.

Valuation of tangible and intangible long-lived assets and goodwill

Our long-lived assets primarily include property, plant, and equipment, and other intangible assets. We periodically evaluate whether current events or circumstances indicate that the carrying value of long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to carrying value to determine whether an impairment exists.

If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. We report an asset to be disposed of at the lower of its carrying value or its estimated net realizable value.

~~Goodwill~~As ~~represents~~part ~~the excess~~ of ~~cost~~our ofbroader anstrategic ~~acquired~~portfolio ~~business~~review, ~~over~~we ~~the~~are ~~fair~~evaluating ~~value~~strategic ofalternatives ~~the~~for ~~identifiable~~our ~~tangible~~APT ~~and~~reportable ~~intangible~~segment, ~~assets~~including ~~acquired and liabilities assumed in~~ a ~~business~~potential ~~combination~~sale. We ~~conduct~~commenced a ~~required~~marketing ~~annual~~process ~~review~~for ofAPT ~~goodwill~~in ~~for~~January ~~potential~~2026, ~~impairment~~subsequent atto ~~October~~the 1December 31, or2025, ~~sooner~~balance ifsheet ~~events~~date. orAs ~~changes~~of inDecember ~~circumstances~~31, ~~indicate~~2025, ~~that~~we ~~the~~had ~~fair~~not ~~value~~engaged ofwith aprospective ~~reporting~~buyers, ~~unit~~distributed ismarketing ~~below~~materials, ~~its~~received ~~carrying~~third-party ~~value.~~indications ~~Our~~of ~~reporting~~interest, ~~units~~or ~~are~~otherwise ~~our~~obtained ~~operating~~market ~~segments,~~based iinformation.~~e.,~~ ~~Performance~~Since ~~Materials,~~the ~~Performance~~APT ~~Chemicals~~asset ~~and~~group ~~Advanced~~continued ~~Polymer~~to ~~Technologies.~~be Ifclassified ~~the~~as ~~carrying~~held ~~value~~and ofused aat ~~reporting~~December ~~unit~~31, ~~that~~2025, ~~includes~~the ~~goodwill~~Company ~~exceeds~~assessed ~~its~~whether ~~fair~~any indicators of

value, which is determined using both the income approach and market approach, goodwill is considered impaired. The income approach determines fair value based on discounted cash flow model derived from a reporting unit’s long-term forecasted cash flows. The market approach determines fair value based on the application of earnings multiples of comparable companies to the projected earnings of the reporting unit. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit but is limited to the total amount of goodwill allocated to the reporting unit. In performing the fair value analysis, management makes various judgments, estimates, and assumptions, the most significant of which are the assumptions related to revenue growth rates, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margin, and discount rate.

The factors we considered in developing our estimates and projections for cash flows include, but are not limited to, the following: (i) macroeconomic conditions; (ii) industry and market considerations; (iii) costs, such as increases in raw materials, labor, or other costs; (iv) our overall financial performance; and (v) other relevant entity-specific events that impact our reporting units.

The determination of whether goodwill is impaired involves a significant level of judgment in the assumptions underlying the approach used to determine the estimated fair values of our reporting units. We believe that the estimates and assumptions used in our impairment assessment are reasonable; however, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. We will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions, or changes in management’s business strategy indicate that there may be a probable indicator of impairment. It is possible that the assumptions used by management related to the evaluation may change or that actual results may vary significantly from management’s estimates.

The results of our October 1st annual review calculated that our APT reporting unit headroom, defined as the percentage difference between the fair value of a reporting unit and its carrying value, is 12 percent. Since the fair value of our APT reporting unit is higher than the carrying value, we have concluded that no impairment to goodwill is necessary. Our analysis includes significant assumptions such as revenue growth rate, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margin, and discount rate, which are judgmental, and variations in any assumptions could result in materially different calculations of fair value.

The below table shows how changes in certain significant assumptions utilized in our annual goodwill testing, specific to our APT reporting unit, impacts the calculated headroom.

Advanced Polymer Technologies Reporting Unit - Headroom Sensitivity Analysis

Revenue growth rate declines by 100 Bps

EBITDA margin declines by 100 Bps

Discount rate increases by 100 Bps

Headroom

(6)%

Business Combinations

Accounting for business combinations, which requires, among other things, the acquiring entity in a business combination to recognize the fair value of the assets acquired and liabilities assumed; the recognition of acquisition-related costs within the consolidated results of operations; the recognition of restructuring costs within the consolidated results of operations for which the acquirer becomes obligated after the acquisition date; and contingent purchase consideration to be recognized at fair value on the acquisition date with subsequent adjustments recognized on the consolidated statements of operations. We generally use qualified third-party consultants to assist management in determining the fair value of assets acquired and liabilities assumed. This includes, when necessary, assistance with the determination of lives and valuation of tangible property, plant, and equipment and identifiable intangibles, assisting management in determining the fair value of obligations associated with employee-related liabilities and assisting management in assessing obligations associated with legal and environmental claims.

asimpairment ~~goodwill.~~existed ~~Based~~under onASC ~~the~~360. ~~acquired~~Management ~~business’~~determined ~~end~~that ~~markets~~no ~~and~~such ~~products,~~indicators aswere ~~well~~present as ~~how~~of ~~the~~year-end. ~~chief~~We ~~operating~~continue ~~decision~~to ~~maker~~evaluate ~~will~~strategic ~~review~~alternatives ~~the~~for ~~business results~~APT, ~~determines~~and the ~~most~~outcome ~~appropriate~~of ~~operating~~a ~~segment~~potential ~~for~~sale ~~which~~remains touncertain. ~~integrate~~Depending on the ~~acquired~~final ~~business.~~terms ~~Goodwill~~of ~~acquired, if~~ any, ispotential ~~allocated~~transaction ~~to the reporting unit within~~ or atchanges ~~the~~in ~~operating~~market ~~segment~~conditions, ~~for~~we ~~which~~may ~~the acquired business will~~ be ~~integrated.~~required ~~Selection~~to ofrecognize ~~the~~an ~~appropriate~~impairment ~~reporting~~charge ~~unit~~or isloss ~~based~~ on ~~the~~sale ~~level~~in atfuture ~~which discrete financial information is available and reviewed by business management post-integration~~periods. ~~Operating results of the acquired entity are reflected within the Consolidated Financial Statements from the date of acquisition.~~

Goodwill represents the excess of cost of an acquired business over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. We conduct a required annual review of goodwill for potential impairment at October 1, or sooner if events or changes in circumstances indicate that the fair value of a reporting unit is below its carrying value. Our reporting units are our operating segments, i.e., Performance Materials, Performance Chemicals and Advanced Polymer Technologies. If the carrying value of a reporting unit that includes goodwill exceeds its fair value, which is determined using both the income approach and market approach, goodwill is considered impaired. The income approach determines fair value based on discounted cash flow model derived from a reporting unit's long-term forecasted cash flows. The market approach determines fair value based on the application of earnings multiples of comparable companies to the projected earnings of the reporting unit. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit but is limited to the total amount of goodwill allocated to the reporting unit. In performing the fair value analysis, management makes various judgments, estimates, and assumptions, the most significant of which are the assumptions related to revenue growth rates, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margins, and discount rate.

The determination of whether goodwill is impaired involves a significant level of judgment in the assumptions underlying the approach used to determine the estimated fair values of our reporting units. We believe that the estimates and assumptions used in our impairment assessment are reasonable; however, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. We will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions, or changes in management's business strategy indicate that there may be a probable indicator of impairment. It is possible that the assumptions used by management related to the evaluation may change or that actual results may vary significantly from management's estimates.

Income taxes

We are subject to income taxes in the U.S. and numerous foreign jurisdictions, including China and the United Kingdom. The provision for income taxes includes income taxes paid, currently payable or receivable, and deferred taxes. We follow the liability method of accounting for income taxes in accordance with current accounting standards regarding the accounting for income taxes. Under this method, deferred income taxes are recorded based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect at the time the underlying assets or liabilities are recovered or settled. The ability to realize deferred tax assets is evaluated through the forecasting of taxable income, historical and projected future operating results, the reversal of existing temporary differences, and the availability of tax planning strategies. Valuation allowances are recognized to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. WeDuring dothe ~~not~~year ~~provide~~ended ~~income~~December ~~taxes~~31, on2025, ~~undistributed~~we determined that the earnings of ~~consolidated~~some ~~foreign~~of our subsidiaries asare itno islonger ~~our~~permanently ~~intention~~reinvested ~~that~~due ~~such~~to global trade volatility. As a result of this change, we recorded $1.3 million of deferred taxes associated with our unremitted China earnings. ~~will~~The ~~remain~~remainder ~~invested~~of inour ~~those~~subsidiaries ~~companies~~remain permanently reinvested.

We recognize income tax positions that are more likely than not to be realized and accrue interest related to unrecognized income tax positions, which is included as a component of the income tax provision, on the consolidated statements of operations.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign currency exchange rate risk

Net sales originating from our foreign-based operations, primarily Europe, South America, and Asia, accounted for approximately 25 percent of our net sales in ~~2024~~2025. We have designated the local currency as the functional currency of our significant operations outside of the U.S. The primary currencies for which we have exchange rate exposure are the U.S. dollar versus the euro, the Japanese yen, the pound sterling, the Brazilian real, and the Chinese renminbi. In addition, certain of our domestic operations have sales to foreign customers. In the conduct of our foreign operations, we also make inter-company sales. All of this exposes us to the effect of changes in foreign currency exchange rates. Our earnings are therefore subject to change due to fluctuations in foreign currency exchange rates when the earnings in foreign currencies are translated into U.S. dollars. In some cases, to minimize the effects of such fluctuations, we use foreign exchange forward contracts to hedge firm and highly anticipated foreign currency cash flows. Our largest exposures are to the Brazilian real, the Chinese renminbi, and the euro. A hypothetical 10 percent adverse change, excluding the impact of any hedging instruments, in the average Brazilian real, Chinese renminbi, and euro to U.S. dollar exchange rates during the year ended December 31, ~~2024~~2025, would have decreased our net sales and income (loss) before income taxes for the year ended December 31, ~~2024~~2025, by approximately $1815 million or one percent and $64 million or ~~one~~three percent, respectively. Comparatively, a hypothetical 10 percent adverse change in the average Brazilian real, Chinese renminbi, and euro to U.S. dollar exchange rates during the year ended December 31, ~~2023~~2024 would have decreased our net sales and income (loss) before income taxes for the year ended December 31, ~~2023~~2024, by approximately $2016 million or one percent and $5 million or ~~two~~four percent, respectively.

Concentration of credit risk

The financial instruments that potentially subject Ingevity to concentrations of credit risk are accounts receivable. We limit our credit risk by performing ongoing credit evaluations and, when necessary, requiring letters of credit, guarantees, or collateral. Our largest customer as of December 31, ~~2024~~2025, had accounts receivable of $811.30 million and $78.53 million as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively. Sales to our largest customer, which is in our Performance Materials segment, were approximately ~~six~~seven percent of total net sales for the year ended December 31, ~~2024~~2025, ~~and~~seven ~~four~~ percent for ~~each of~~ the ~~years~~year ended December 31, ~~2023~~2024, and ~~2022~~six percent for the year ended December 31, ~~respectively~~2023. Sales to the automotive industry, which represents our largest industry concentration, were approximately 4048 percent of our consolidated Net sales. No customer individually accounted for greater than 10 percent of Ingevity's consolidated Net sales.

Commodity price risk

A portion of our manufacturing costs includes purchased raw materials, which are commodities whose prices fluctuate as market supply and demand fundamentals change. Accordingly, product margins and the level of our profitability tend to fluctuate with the changes in these commodity prices. The cost of energy is a manufacturing cost that is exposed to commodity pricing. Our sources of energy costs are diversified among electricity, steam and natural gas, with natural gas comprising our largest energy input.

Crude tall oil price risk

Our results of operations are directly affected by the cost of our raw materials, particularly CTO, which, excluding CTO resales, represents approximately 14 percent of consolidated cost of sales and 38 percent of our full company raw materials purchases for the year ended December 31, 2024. Pricing for CTO is driven by the limited supply of the product and competing demands for its use, both of which drive pressure on its price. Our gross profit and margins could be adversely affected by increases in the cost of CTO if we are unable to pass the increases on to our customers. Based on average pricing during the year ended December 31, 2024, a hypothetical unhedged, unfavorable 10 percent increase in the market price for CTO would have increased our cost of sales for the year ended December 31, 2024, by approximately $13.0 million or one percent, which we may not have been able to pass on to our customers. Comparatively, based on average pricing during the year ended December 31, 2023, a hypothetical unhedged, unfavorable 10 percent increase in the market price for CTO would have increased our cost of sales for the year ended December 31, 2023 by approximately $29.3 million or two percent. The repositioning of the Performance Chemicals reportable segment and the termination of the long-term CTO supply contract have significantly reduced the Company's volume requirements and exposure to CTO beginning in 2025.

Natural gas price risk

Natural gas, both direct and indirect, is our largest form of energy costs constituting approximately four percent of our ~~cost~~Cost of ~~goods~~sales ~~sold~~ for the year ended December 31, ~~2024~~2025. Increases in natural gas costs, unless passed on to our customers, would adversely affect our results of operations. If natural gas prices increase significantly, our business or results of operations may be adversely affected. We enter into certain derivative financial instruments to mitigate expected fluctuations in market prices and the volatility to earnings and cash flow resulting from changes to the pricing of natural gas purchases. Refer to Note 9 for more information on our natural gas price risk hedging program. For the year ended December 31, ~~2024~~2025, a hypothetical, unhedged 10 percent increase in natural gas pricing would have resulted in an increase to cost of sales of approximately $3.60 million or 3742 basis points. Comparatively, for the year ended December 31, ~~2023~~2024, a hypothetical, unhedged 10 percent increase in natural gas pricing would have resulted in an increase to ~~cost~~Cost of sales of approximately $43.76 million or 3948 basis points. As of December 31, ~~2024~~2025, we had 10.89 million mmBTUS (millions of British Thermal Units) in open natural gas derivative contracts, designated as cash flow hedges. As of December 31, ~~2024~~2025, open natural gas derivative contracts hedge a portion of forecasted transactions until ~~December~~September ~~2025~~2026. The fair value of the open natural gas derivative contracts as of December 31, ~~2024~~2025 and ~~2023~~2024 was a net asset (liability) of $(0.35) million and $(0.9)3 million, respectively.

Interest rate risk

During the third quarter of 2024, we entered into a floating-to-fixed interest rate swap with a notional amount of $200.0 million to manage the variability of cash flows in the interest rate payments associated with our existing Secured Overnight Financing Rate ("SOFR") based interest payments, effectively converting $200.0 million of our floating rate debt to a fixed rate. In accordance with the terms of this instrument, we receive floating rate interest payments based upon one-month U.S. dollar SOFR and in return are obligated to pay interest at a fixed rate of 3.84 percent until August 2026. The fair value of outstanding interest rate instruments at December 31, 2024 and 2023 was an asset of $0.6 million and zero, respectively.

As of December 31, 2024, approximately $555 million of our borrowings, adjusted for our $200 million floating-to-fixed interest rate swap, include a variable interest rate component. As a result, we are subject to interest rate risk with respect to such floating-rate debt. The weighted average interest rate associated with our variable interest rate borrowings, was 6.52 percent for the period ended December 31, 2024. For the year ended December 31, 2024, a hypothetical 100 basis point increase in the variable interest rate component of our borrowings would increase our annual interest expense by approximately $6 million or eight percent. Comparatively, for the year ended December 31, 2023, a hypothetical 100 basis point increase in the variable interest rate component of our borrowings would have increased our annual interest expense by approximately $8 million or 10 percent.

Interest rate risk

During the third quarter of 2024, we entered into a floating-to-fixed interest rate swap with a notional amount of $200.0 million to manage the variability of cash flows in the interest rate payments associated with our existing Secured Overnight Financing Rate ("SOFR") based interest payments, effectively converting $200.0 million of our floating rate debt to a fixed rate. In accordance with the terms of this instrument, we receive floating rate interest payments based upon one-month U.S. dollar SOFR and in return are obligated to pay interest at a fixed rate of 3.84 percent until August 2026. The fair value of outstanding interest rate instruments at December 31, 2025 and 2024 was an asset (liability) of $(0.4) million and $0.6 million, respectively.

As of December 31, 2025, $362.8 million of our borrowings, adjusted for our $200 million floating-to-fixed interest rate swap, include a variable interest rate component. As a result, we are subject to interest rate risk with respect to such floating-rate debt. The weighted average interest rate associated with our variable interest rate borrowings, was 5.60 percent for the period ended December 31, 2025. For the year ended December 31, 2025, a hypothetical 100 basis point increase in the variable interest rate component of our borrowings would increase our annual interest expense by approximately $4 million or 6 percent. Comparatively, for the year ended December 31, 2024, a hypothetical 100 basis point increase in the variable interest rate component of our borrowings would have increased our annual interest expense by approximately $6 million or 8 percent.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INDEX TO THE FINANCIAL STATEMENTS

Description									Page No.
Management's Report on Internal Control over Financial Reporting									4950
Report of Independent Registered Public Accounting Firm (PCAOB ID: 238)									5051
Consolidated Statements of Operations									5254
Consolidated Statements of Comprehensive Income (Loss)									5355
Consolidated Balance Sheets									5456
Consolidated Statements of Stockholders' Equity									5557
Consolidated Statements of Cash Flows									5658
Notes to the Consolidated Financial Statements									5860

4849

Ingevity Corporation

Management's Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company's internal control over financial reporting includes those policies and procedures that:

i.pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

ii.provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and

iii.provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the Company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, ~~2024~~2025, based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on its assessment and those criteria, management concluded that the Company maintained effective internal control over financial reporting as of December 31, ~~2024~~2025.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited the effectiveness of the Company's internal control over financial reporting as of December 31, ~~2024~~2025, as stated in their report, which is presented on the following page.

Date:	February 1926, ~~2025~~2026
By:	/S/ ~~LUIS~~DAVID ~~FERNANDEZ-MORENO~~H. LI	/S/ MARY DEAN HALL
	Luis Fernandez-Moreno	Mary Dean Hall
	David H. Li	Mary Dean Hall
	Interim President and Chief Executive Officer	Executive Vice President and Chief Financial Officer
	President and Chief Executive Officer	Executive Vice President and Chief Financial Officer

4950

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Ingevity Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Ingevity Corporation and its subsidiaries (the "Company") as of December 31, ~~2024~~2025 and ~~2023~~2024, and the related consolidated statements of operations, of comprehensive income (loss), of stockholders’' equity and of cash flows for each of the three years in the period ended December 31, ~~2024~~2025, including the related notes and financial statement schedule listed in the index appearing under Item 15(a)(2ii) (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, ~~2024~~2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, ~~2024~~2025 and ~~2023~~2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, ~~2024~~2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, ~~2024~~2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’'s Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on the Company’'s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’'s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’'s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the ~~Company~~company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the ~~Company~~company are being made only in accordance with authorizations of management and directors of the ~~Company~~company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the ~~Company’~~company's assets that could have a material effect on the financial statements.

5051

Critical Audit Matters

The critical audit ~~matter~~matters communicated below isare amatters ~~matter~~ arising from the current period audit of the consolidated financial statements that ~~was~~were communicated or required to be communicated to the audit committee and that (i) ~~relates~~relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit ~~matter~~matters below, providing a separate ~~opinion~~opinions on the critical audit ~~matter~~matters or on the accounts or disclosures to which itthey ~~relates~~relate.

~~Annual~~Interim Goodwill Impairment Assessment – Advanced Polymer Technologies Reporting Unit

As described in Notes 2 and 8 to the consolidated financial statements, the Company’'s consolidated goodwill balance was $~~175~~4.23 million as of December 31, ~~2024, of which $170~~2025.9 ~~million relates to the Advanced Polymer Technologies reporting unit.~~ Management conducts an annual review of goodwill for potential impairment at October 1, or sooner if events or changes in circumstances indicate that the fair value of a reporting unit is below its carrying value. During the second quarter of 2025, management performed an analysis of the Advanced Polymer Technologies ("APT") reporting unit's goodwill. The fair value of the reporting unit was determined by management using both the income approach and market approach. The income approach determines fair value based on a discounted cash flow model derived from a reporting unit’'s long-term forecasted cash flows,. ~~and~~The ~~the~~ market approach determines fair value based on the application of earnings multiples of comparable companies to projected earnings of the reporting unit. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit but is limited to the total amount of goodwill allocated to a reporting unit. The calculated estimated fair value of the reporting unit reflects a number of significant management assumptions and estimates including forecasted revenue growth rates, forecasted Earnings before Interest, Taxes, Depreciation and Amortization (“"EBITDA”") margins, and discount rate. ~~Management~~Based on the results of the interim quantitative analysis, management concluded that ~~there~~the ~~was~~carrying novalue of the APT reporting unit exceeded its fair value and recorded a non-cash goodwill impairment ~~for~~charge of $183.8 million, representing all of the ~~year~~goodwill ~~ended~~associated ~~December~~with ~~31,~~the ~~2024~~APT reporting unit.

The principal considerations for our determination that performing procedures relating to the ~~annual~~interim goodwill impairment assessment of the ~~Advanced~~APT ~~Polymer Technologies~~ reporting unit is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the reporting unit; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management’'s significant assumptions related to forecasted revenue growth rates, forecasted EBITDA margins, and discount rate used in the discounted cash flow model; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’'s ~~annual~~ goodwill impairment assessment, including controls over the valuation of the ~~Advanced~~APT ~~Polymer Technologies~~ reporting unit. These procedures also included, among others (i) testing management’'s process for developing the fair value estimate of the reporting unit; (ii) evaluating the appropriateness of the ~~income~~discounted ~~and~~cash ~~market~~flow ~~approaches~~model; (iii) testing the completeness and accuracy of underlying data used in the discounted cash flow model; and (iv) evaluating the reasonableness of the significant assumptions used by management related to the forecasted revenue growth rates, forecasted EBITDA margins, and discount rate. Evaluating management’'s significant assumptions related to the ~~forecast of~~ forecasted revenue growth rates and forecasted EBITDA margins involved evaluating whether the significant assumptions used by management were reasonable considering (i) the current and past performance of the ~~Advanced~~APT ~~Polymer Technologies~~ reporting unit; (ii) the consistency with external market data; and (iii) whether these significant assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the Company’'s discounted cash flow model and (ii) the reasonableness of the discount rate.

Long-Lived Asset Impairment Assessments – APT and Performance Chemicals Road Markings Asset Groups

As described in Notes 2, 7 and 8 to the consolidated financial statements, management periodically evaluates whether current events or circumstances indicate that the carrying value of long-lived assets, including intangible assets, to be held and used may not be recoverable. If such circumstances are determined by management to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. During the second quarter of 2025, management concluded that a triggering event occurred for the APT asset group. Management performed a recoverability test for the APT asset group and concluded that the estimated undiscounted cash flows exceeded the related carrying value and, therefore, no adjustment to the carrying value of the long-lived assets was recorded. The calculated estimated undiscounted cash flows of the APT asset group reflects a number of significant management assumptions and estimates including forecasted revenue growth rates, forecasted EBITDA margins, and EBITDA exit multiple. Additionally, during the fourth quarter of 2025, management concluded that a triggering event occurred for the Performance Chemicals road markings asset group. Based on the results of

management's quantitative analysis, which was based on both quoted market prices in active markets and a discounted value of estimated future cash flows, management concluded that the carrying value of the Performance Chemicals road markings asset group exceeded its fair value, which resulted in recording a non-cash long-lived assets impairment charge of $109.3 million. The calculated estimated fair value of the Performance Chemicals road markings asset group included significant management assumptions and estimates such as forecasted revenue growth rates, forecasted EBITDA margins, and discount rate.

The principal considerations for our determination that performing procedures relating to the long-lived asset impairment assessments of the APT and Performance Chemicals road markings asset groups is a critical audit matter are (i) the significant judgment by management when assessing recoverability of the APT asset group and developing the fair value estimate of the Performance Chemicals road markings asset group; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to (a) revenue growth rates, EBITDA margins, and EBITDA exit multiple used in the undiscounted cash flows for the APT asset group, and (b) revenue growth rates, EBITDA margins, and discount rate used in the fair value estimate for the Performance Chemicals road markings asset group; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's long-lived asset impairment assessment. These procedures also included, among others (i) testing management's process for assessing recoverability of the APT and Performance Chemicals road markings asset groups; (ii) evaluating the appropriateness of the undiscounted and discounted cash flow models used to assess recoverability and estimate the fair value of the Performance Chemicals road markings asset group; (iii) testing the completeness and accuracy of underlying data used in undiscounted and discounted cash flow models; and (iv) evaluating the reasonableness of the significant assumptions used by management related to (a) revenue growth rates, EBITDA margins and EBITDA exit multiple for the APT asset group, and (b) revenue growth rates, EBITDA margins and discount rate for the Performance Chemicals road markings asset group. Evaluating management's assumptions related to revenue growth rates and forecasted EBITDA margins involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the APT and Performance Chemicals road markings asset groups; (ii) the consistency with external market data; (iii) quoted market prices in active markets for the Performance Chemicals road markings asset group; and (iv) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the Company's undiscounted and discounted cash flow models; (ii) the reasonableness of the EBITDA exit multiple assumption for the APT asset group; and (iii) the reasonableness of the discount rate assumption for the Performance Chemicals road markings asset group.

/s/ PricewaterhouseCoopers LLP

Charlotte, North Carolina

February 1926, ~~2025~~2026

We have served as the Company’'s auditor since 2015.

5153

INGEVITY CORPORATION

Consolidated Statements of Operations

	Years Ended December 31,
In millions, except per share data	~~2024~~2025		~~2023~~2024		~~2022~~2023
Net sales	$	1,~~406~~167.46	$	1,~~692~~200.1	$	1,~~668~~215.35
Cost of sales	~~951~~706.71		~~1,220~~735.23		~~1,098~~770.25
Gross profit	~~454~~461.75		~~471~~464.98		~~570~~445.10
Selling, general, and administrative expenses	~~166~~171.72		~~183~~157.78		~~198~~161.8
Research and technical expenses	28.14		3124.85		3025.34
Restructuring and other (income) charges, net	~~186~~12.28		~~170~~18.21		1353.84
Goodwill impairment charge	~~349~~183.18		—306.6		—
Acquisition-related costs	0.3		3.6		5.0
Long lived asset impairment charge	109.3		—		—
Other (income) expense, net	169.8		5.7		(1.7)
Acquisition-related costs	—		0.3		3.6
Interest expense	97.8		93.3		61.8
Other (income) expense, net	25.0		7.9		(16.2)
Interest income	(7.7)		(6.3)		(7.5)
Interest expense	78.3		97.8		93.3
Income (loss) before income taxes	(535.6)		(10.1)		269.6
Interest income	(5.2)		(7.7)		(6.3)
Provision (benefit) for income taxes	(105.3)		(4.7)		58.0
Income (loss) from continuing operations before income taxes	(142.1)		(140.5)		130.0
Net income (loss)	$	(430.3)	$	(5.4)	$	211.6
Provision (benefit) for income taxes on continuing operations	8.2		(19.1)		24.2
Net income (loss) from continuing operations	(150.3)		(121.4)		105.8
Income (loss) from discontinued operations, net of income taxes	(16.8)		(308.9)		(111.2)
Net income (loss)	$	(167.1)	$	(430.3)	$	(5.4)
Per share data
Basic earnings (loss) per share	$	(11.85)	$	(0.15)	$	5.54
Basic earnings (loss) per share from continuing operations	$	(4.15)	$	(3.34)	$	2.90
Diluted earnings (loss) per share	(11.85)		(0.15)		5.50
Basic earnings (loss) per share from discontinued operations	(0.46)		(8.51)		(3.05)
Basic earnings (loss) per share	$	(4.61)	$	(11.85)	$	(0.15)
Diluted earnings (loss) per share from continuing operations	$	(4.15)	$	(3.34)	$	2.88
Diluted earnings (loss) per share from discontinued operations	(0.46)		(8.51)		(3.03)
Diluted earnings (loss) per share	$	(4.61)	$	(11.85)	$	(0.15)

The accompanying notes are an integral part of these financial statements.

5254

INGEVITY CORPORATION

Consolidated Statements of Comprehensive Income (Loss)

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Net income (loss)	$	(~~430~~167.31)	$	(5430.43)	$	~~211~~(5.64)
Other comprehensive income (loss), net of tax:
Foreign currency adjustments:
Foreign currency translation adjustment	~~(18~~42.6)5		20(18.26)		~~(74~~20.9)2
Reclassification of foreign currency translation losses	~~(0.2)~~—		—(0.2)		—
Unrealized gain (loss) on net investment hedges, net of tax provision (benefit) of zero, zero, and $3.2	—		—		10.7
Total foreign currency adjustments, net of tax provision (benefit) of zero, zero, and zero	42.5		(18.8)		20.2
Total foreign currency adjustments, net of tax provision (benefit) of zero, zero, and $3.2	(18.8)		20.2		(64.2)
Derivative instruments:
Unrealized gain (loss), net of tax provision (benefit) of $0.1, $(1.0), and $2.6	0.3		(3.2)		8.5
Unrealized gain (loss), net of tax provision (benefit) of $(0.6), $0.1, and $(1.0)	(2.0)		0.3		(3.2)
Reclassifications of deferred derivative instruments (gain) loss, included within net income (loss), net of tax (provision) benefit of $0.6, $0.9, and $(2.4)	1.8		3.0		(7.8)
Reclassifications of deferred derivative instruments (gain) loss, included within net income (loss), net of tax (provision) benefit of $0.1, $0.6, and $0.9	0.5		1.8		3.0
Total derivative instruments, net of tax provision (benefit) of $0.7, $(0.1), and $0.2	2.1		(0.2)		0.7
Total derivative instruments, net of tax provision (benefit) of $(0.5), $0.7, and $(0.1)	(1.5)		2.1		(0.2)
Pension & other postretirement benefits:
Unrealized actuarial gains (losses) and prior service (costs) credits, net of tax provision (benefit) of $0.5, zero, and $1.0	1.8		0.1		3.4
Unrealized actuarial gains (losses) and prior service (costs) credits, net of tax provision (benefit) of $0.2, $0.5, and zero	0.9		1.8		0.1
Reclassifications of net actuarial and other (gain) loss, amortization of prior service cost, and settlement and curtailment (income) charges, included within net income, net of tax (provision) benefit of $0.1, $0.1, and $0.1	0.2		—		0.2
Reclassifications of net actuarial and other (gain) loss, amortization of prior service cost, and settlement and curtailment (income) charges, included within net income, net of tax (provision) benefit of zero, $0.1, and $0.1	—		0.2		—
Total pension and other postretirement benefits, net of tax provision (benefit) of $0.6, $0.1, and $1.1	2.0		0.1		3.6
Total pension and other postretirement benefits, net of tax provision (benefit) of $0.2, $0.6, and $0.1	0.9		2.0		0.1
Other comprehensive income (loss), net of tax provision (benefit) of $1.3, zero, and $4.5	(14.7)		20.1		(59.9)
Other comprehensive income (loss), net of tax provision (benefit) of $(0.3), $1.3, and zero	41.9		(14.7)		20.1
Comprehensive income (loss)	$	(~~445~~125.02)	$	14(445.70)	$	~~151~~14.7

The accompanying notes are an integral part of these financial statements.

5355

INGEVITY CORPORATION

Consolidated Balance Sheets

	December 31,
In millions, except share and par value data	~~2024~~2025		~~2023~~2024
Assets
Cash and cash equivalents	$	6878.01	$	9568.90
Accounts receivable, net of allowance of $0.6 million - 2024 and $1.1 million - 2023	141.0		182.0
Accounts receivable, net of allowance of $1.5 - 2025 and $0.6 - 2024	127.2		131.7
Inventories, net	~~226~~186.80		~~308~~195.89
Prepaid and other current assets	5747.40		7151.91
Current assets	493.2		658.6
Current assets of discontinued operations	15.9		46.5
Property, plant, and equipment, net	658.9		762.2
Current assets	454.2		493.2
Operating lease assets, net	50.4		67.1
Property, plant, and equipment, net	608.1		642.9
Goodwill	175.2		527.5
Operating lease assets, net	29.5		44.7
Other intangibles, net	278.8		336.1
Goodwill	4.3		175.2
Deferred income taxes	117.9		11.6
Other intangibles, net	176.1		278.8
Restricted investment, net of allowance of $0.2 million - 2024 and $0.2 million - 2023	81.6		79.1
Deferred income taxes	117.0		117.9
Strategic investments	87.3		99.2
Restricted investment, net of allowance of $0.2 - 2025 and $0.2 - 2024	84.4		81.6
Other assets	79.3		81.9
Strategic investments	83.1		87.3
Total Assets	$	2,022.6	$	2,623.3
Other assets	74.9		79.2
Noncurrent assets of discontinued operations	19.5		21.8
Total Assets	$	1,651.1	$	2,022.6
Liabilities
Accounts payable	$	9492.50	$	~~158~~94.45
Accrued expenses	58148.10		7258.31
Accrued payroll and employee benefits	2734.76		1927.93
Current operating lease liabilities	1611.98		1814.74
Notes payable and current maturities of long-term debt	6147.31		8461.43
Income taxes payable	54.67		95.26
Current liabilities	264.1		362.9
Current liabilities of discontinued operations	3.1		2.9
Long-term debt including finance lease obligations	1,339.7		1,382.8
Current liabilities	341.3		264.1
Noncurrent operating lease liabilities	36.8		48.6
Long-term debt including finance lease obligations	1,161.4		1,339.7
Deferred income taxes	56.2		70.9
Noncurrent operating lease liabilities	22.4		33.6
Other liabilities	130.6		126.7
Deferred income taxes	55.1		56.2
Total Liabilities	1,827.4		1,991.9
Other liabilities	40.5		130.6
Commitments and contingencies (Note 18)
Noncurrent liabilities of discontinued operations	0.7		3.2
Total Liabilities	1,621.4		1,827.4
Commitments and contingencies (Note 17)
Equity
Preferred stock (par value $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at 2024 and 2023)	—		—
Preferred stock (par value $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at 2025 and 2024)	—		—
Common stock (par value $0.01 per share; 300,000,000 shares authorized; 43,630,211 and 43,446,513 issued and 36,350,425 and 36,233,092 outstanding at 2024 and 2023, respectively)	0.4		0.4
Common stock (par value $0.01 per share; 300,000,000 shares authorized; 43,891,710 and 43,630,211 issued and 35,485,876 and 36,350,425 outstanding at 2025 and 2024, respectively)	0.4		0.4
Additional paid-in capital	~~176~~195.87		~~164~~176.98
Retained earnings	~~572~~404.09		~~1,002~~572.30
Accumulated other comprehensive income (loss)	~~(41~~0.4)5		(2641.74)
Treasury stock, common stock, at cost (7,279,786 shares - 2024 and 7,213,421 shares - 2023)	(512.6)		(509.5)
Treasury stock, common stock, at cost (8,405,834 shares - 2025 and 7,279,786 shares - 2024)	(571.8)		(512.6)
Total Equity	~~195~~29.27		~~631~~195.42
Total Liabilities and Equity	$	21,~~022~~651.61	$	2,~~623~~022.36

The accompanying notes are an integral part of these financial statements.

5456

INGEVITY CORPORATION

Consolidated Statements of Stockholders' Equity

	Ingevity Stockholders'
	Common Stock
In millions, shares in thousands	Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss)		Treasury stock		Total Equity
Balance at December 31, 2021	43,102.0	$	0.4	$	136.3	$	796.1	$	13.1	$	(272.1)	$	673.8
Net income (loss)	—	—		—		211.6		—		—		211.6
Other comprehensive income (loss)	—	—		—		—		(59.9)		—		(59.9)
Common stock issued	82.9	—		—		—		—		—		—
Exercise of stock options, net	43.2	—		1.6		—		—		—		1.6
Tax payments related to vested restricted stock units	—	—		—		—		—		(2.2)		(2.2)
Share repurchase program	—	—		—		—		—		(145.2)		(145.2)
Share-based compensation plans	—	—		15.1		—		—		3.5		18.6
Balance at December 31, 2022	43,228.1	$	0.4	$	153.0	$	1,007.7	$	(46.8)	$	(416.0)	$	698.3
Net income (loss)	—	—		—		(5.4)		—		—		(5.4)
Other comprehensive income (loss)	—	—		—		—		20.1		—		20.1
Common stock issued	177.2	—		—		—		—		—		—
Exercise of stock options, net	41.2	—		2.2		—		—		—		2.2
Tax payments related to vested restricted stock units	—	—		—		—		—		(4.9)		(4.9)
Share repurchase program	—	—		—		—		—		(92.1)		(92.1)
Share-based compensation plans	—	—		9.7		—		—		3.5		13.2
Balance at December 31, 2023	43,446.5	$	0.4	$	164.9	$	1,002.3	$	(26.7)	$	(509.5)	$	631.4
Net income (loss)	—	—		—		(430.3)		—		—		(430.3)
Other comprehensive income (loss)	—	—		—		—		(14.7)		—		(14.7)
Common stock issued	183.7	—		—		—		—		—		—
Tax payments related to vested restricted stock units	—	—		—		—		—		(3.1)		(3.1)
Share-based compensation plans	—	—		11.9		—		—		—		11.9
Balance at December 31, 2024	43,630.2	$	0.4	$	176.8	$	572.0	$	(41.4)	$	(512.6)	$	195.2
Net income (loss)	—	—		—		(167.1)		—		—		(167.1)
Other comprehensive income (loss)	—	—		—		—		41.9		—		41.9
Common stock issued	227.8	—		—		—		—		—		—
Exercise of stock options, net	33.7	—		0.9		—		—		—		0.9
Tax payments related to vested restricted stock units	—	—		—		—		—		(3.7)		(3.7)
Share repurchase program	—	—		—		—		—		(56.3)		(56.3)
Share-based compensation plans	—	—		18.0		—		—		0.8		18.8
Balance at December 31, 2025	43,891.7	$	0.4	$	195.7	$	404.9	$	0.5	$	(571.8)	$	29.7

The accompanying notes are an integral part of these financial statements.

5557

INGEVITY CORPORATION

Consolidated Statements of Cash Flows

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Cash provided by (used in) operating activities:
Net income (loss)	$	(~~430~~167.31)	$	(5430.43)	$	~~211~~(5.64)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization	~~108~~106.34		~~122~~108.83		~~108~~122.8
Non cash operating lease costs	1914.17		1819.61		1618.16
Deferred income taxes	(~~121.~~4.7)		(44121.74)		(544.07)
Disposal/impairment of assets	1.3.2		41.3		24.53
Restructuring and other (income) charges, net	~~186~~55.27		~~170~~186.2		13170.82
CTO resales	~~52.7~~—		2252.07		—22.0
LIFO reserve	(18.7)		72.9		10.0
LIFO liquidation	(6.8)		(5.8)		(28.5)
Share-based compensation	1118.93		1011.69		1610.16
(Gain) loss on strategic investment	1126.42		~~(19~~11.3)4		—(19.3)
Pension and other postretirement benefit costs	1.52		1.65		1.46
Goodwill impairment charge	~~349~~183.18		—349.1		—
Other non-cash items	17.0		36.2		18.4
Long lived assets impairment charge	109.3		—		—
Changes in operating assets and liabilities, net of effect of acquisitions:
Other non-cash items	7.6		17.0		36.2
Accounts receivable, net	38.2		42.7		(42.1)
Changes in operating assets and liabilities:
Inventories, net	86.2		(75.6)		(63.7)
Accounts receivable, net	12.2		38.2		42.7
Prepaid and other current assets	7.7		(28.6)		(0.8)
Inventories, net	40.2		73.3		25.8
Planned major maintenance outage	(6.5)		(12.8)		(9.1)
Prepaid and other current assets	1.3		7.7		(28.6)
Accounts payable	(63.4)		(14.6)		42.7
Planned major maintenance outage	(6.5)		(6.5)		(12.8)
Accrued expenses	(1.0)		(7.7)		0.8
Accounts payable	(2.6)		(63.4)		(14.6)
Accrued payroll and employee benefits	8.0		(33.5)		5.4
Accrued expenses	(14.1)		(1.0)		(7.7)
Income taxes	(13.8)		6.4		4.9
Accrued payroll and employee benefits	6.9		8.0		(33.5)
Operating leases	(21.7)		(22.5)		(18.8)
Income taxes	(1.2)		(13.8)		6.4
Restructuring and other spending	(59.3)		(44.0)		(13.8)
Operating leases	(19.5)		(21.7)		(22.5)
CTO resales	(46.1)		(10.6)		—
Restructuring and other spending	(46.1)		(59.3)		(44.0)
Changes in all other operating assets and liabilities, net	12.2		16.1		14.2
CTO resales	6.2		(46.1)		(10.6)
Net cash provided by (used in) operating activities	$	128.6	$	205.1	$	313.4
Changes in all other operating assets and liabilities, net	6.6		12.2		16.1
Net cash provided by (used in) operating activities	$	331.2	$	128.6	$	205.1
Cash provided by (used in) investing activities:
Capital expenditures	(7757.67)		(~~109~~77.86)		(~~142~~109.58)
Payments for acquired businesses, net of cash acquired	—		—		(344.5)
Proceeds from disposition of assets	3.6		—
Proceeds from sale of strategic investment	—		31.5		—
Sale (purchase) of strategic investments, net	(16.4)		(0.3)		29.1
Net investment hedge settlement	—		—		14.7
Restricted investment	13.0		—		7.0
Purchase of strategic investments	(0.3)		(2.4)		(77.4)
Other investing activities, net	—		(1.6)		(3.6)
Other investing activities, net	(1.6)		3.4		(2.2)
Net cash provided by (used in) investing activities	$	(57.5)	$	(79.5)	$	(77.3)
Net cash provided by (used in) investing activities	$	(79.5)	$	(77.3)	$	(551.9)

The accompanying notes are an integral part of these financial statements.

INGEVITY CORPORATION

Consolidated Statements of Cash Flows (continued)


	Years Ended December 31,
In millions	2025		2024		2023
Cash provided by (used in) financing activities:
Proceeds from revolving credit facility and other borrowings	291.3		404.5		376.3

Payments on revolving credit facility and other borrowings	(483.6)		(470.6)		(382.9)

Debt issuance costs	—		—		(0.4)

Financing lease obligations, net	(1.3)		(1.0)		(0.7)

Tax payments related to withholdings on vested equity awards	(3.7)		(3.1)		(4.8)
Proceeds and withholdings from share-based compensation plans, net	1.4		—		4.7
Repurchases of common stock under publicly announced plan	(56.3)		—		(92.1)



Net cash provided by (used in) financing activities	$	(252.2)	$	(70.2)	$	(99.9)
Increase (decrease) in cash, cash equivalents, and restricted cash	21.5		(21.1)		27.9
Effect of exchange rate changes on cash	4.5		(4.2)		(0.3)
Change in cash, cash equivalents, and restricted cash	26.0		(25.3)		27.6
Cash, cash equivalents, and restricted cash at beginning of period	86.6		111.9		84.3
Cash, cash equivalents, and restricted cash at end of period (1)	$	112.6	$	86.6	$	111.9
_______________
(1) Includes restricted cash of $34.5 million, $18.6 million, and $16.0 million and cash and cash equivalents of $78.1 million, $68.0 million, and $95.9 million for the years ended December 31, 2025, 2024, and 2023, respectively. Restricted cash is included within "Prepaid and other current assets" and "Restricted investment" within the consolidated balance sheets.

Supplemental cash flow information:
Cash paid for interest, net of capitalized interest	$	70.4	$	85.4	$	82.7
Cash paid for income taxes, net of refunds	8.7		26.9		29.7
Purchases of property, plant, and equipment in accounts payable	1.7		2.4		2.8
Leased assets obtained in exchange for new finance lease liabilities	—		—		0.2
Leased assets obtained in exchange for new operating lease liabilities	1.8		6.0		29.1

	Years Ended December 31,
In millions	2024		2023		2022
Cash provided by (used in) financing activities:
Proceeds from revolving credit facility and other borrowings	404.5		376.3		1,164.7
Payments on revolving credit facility and other borrowings	(470.6)		(382.9)		(336.7)
Payments on long-term borrowings	—		—		(628.1)
Debt issuance costs	—		(0.4)		(3.0)
Debt repayment costs	—		—		(3.8)
Financing lease obligations, net	(1.0)		(0.7)		(0.9)
Tax payments related to withholdings on vested equity awards	(3.1)		(4.8)		(2.2)
Proceeds and withholdings from share-based compensation plans, net	—		4.7		4.1
Repurchases of common stock under publicly announced plan	—		(92.1)		(145.2)
Other financing activities, net	—		—		(0.8)
Net cash provided by (used in) financing activities	$	(70.2)	$	(99.9)	$	48.1
Increase (decrease) in cash, cash equivalents, and restricted cash	(21.1)		27.9		(190.4)
Effect of exchange rate changes on cash	(4.2)		(0.3)		(6.0)
Change in cash, cash equivalents, and restricted cash	(25.3)		27.6		(196.4)
Cash, cash equivalents, and restricted cash at beginning of period	111.9		84.3		280.7
Cash, cash equivalents, and restricted cash at end of period (1)	$	86.6	$	111.9	$	84.3
_______________
(1) Includes restricted cash of $18.6 million, $16.0 million, and $7.6 million and cash and cash equivalents of $68.0 million, $95.9 million, and $76.7 million for the years ended December 31, 2024, 2023, and 2022, respectively. Restricted cash is included within "Prepaid and other current assets" and "Restricted investment" within the consolidated balance sheets.
Supplemental cash flow information:
Cash paid for interest, net of capitalized interest	$	85.4	$	82.7	$	54.8
Cash paid for income taxes, net of refunds	26.9		29.7		54.8
Purchases of property, plant, and equipment in accounts payable	2.4		2.8		4.9
Leased assets obtained in exchange for new finance lease liabilities	—		0.2		—
Leased assets obtained in exchange for new operating lease liabilities	6.0		29.1		23.7

The accompanying notes are an integral part of these financial statements.

5759

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

INDEX
Note		Page No.
1	Background	5961
2	Summary of Significant Accounting Policies	5961
3	New Accounting Guidance	6668
4	Net Sales	6769
5	Fair Value Measurements	6870
6	Inventories, net	7072
7	Property, Plant, and Equipment, net	7073
8	Goodwill and Other Intangible Assets, net	7174
9	Financial Instruments and Risk Management	7376
10	Debt, including Finance Lease Obligations	7679
11	Share-based Compensation	7881
12	Equity	8184
13	Leases	8386
14	Retirement Plans	8588
15	Restructuring and Other (Income) Charges, net	9093
16	~~Acquisitions~~Income Taxes	9396
17	~~Income~~Commitments ~~Taxes~~and Contingencies	94101
18	~~Commitments~~Segment ~~and Contingencies~~Information	98102
19	~~Segment~~Earnings ~~Information~~(Loss) per Share	99107
20	~~Earnings~~Discontinued ~~(Loss) per Share~~Operations	~~103~~108
21	Supplemental Information	~~104~~110

5860

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

Note 1: Background

Description of Business

Ingevity Corporation ("Ingevity," "the Company," "we," "us," or "our") provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable. Our products are used in a variety of demanding applications, including ~~adhesives~~automotive gasoline vapor emissions control systems, ~~agrochemicals~~food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers, ~~lubricants,~~and paint for road markings~~, oil drilling, and automotive components~~. We operate in three reportable segments: Performance Materials, Performance Chemicals and Advanced Polymer Technologies.

Our Performance Materials segment manufactures products in the form of powder, granular, extruded pellets, extruded honeycombs, and activated carbon sheets. Performance Materials engineers, manufactures, and sells hardwood-based, chemically activated carbon products which are produced through a highly technical and specialized process primarily for use in gasoline vapor emission control systems in internal combustion engines and hybrid electric vehicles including cars, trucks, motorcycles, and boats. ToWe ~~maximize the productivity of our manufacturing assets, we~~ also produce several other activated carbon products for food, water, beverage, and chemical purification applications.

Our Performance Chemicals segment ~~consists of our road technologies and industrial specialties product lines. Performance Chemicals~~ products serve as critical inputs used in a variety of high-performance applications, including asphalt pavement construction, ~~pavement~~ preservation, ~~pavement~~ reconstruction and recycling, ~~and~~ paint for road markings ~~(road technologies product line)~~, asand ~~well as~~ agrochemical dispersants~~, lubricants, certain adhesives, rubber, and other diverse industrial uses (industrial specialties product line)~~.

Our Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices.

Industrial Specialties Divestiture

Basis of Consolidation and Presentation

The accompanying Consolidated Financial Statements of Ingevity were prepared in accordance with accounting principles generally accepted in the United States of America (“"U.S. GAAP”"). The significant accounting policies described in Note 2, together with the other notes that follow, are an integral part of the Consolidated Financial Statements. The Consolidated Financial Statements include the accounts of Ingevity and subsidiaries in which a controlling interest is maintained.

Note 2: Summary of Significant Accounting Policies

Estimates and assumptions: We are required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Our estimates are based on historical experiences, facts, and circumstances available at the time and various other assumptions that we believe are reasonable. Actual results may differ from those estimates.

Cash equivalents: Highly liquid securities with an original maturity of three months or less are considered cash equivalents.

Accounts receivable, net of allowance: Accounts receivable, net on the consolidated balance sheets are comprised of trade receivables less allowances for doubtful accounts and credit losses (herein referred to as "credit losses"). Trade receivables consist of amounts owed to Ingevity from customer sales and are recorded at the invoiced amounts when revenue is recognized and generally do not bear interest. The allowance for credit losses is our best estimate of the amount of probable loss in the existing accounts receivable. We determine the allowance based on our expected future credit losses, which is partly based on historical write-off experience, current collection trends, and external business factors such as economic factors, including regional bankruptcy rates and political factors. Past-due balances over a specified amount are reviewed individually for collectability. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. Allowance for credit losses at December 31, 2024 and 2023, were $0.6 million and $1.1 million, respectively.61

Concentration of credit risk: The financial instruments that potentially subject Ingevity to concentrations of credit risk are accounts receivable. We limit our credit risk by performing ongoing credit evaluations and, when necessary, requiring

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~letters~~Accounts receivable, net of ~~credit,~~allowance: Accounts ~~guarantees~~receivable, ornet ~~collateral.~~on ~~Our~~the ~~largest~~consolidated ~~customer~~balance assheets are comprised of ~~December 31,~~trade ~~2024~~receivables ~~had~~less allowances for doubtful accounts ~~receivable~~and ofcredit ~~$8.3~~losses ~~million~~(herein ~~and~~referred $7to as "credit losses").5 ~~million~~Trade asreceivables consist of ~~December 31,~~amounts ~~2024~~owed to Ingevity from customer sales and ~~2023,~~are ~~respectively.~~recorded ~~Sales~~at tothe ~~our~~invoiced ~~largest~~amounts ~~customer~~when ~~were~~revenue ~~approximately~~is ~~six~~recognized ~~percent~~and ofgenerally ~~total~~do ~~Net~~not ~~sales~~bear interest. The allowance for ~~the~~credit ~~year~~losses ~~ended~~is ~~December~~our ~~31,~~best ~~2024,~~estimate ~~and~~of ~~four~~the ~~percent~~amount of ~~total~~probable ~~Net~~loss ~~sales~~in ~~for~~the existing accounts receivable. We determine the ~~years~~allowance ~~ended~~based ~~December~~on 31our expected future credit losses, ~~2023~~which is partly based on historical write-off experience, ~~and~~current ~~2022~~collection trends, ~~respectively.~~and ~~Sales~~external tobusiness ~~the~~factors ~~automotive~~such ~~industry~~as economic factors, ~~which~~including ~~represents~~regional ~~our~~bankruptcy ~~largest~~rates ~~industry~~and ~~concentration,~~political ~~were~~factors. ~~approximately~~Past-due 40balances ~~percent~~over ofa ~~our~~specified ~~consolidated~~amount ~~Net~~are ~~sales~~reviewed individually for collectability. NoAccount ~~customers~~balances ~~individually~~are ~~accounted~~charged off against the allowance when it is probable that the receivable will not be recovered. Allowance for ~~greater~~credit ~~than~~losses 10at ~~percent~~December 31, of2025 ~~Ingevity's~~and ~~consolidated~~2024, ~~Net~~were ~~sales~~$1.5 million and $0.6 million, respectively.

~~Inventories,~~Concentration ~~net:~~of Wecredit ~~value~~risk: The ~~our~~financial ~~U.S.~~instruments ~~inventories~~that atpotentially ~~the~~subject ~~lower~~Ingevity ofto ~~cost~~concentrations ~~or market, with cost for the majority~~ of ~~our~~credit ~~U.S.~~risk ~~inventories~~are ~~determined~~accounts ~~using the last-in first-out (“LIFO”) basis~~receivable. We ~~value~~limit ~~all~~our ~~other~~credit ~~inventories~~risk atby ~~the~~performing ~~lower~~ongoing ofcredit ~~cost~~evaluations and, ~~net~~when ~~realizable value~~necessary, ~~with~~requiring ~~cost~~letters ~~determined~~of ~~using~~credit, ~~methods~~guarantees, ~~that~~or ~~approximate~~collateral. ~~cost~~Our ~~computed~~largest oncustomer aas ~~first-in~~of ~~first-out~~December 31, ~~inventory~~2025 ~~valuation~~had ~~(“FIFO”)~~accounts ~~basis.~~receivable ~~Elements~~ of ~~cost~~$11.0 inmillion ~~inventories~~and ~~include~~$8.3 ~~raw~~million ~~materials,~~as ~~direct~~of ~~labor~~December 31, 2025 and ~~manufacturing~~2024, ~~overhead~~respectively. WeSales ~~routinely~~to ~~assess~~our ~~inventory~~largest ~~for~~customer ~~both~~were ~~potential~~approximately ~~obsolescence~~seven ~~and~~percent ~~potential~~of ~~declines~~total inNet ~~anticipated~~sales ~~selling prices to derive a market value~~ for the ~~inventory~~year onended ~~hand.~~December ~~This~~31, ~~review~~2025, ~~also~~and ~~includes~~seven anpercent ~~analysis~~ of ~~potentially~~total ~~obsolete,~~Net ~~unmarketable,~~sales ~~slow-moving,~~for orthe ~~overvalued~~year ~~inventory.~~ended IfDecember ~~necessary~~31, we2024. ~~will~~Sales ~~impair~~to ~~any~~the ~~inventories~~automotive byindustry, anwhich ~~amount~~represents ~~equal~~our tolargest ~~the~~industry ~~difference~~concentration, ~~between~~were ~~the~~approximately ~~value~~48 percent of ~~the~~our ~~held~~consolidated ~~inventory~~Net (isales.~~e.,~~ ~~cost)~~No ~~and~~customers ~~its~~individually ~~estimated~~accounted ~~net realizable value~~ for ~~FIFO~~greater ~~and~~than ~~average~~10 ~~cost~~percent ~~inventories~~of ~~and~~Ingevity's ~~market~~consolidated ~~value~~Net ~~for LIFO inventories~~sales.

Inventories, net: We value our U.S. inventories at the lower of cost or market, with cost for the majority of our U.S. inventories determined using the last-in first-out ("LIFO") basis. We value all other inventories at the lower of cost and net realizable value, with cost determined using methods that approximate cost computed on a first-in first-out inventory valuation ("FIFO") basis. Elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. We routinely assess inventory for both potential obsolescence and potential declines in anticipated selling prices to derive a market value for the inventory on hand. This review also includes an analysis of potentially obsolete, unmarketable, slow-moving, or overvalued inventory. If necessary, we will impair any inventories by an amount equal to the difference between the value of the held inventory (i.e., cost) and its estimated net realizable value for FIFO and average cost inventories and market value for LIFO inventories.

Property, plant, and equipment: Owned assets are recorded at cost. Also included in the cost of these assets is interest on funds borrowed during the construction period. When assets are sold, retired or disposed of, their cost and related accumulated depreciation are removed from the consolidated balance sheet, and any resulting gain or loss is reflected within the consolidated statement of operations. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on the extension of the useful life.

Repair and maintenance costs: We expense routine repair and maintenance costs as we incur them. We defer expenses incurred during planned major maintenance activities and record these amounts to Prepaid and other current assets on our consolidated balance sheets. Deferred amounts are recognized as expense ratably over the shorter of the estimated interval until the next major maintenance activity or the life of the deferred item. The cash outflows related to these costs are included in operating activities within the consolidated statement of cash flows. The timing of this maintenance can vary by manufacturing plant and has a significant impact on our results of operations in the period performed primarily due to lost production during the maintenance period.

Depreciation: The cost of property, plant, and equipment is depreciated, utilizing the straight-line method, over the estimated useful lives of the assets, the majority of which range from 20 to 40 years for buildings and leasehold improvements and 5 to 30 years for machinery and equipment. The following table provides details on the useful lives and proportion of our machinery and equipment (“"M&E”") in each useful life category.

Percent of M&E Cost	Depreciable Life in Years	Types of Assets
27	5 to 10	Production control system equipment and hardware, laboratory testing equipment
13	15	Control systems, instrumentation, metering equipment
37	20	Production vessels and kilns, storage tanks, piping
6	25 to 30	Blending equipment, storage tanks, piping, shipping equipment and platforms, safety equipment
2	40	Machinery & equipment support structures and foundations
15	Various	Various

Leases: We lease various assets for use in our operations that are classified as both operating and financing leases. At contract inception, we determine that a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as the right to direct the use of that asset. If a contract is considered to be a lease, we recognize a lease liability based on the present value of the future lease payments, with an offsetting entry to recognize a right-of-use asset. As a majority of our leases do not provide an explicit rate within the lease, an incremental borrowing rate is used, which is based on information available at the commencement date. The determination of the incremental borrowing rate for each individual lease was impacted by the following assumptions: lease term, currency, and the economic environment for the physical location of the leased asset.

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025


Percent of M&E Cost	Depreciable Life in Years	Types of Assets
25	5 to 10	Production control system equipment and hardware, laboratory testing equipment
13	15	Control systems, instrumentation, metering equipment
40	20	Production vessels and kilns, storage tanks, piping
6	25 to 30	Blending equipment, storage tanks, piping, shipping equipment and platforms, safety equipment
2	40	Machinery & equipment support structures and foundations
14	Various	Various

Our operating leases principally relate to the following leased asset classes:

Leased Asset Class						Remaining Lease Term
Administrative offices						21 to 15 years
Manufacturing buildings						42 to 50 years
Manufacturing and office equipment						1 to 11 years
Warehousing and storage facilities						3 to 10 years
Rail cars						0 to 10 years
Vehicles						4 years
Rail cars						1 to 10 years

Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. Lease expense is recognized on a straight-line basis over the expected lease term. Some of our leases include options to extend the lease term at our sole discretion. We account for lease and non-lease components together as a single component for all lease asset classes. The depreciable life of assets and leasehold improvements is limited by the expected lease term unless there is a transfer of title or purchase option reasonably certain of exercise. Certain leases provide for escalation of the lease payments, as well as maintenance costs and taxes increase.

Asset retirement obligations: We record asset retirement obligations (“"AROs”") at fair value at the time the liability is incurred if we can reasonably estimate the settlement date. The associated AROs are capitalized as part of the carrying amount of related long-lived assets. In future periods, the liability is accreted to its present value and the capitalized cost is depreciated over the useful life of the related asset. We also adjust the liability for changes resulting from the passage of time and/or revisions to the timing or the amount of the original estimate. Upon the retirement of the long-lived asset, we either settle the obligation for its recorded amount or incur a gain or loss. The carrying amounts for the AROs for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 are $1611.3 million and $1216.93 million, respectively, and are included in Accrued expenses and Other liabilities on the consolidated balance sheets.

Impairment of long-lived assets: We periodically evaluate whether current events or circumstances indicate that the carrying value of our long-lived assets, including intangible assets, to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, or the appropriate grouping of assets, is compared to carrying value to determine whether impairment exists.

If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, ~~including a discounted value of estimated future cash flows. We report an asset to be disposed of at the lower of its carrying value or its estimated net realizable value.~~

Goodwill and other intangible assets: Goodwill represents the excess of cost of an acquired business over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. We conduct a required annual review of goodwill for potential impairment at October 1, or sooner if events or changes in circumstances indicate that the fair value of a reporting unit is below its carrying value. Our reporting units are our operating segments, i.e., Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. If the carrying value of a reporting unit that includes goodwill exceeds its fair value, which is determined using both the income approach and market approach, goodwill is considered impaired. The income approach determines fair value based on discounted cash flow model derived from a reporting unit’s long-term forecasted cash flows. The market approach determines fair value based on the application of earnings multiples of comparable companies to projected earnings of the reporting unit. The amount of impairment loss is measured as the difference between the carrying value and the fair value of a reporting unit but is limited to the total amount of goodwill allocated to the reporting unit. In performing the fair value analysis, management makes various judgments, estimates and assumptions, the most significant of which are the assumptions related to revenue growth rates, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margin, and discount rate.63

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~The~~including ~~determination of whether goodwill is impaired involves~~ a ~~significant~~discounted ~~level~~value of ~~judgment in the assumptions underlying the approach used to determine the~~ estimated ~~fair~~future ~~values~~cash ~~of our reporting units~~flows. We ~~believe~~report ~~that~~an ~~the~~asset estimates and assumptions used in our impairment assessment are reasonable; however, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. We will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions, or changes in management’s business strategy indicate that there may be adisposed ~~probable indicator~~ of ~~impairment.~~at ~~It is possible that~~ the ~~assumptions~~lower ~~used~~of byits ~~management~~carrying ~~related~~value ~~to the evaluation may change~~ or ~~that~~its ~~actual~~estimated ~~results~~net ~~may~~realizable ~~vary significantly from management’s estimates~~value.

~~Other~~Goodwill and other intangible assets: Goodwill ~~are~~represents ~~comprised~~the excess of ~~finite-lived~~cost of an acquired business over the fair value of the identifiable tangible and intangible assets ~~consisting~~acquired ~~primarily~~and liabilities assumed in a business combination. We conduct a required annual review of ~~brands~~goodwill ~~(representing~~for ~~trademarks~~potential impairment at October 1, ~~trade~~or ~~names~~sooner ~~and~~if ~~know-how)~~events or changes in circumstances indicate that the fair value of a reporting unit is below its carrying value. Our reporting units are our operating segments, ~~customer~~i.e., ~~contracts~~Performance ~~and~~Materials, ~~relationships~~Performance Chemicals, and ~~developed~~Advanced ~~technology~~Polymer Technologies. ~~Other~~If ~~intangible~~the ~~assets~~carrying ~~are~~value ~~amortized~~of ~~over~~a ~~their~~reporting ~~estimated~~unit ~~useful~~that ~~lives~~includes goodwill exceeds its fair value, which ~~range~~is determined using both the income approach and market approach, goodwill is considered impaired. The income approach determines fair value based on discounted cash flow model derived from 3a reporting unit's long-term forecasted cash flows. The market approach determines fair value based on the application of earnings multiples of comparable companies to 20projected ~~years~~earnings of the reporting unit. ~~Any~~The ~~potential~~amount of impairment ~~for~~loss ~~definite-lived~~is ~~intangible~~measured ~~assets~~as ~~will~~the bedifference ~~calculated~~between inthe carrying value and the ~~same~~fair ~~manner~~value asof ~~disclosed~~a ~~under~~reporting ~~impairment~~unit but is limited to the total amount of ~~property,~~goodwill ~~plant,~~allocated ~~and~~to ~~equipment~~the reporting unit. ~~Customer~~In ~~relationships~~performing ~~are~~the ~~amortized~~fair invalue aanalysis, ~~manner~~management ~~that~~makes ~~reflects~~various ~~the~~judgments, ~~pattern~~estimates inand ~~which~~assumptions, the ~~economic~~most ~~benefits~~significant of which are the ~~intangible~~assumptions ~~asset~~related ~~are~~to ~~consumed~~revenue growth rates, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margins, and discount rate.

~~Capitalized~~The ~~software: Capitalized~~factors ~~software~~we ~~for~~considered ~~internal use is included within Other assets on the consolidated balance sheets. Amounts capitalized are presented~~ in ~~Capital~~developing ~~expenditures on~~ our ~~consolidated~~estimates ~~statements~~and ofprojections for cash ~~flow.~~flows ~~Capitalized~~include, ~~software~~but isare ~~amortized~~not ~~using~~limited ~~the~~to, ~~straight-line over~~ the ~~estimated~~following: ~~useful~~(i) ~~lives~~macroeconomic ~~ranging~~conditions; ~~from~~(ii) 3industry toand 15market ~~years.~~considerations; ~~Amortization~~(iii) iscosts, ~~recorded~~such toas ~~Costs~~increases ~~of sales on our consolidated statements of operations for software directly used~~ in ~~the~~raw ~~production of inventory and Selling~~materials, ~~general~~labor, ~~and~~or ~~administrative~~other ~~expenses~~costs; on(iv) our ~~consolidated~~overall ~~statements~~financial ofperformance; ~~operations~~and ~~for~~(v) ~~software~~other ~~used~~relevant ~~for non~~entity-~~production~~specific ~~related~~events ~~activities~~that impact our reporting units.

The determination of whether goodwill is impaired involves a significant level of judgment in the assumptions underlying the approach used to determine the estimated fair values of our reporting units. We believe that the estimates and assumptions used in our impairment assessment are reasonable; however, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. We will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions, or changes in management's business strategy indicate that there may be a probable indicator of impairment. It is possible that the assumptions used by management related to the evaluation may change or that actual results may vary significantly from management's estimates.

Other intangible assets are comprised of finite-lived intangible assets consisting primarily of brands (representing trademarks, trade names and know-how), customer contracts and relationships, and developed technology. Other intangible assets are amortized over their estimated useful lives which range from 3 to 17 years. Any potential impairment for definite-lived intangible assets will be calculated in the same manner as disclosed under impairment of long lived assets. Customer relationships are amortized in a manner that reflects the pattern in which the economic benefits of the intangible asset are consumed.

Capitalized software: Capitalized software for internal use is included within Other assets on the consolidated balance sheets. Amounts capitalized are presented in Capital expenditures on our consolidated statements of cash flow. Capitalized software is amortized using the straight-line over the estimated useful lives ranging from 5 to 15 years. Amortization is recorded to Costs of sales on our consolidated statements of operations for software directly used in the production of inventory and Selling, general, and administrative expenses on our consolidated statements of operations for software used for non-production related activities.

Strategic investments: We have a variety of strategic investments that are classified as long-term assets on the consolidated balance sheets. Our strategic investments are accounted for under either the equity method of accounting or the measurement alternative, where fair value is not readily determinable. We use the equity method of accounting for investments that we do not control, but for which we have the ability to exercise significant influence.

For strategic investments that are accounted for under the equity method of accounting, our initial investment is recorded at cost. Subsequently, the carrying value for these investments will be impacted by our proportionate share of undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments. Subsequent adjustments to our initial investment are recorded within Other (income) expense, net on the consolidated statement of operations.

Strategic investments accounted for under the measurement alternative, where fair value is not readily determinable, are accounted for at cost. Adjustments for observable changes in prices or impairments are recognized in Other (income) expense, net in our consolidated statements of operations.64

At each reporting period, we evaluate each investment to determine whether events or changes in business circumstances indicate that the carrying value of the investment may not be fully recoverable.

Legal liabilities: We recognize a liability for legal contingencies when a loss is probable and reasonably estimable. Third-party fees for legal services are expensed as incurred. If only a range of estimated losses can be determined, we accrue an amount that reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we accrue the low end of the range. If an unfavorable outcome is reasonably possible but not probable, we will disclose an estimate of the reasonably possible loss or range of loss. If we cannot estimate the loss or range of losses arising from a legal proceeding, we will disclose that an estimate cannot be made. In assessing the materiality of a legal proceeding, we evaluate, among other factors, the amount of monetary damages claimed, as well as the potential impact of non-monetary remedies sought by plaintiffs that may require us to change our business practices in a manner that could have a material adverse impact on our business.

Revenue recognition: Our revenue is derived from contracts with customers, and substantially all our revenue is recognized when products are either shipped from our manufacturing and warehousing facilities or delivered to the customer. Revenue, net of returns and customer incentives, is based on the sale of manufactured products. Revenues are recognized when performance obligations under the terms of a contract with our customer are satisfied; generally, this occurs with the transfer of control of our products. For certain limited contracts, where we are producing goods with no alternative use and for which we have an enforceable right to payment for performance completed to date, we are recognizing revenue as goods are

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~manufactured~~Strategic investments accounted for under the measurement alternative, ~~rather~~where ~~than~~fair ~~when~~value ~~they~~is not readily determinable, are ~~shipped~~accounted for at cost. ~~Revenues~~Adjustments for observable changes in prices or impairments are ~~presented~~recognized asin ~~Net~~Other ~~sales~~(income) onexpense, ~~the~~net in our consolidated statements of operations.

At each reporting period, we evaluate each investment to determine whether events or changes in business circumstances indicate that the carrying value of the investment may not be fully recoverable.

Since Net sales are derived from product sales only, we have disaggregated our Net sales by our product lines within each reportable segment. Net sales are measured as the amount of consideration we expect to receive in exchange for transferring goods. Sales, value add, and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Sales returns and allowances are not a normal practice in the industry and are not significant. Certain customers may receive cash-based incentives, including discounts and volume rebates, which are accounted for as variable consideration and included within Net sales. Shipping and handling fees billed to customers are included within Net sales. If we pay for the freight and shipping, we recognize the cost when control of the product has transferred to the customer as an expense within Cost of sales on the consolidated statements of operations. Payment terms with our customers are typically in the range of zero to sixty days. Because the period between when we transfer a promised good to a customer and when the customer pays for that good will be one year or less, we elect not to adjust the promised amount of consideration for the effects of any financing component, as it is not significant.

Cost of sales: Costs primarily consist of the cost of inventory sold and other production related costs. These costs include raw materials, direct labor, manufacturing overhead, packaging costs, and maintenance costs. Shipping and handling costs are recorded within Cost of sales on the consolidated statements of operations.

Royalty expense: We have licensing agreements with third parties requiring us to pay royalties for certain technologies we use in the manufacturing of our products. Royalty expense is recognized as incurred and recorded within Cost of sales on the consolidated statements of operations.

Selling, general, and administrative expenses: Costs are expensed as incurred and primarily include employee compensation costs related to sales and office personnel, office expenses, and other expenses not directly related to our manufacturing operations. Costs also include advertising and promotional costs.

Research and technical expenses: Costs are expensed as incurred and primarily include employee compensation, technical equipment costs, material testing, and innovation-related expenses.

Restructuring and other (income) charges, net: We regularly perform strategic reviews and assess the return on our operations, which sometimes results in a plan to restructure the business. The cost and benefit of these strategic restructuring initiatives are recorded within Restructuring and other (income) charges, net on the consolidated statement of operations. These costs are excluded from our operating segment results.65

We record an accrual for severance and other costs under the provisions of the relevant accounting guidance. Additionally, in some restructuring plans, write-downs of long-lived assets may occur. Two types of assets are impacted: assets to be disposed of by sale and assets to be abandoned. Assets to be disposed of by sale are measured at the lower of carrying amount or estimated net proceeds from the sale. Assets to be abandoned with no remaining future service potential are written down to amounts expected to be recovered. The useful lives of assets to be abandoned that have a remaining future service potential are adjusted and depreciation is recorded over the adjusted useful life.

Non-operating income and expense: Non-operating income and expenses are included within Other (income) expense, net on the consolidated statement of operations. Included within Other (income) expense, net, among other items, are gains and losses associated with crude tall oil ("CTO") resales and CTO supply contract termination charges. As further described in Note 15, due to the actions taken and the corresponding reduced CTO refining capacity, we were obligated, under an existing CTO supply contract, to purchase CTO volumes through 2025 at amounts in excess of required CTO volumes. To manage this excess inventory, we sold CTO volumes (herein referred to as "CTO resales") in the open market.

Our Performance Chemicals reportable segment is in the business of producing, primarily from CTO-based feedstocks, derivative specialty chemicals for sale to third-party customers. As a result of the Performance Chemicals repositioning, we sold excess CTO volumes, which is outside of the ordinary course of business, that is, not a normal ongoing part of our operations and not core to our business. The excess CTO volumes, calculated as the volume directly attributable to reduced CTO refining capacity as defined under the contractual terms of the CTO supply contract, on hand at period end will be valued at the lower of cost or expected selling price, less costs to sell. Volumes on hand at period end and any pending CTO resale receivables will be recorded to Other current assets on the consolidated balance sheets. Any payables associated with the purchases of the excess CTO volumes will be recorded to Accrued expenses on the consolidated balance sheets. We will

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~recognize~~Indirect costs allocated to divestiture: The historical industrial specialties product line that is classified as discontinued operations includes only direct operating expenses which the ~~net~~Company ~~gains~~will orno ~~losses~~longer ~~associated~~incur ~~with~~upon the ~~CTO~~close ~~resale~~of ~~activities~~the ~~within~~Divestiture. ~~Other~~Indirect ~~(income)~~costs, ~~expenses~~such as those related to corporate and shared service functions previously allocated to the industrial specialties product line, ~~net~~do onnot meet the ~~consolidated~~criteria ~~statement~~for ofdiscontinued operations and remain reported within continuing operations in Indirect costs allocated to Divestiture.

OnCorporate ~~July~~and 1,other ~~2024,~~costs: weCosts ~~terminated~~are ~~our~~expensed ~~last~~as ~~long-term~~incurred ~~CTO~~and ~~supply~~are ~~contract.~~associated Aswith acorporate ~~result~~administrative offunctions ~~the termination~~(e.g., ~~the~~executive ~~purchases~~office, ~~under~~corporate ~~the~~finance, ~~CTO~~legal, ~~supply~~human ~~contract~~resources) ~~ended~~and ~~effective~~other ~~June~~compliance ~~30,~~costs ~~2024.~~to ~~The~~operate ~~CTO~~as ~~resale~~a ~~activity~~New ~~described~~York ~~above~~Stock ~~ended~~Exchange in("NYSE") ~~2024~~listed ~~and~~entity. noAlso ~~excess~~includes ~~CTO~~corporate ~~volumes~~administrative ~~were~~function onshare ~~hand~~of atinformation ~~December~~technology, 31safety, ~~2024~~health, accounting and human resource departments.

~~Income~~Restructuring ~~taxes: We are subject to income taxes in the U.S.~~ and ~~numerous~~other ~~foreign jurisdictions, including China and the United Kingdom~~ (~~"UK"~~income). ~~The~~charges, ~~provision~~net: ~~for~~We ~~income~~regularly ~~taxes~~perform ~~includes~~strategic ~~income~~reviews ~~taxes paid, currently payable or receivable,~~ and ~~deferred~~assess ~~taxes. We follow~~ the ~~asset~~return ~~and~~on ~~liability~~our ~~method~~operations, ofwhich ~~accounting~~sometimes ~~for~~results ~~income taxes~~ in ~~accordance~~a ~~with~~plan ~~current~~to ~~accounting~~restructure ~~standards regarding~~ the ~~accounting for income taxes~~business. ~~Under~~The ~~this~~cost ~~method, deferred income taxes are recognized based on the temporary differences between the financial reporting~~ and ~~tax~~benefit ~~bases~~ of ~~assets~~these ~~and~~strategic ~~liabilities,~~restructuring ~~and~~initiatives are ~~measured~~recorded ~~using~~within ~~the~~Restructuring ~~enacted tax rates~~ and ~~laws~~other ~~in effect at the time the underlying assets or liabilities are recovered or settled. The ability to realize deferred tax assets is evaluated through the forecasting of taxable~~ (income,) ~~historical and projected future operating results~~charges, ~~the~~net ~~reversal~~on ~~of existing temporary differences, and~~ the ~~availability~~consolidated statement of ~~tax planning strategies~~operations. ~~Valuation~~These ~~allowances~~costs are ~~recognized~~excluded tofrom reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized. We do not provide income taxes on undistributed earnings of consolidated foreign subsidiaries, as it is our ~~intention~~operating ~~that~~segment ~~such earnings will remain invested in those companies~~results.

Income taxes: We are subject to income taxes in the U.S. and numerous foreign jurisdictions, including China and the United Kingdom ("UK"). The provision for income taxes includes income taxes paid, currently payable or receivable, and deferred taxes. We follow the asset and liability method of accounting for income taxes in accordance with current accounting standards regarding the accounting for income taxes. Under this method, deferred income taxes are recognized based on the temporary differences between the financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws in effect at the time the underlying assets or liabilities are recovered or settled. The ability to realize deferred tax assets is evaluated through the forecasting of taxable income, historical and projected future operating results, the reversal of existing temporary differences, and the availability of tax planning strategies. Valuation allowances are recognized to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized. During the year ended December 31, 2025, we determined that the earnings of some of our subsidiaries are no longer permanently reinvested due to global trade volatility. As a result of this change, we recorded $1.3 million of deferred taxes associated with our unremitted China earnings. The remainder of our subsidiaries remain permanently reinvested.

We recognize income tax positions that are more-likely-than-not to be realized and accrue interest related to unrecognized income tax positions, which is included as a component of the income tax provision, on the consolidated statements of operations.

Earnings per Share: Basic earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share reflects the dilution that could occur if the outstanding stock-based compensation awards, including any unvested awards, were vested and exercised, resulting in the issuance of common stock as determined under the treasury stock method. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of shares of common stock and potentially dilutive common stock outstanding for the period. The calculation of diluted net income per share excludes all anti-dilutive common shares. In periods where we incur a net loss, stock-based compensation awards are excluded from the calculation of earnings per share as their inclusion would have an anti-dilutive effect.

Pension and postretirement benefits: We provide both qualified and non-qualified pension and postretirement benefit plans to our employees. The expense related to the current employees, as well as the expense related to retirees, are included within the Consolidated Financial Statements. The costs (or benefits) and obligations related to these benefits reflect key assumptions related to general economic conditions, including interest (discount) rates, healthcare cost trend rates, and expected return on plan assets. The costs (or benefits) and obligations for these benefit programs are also affected by other assumptions, such as average retirement age, mortality rates, employee turnover, and plan participation. To the extent our plans' actual experience, as influenced by changing economic and financial market conditions or by changes to our own plans' demographics, differs from these assumptions, the costs and obligations for providing these benefits, as well as the plans' funding requirements, could increase or decrease. When actual results differ from our assumptions, the difference is typically recognized over future periods. In addition, the unrealized gains and losses related to our pension and postretirement benefit obligations may also affect periodic benefit costs (or benefits) in future periods.

Share-based compensation: We recognize compensation expense within our Consolidated Financial Statements for all share-based compensation arrangements. Share-based compensation cost is measured at the date of grant, based on the fair value of the award, and expense is recognized over the grantee's requisite service period; forfeitures are recognized as they occur. We calculate the fair value of our stock options using the Black-Scholes option pricing model. The fair value of restricted stock units ("RSUs"), non-employee director deferred stock units ("DSUs"), and performance-based restricted stock units ("PSUs") is determined using our closing stock price on the date of the grant. Beginning in 2023, certain granted PSUs include a market condition, relative total shareholder return ("rTSR"), which requires that the fair value of the award be calculated using a Monte Carlo simulation. Substantially all compensation expense related to share-based awards is recorded as a component of Selling, general and administrative expenses within the consolidated statements of operations. 66

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~the~~funding ~~production process~~requirements, ~~the~~could ~~type~~increase ofor ~~customer~~decrease. ~~for~~When ~~the~~actual ~~products,~~results ~~the~~differ ~~similarity~~from ofour ~~economic characteristics~~assumptions, ~~and~~ the ~~manner~~difference inis ~~which~~typically ~~management~~recognized ~~reviews~~over ~~results~~future periods. ~~Our~~In ~~chief~~addition, ~~operating~~the ~~decision~~unrealized ~~maker~~gains ~~evaluates~~and ~~the~~losses ~~business~~related atto ~~the~~our ~~segment~~pension ~~level~~and ~~when~~postretirement ~~making~~benefit ~~decisions~~obligations ~~about~~may ~~allocating~~also ~~resources~~affect ~~and~~periodic ~~assessing~~benefit ~~the~~costs ~~performance~~(or ofbenefits) ~~Ingevity~~in asfuture ~~a whole~~periods.

Operating segments: Our operating segments are Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. Our operating segments were determined based upon the nature of the products produced, the nature of the production process, the type of customer for the products, the similarity of economic characteristics, and the manner in which management reviews results. Our chief operating decision maker evaluates the business at the segment level when making decisions about allocating resources and assessing the performance of Ingevity as a whole.

Fair value measurements: We have categorized our assets and liabilities that are recorded at fair value, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the assets and liabilities fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying value of our financial instruments: cash and cash equivalents, other receivables, other payables, and accrued liabilities, approximate their fair values due to the short-term nature of these financial instruments.

Derivative financial instruments: We are exposed to market risks, such as the impact of changes in interest rates on our floating rate debt, foreign currency exchange rates due to transactions denominated in a variety of foreign currencies, and commodity prices due to purchases of certain raw materials and inputs. Changes in these rates and prices may have an impact on our future cash flow and earnings. We formally document all relationships between the derivative financial instrument and the hedged item, as well as the risk management objective and strategy for undertaking various hedge transactions. We do not hold or issue derivative financial instruments for speculative or trading purposes. We enter into derivative financial instruments which are governed by policies, procedures, and internal processes set forth by our Board of Directors.

Our risk management program also addresses counterparty credit risk by selecting only major financial institutions with investment grade ratings. Once the derivative financial instrument is entered into, we continuously monitor the financial institutions’' credit ratings and our credit risk exposure held by the financial institution. When appropriate, we reallocate exposures across multiple financial institutions to limit credit risk. If a counterparty fails to fulfill its performance obligations under the derivative financial instrument, then Ingevity is exposed to credit risk equal to the fair value of the financial instrument. Derivative assets and liabilities are recorded on our consolidated balance sheets at fair value and are presented on a gross basis. Due to our proactive mitigation of these potential credit risks, we anticipate performance by our counterparties to these contracts, and therefore, no material loss is expected. In order to mitigate the impact of market risks, we have and may enter into ~~both net investment hedges and~~ cash flow hedges.

Cash flow hedges: Cash flow hedges are derivative financial instruments designated as and used to hedge the exposure to variability in expected future cash flows that are attributable to a particular risk. The derivative financial instruments that are designated and qualify as a cash flow hedge are recorded on the consolidated balance ~~sheetsat~~sheets at fair value, and the changes in fair value of these hedging instruments are offset in part or in whole by corresponding changes in the anticipated cash flows of the underlying exposures being hedged. The gains and losses arising from qualifying hedging instruments are reported as a component of Accumulated other comprehensive income (loss) (“"AOCI”") located within the consolidated balance sheets and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The reclassification gains or losses of the hedge from AOCI are recorded in the same financial statement caption on the consolidated statements of operations as the hedged item. For example, designated cash flow hedges entered to minimize foreign currency exchange risk of forecasted revenue transactions are recorded to Net sales on the consolidated statements of operations when the forecasted transaction occurs. Designated commodity cash flow hedges gains or losses recorded in AOCI are recognized within Cost of sales on the consolidated statements of operations when the inventory is sold. Designated interest rate cash flow hedge gains or losses are recorded in Accumulated other comprehensive income (loss) AOCI and are recognized in Interest expense on the consolidated statements of operations on a straight-line basis over the remaining maturity of the underlying debt.

Net investment hedges: Net investment hedges are defined as derivative or non-derivative instruments, which are designated as and used to hedge the foreign currency exposure of the net investment in certain foreign operations. The net of the change in the hedge instrument and the item being hedged against for qualifying net investment hedges is reported as a component of the foreign currency adjustments ("CTA") within AOCI on the consolidated balance sheets. The gains (losses) on net investment hedges are reclassified to earnings only when the related CTA are required to be reclassified, usually upon the sale or liquidation of the investment. 67

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~Treasury~~the ~~stock:~~forecasted Wetransaction ~~record~~occurs. ~~shares~~Designated ofcommodity ~~common~~cash ~~stock~~flow ~~repurchased~~hedges atgains ~~cost~~or aslosses ~~treasury~~recorded ~~stock,~~in ~~resulting~~AOCI inare arecognized ~~reduction~~within Cost of ~~stockholders’~~sales ~~equity~~ on the consolidated ~~balance~~statements ~~sheets.~~of ~~When~~operations when the ~~treasury~~inventory ~~shares~~is ~~are~~sold. ~~contributed~~Designated ~~under~~interest ~~our~~rate ~~employee~~cash ~~benefit~~flow ~~plans~~hedge gains or ~~issued~~losses ~~for~~are ~~option~~recorded ~~exercises,~~in weAccumulated ~~use~~other acomprehensive ~~first-in,~~income ~~first-out~~ (~~“FIFO”~~loss) ~~method~~AOCI ~~for~~and ~~determining~~are ~~cost.~~recognized ~~The~~in ~~difference~~Interest ~~between~~expense ~~the~~or ~~cost~~Interest ofincome ~~the~~on ~~shares and~~ the ~~market~~consolidated ~~price~~statements ~~at the time~~ of ~~contribution~~operations toon ana ~~employee~~straight-line ~~benefit~~basis ~~plan~~over isthe ~~added~~remaining tomaturity orof ~~deducted from Additional paid-in capital on~~ the ~~consolidated~~underlying ~~balance sheets~~debt.

Treasury stock: We record shares of common stock repurchased at cost as treasury stock, resulting in a reduction of stockholders' equity on the consolidated balance sheets. When the treasury shares are contributed under our employee benefit plans or issued for option exercises, we use a first-in, first-out ("FIFO") method for determining cost. The difference between the cost of the shares and the market price at the time of contribution to an employee benefit plan is added to or deducted from Additional paid-in capital on the consolidated balance sheets.

Translation of foreign currencies: The local currency is the functional currency for all of our significant operations outside the U.S., consisting primarily of the euro, the Japanese yen, the pound sterling, and the Chinese renminbi. The assets and liabilities of our foreign subsidiaries are translated into U.S. dollars using period-end exchange rates, and adjustments resulting from these financial statement translations are reported as a component of CTA within AOCI on the consolidated balance sheets. Revenues and expenses are translated at average rates prevailing during each period.

Business combinations: Accounting for business combinations which requires, among other things, the acquiring entity in a business combination to recognize the fair value of the assets acquired and liabilities assumed; the recognition of acquisition-related costs within the consolidated results of operations; the recognition of restructuring costs within the consolidated results of operations for which the acquirer becomes obligated after the acquisition date; and contingent purchase consideration to be recognized at fair value on the acquisition date with subsequent adjustments recognized on the consolidated statement of operations. We generally use qualified third-party consultants to assist management in determining the fair value of assets acquired and liabilities assumed. This includes, when necessary, assistance with the determination of lives and valuation of tangible property, plant, and equipment and identifiable intangibles, assisting management in determining the fair value of obligations associated with employee-related liabilities, and assisting management in assessing obligations associated with legal and environmental claims. The purchase price allocation process allows us to refine these estimates over a measurement period not to exceed one year to reflect new information obtained surrounding facts and circumstances existing at the acquisition date.

The fair value assigned to identifiable intangible assets acquired is determined primarily by using an income approach, which is based on assumptions and estimates made by management. Significant assumptions utilized in the income approach are the attrition rate, revenue growth rates, EBITDA margins, royalty rates, and the discount rate. These assumptions are based on company-specific information and projections, which are not observable in the market and are therefore considered Level 2 and Level 3 measurements. The excess of the purchase price over the fair value of the identified assets and liabilities is recorded as goodwill. Based on the acquired business’' end markets and products, as well as how the chief operating decision maker will review the business results, determines the most appropriate operating segment for which to integrate the acquired business. Goodwill acquired, if any, is allocated to the reporting unit within or at the operating segment for which the acquired business will be integrated. Selection of the appropriate reporting unit is based on the level at which discrete financial information is available and reviewed by business management post-integration. Operating results of the acquired entity are reflected within the Consolidated Financial Statements from the date of acquisition.

Reclassifications: Certain prior year amounts have been reclassified to conform with the current year's presentation.

Note 3: New Accounting Guidance

The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC" or "Codification") is the sole source of authoritative GAAP other than the U.S. Securities and Exchange Commission ("SEC") issued rules and regulations that apply only to SEC registrants. The FASB issues an Accounting Standards Update ("ASU") to communicate changes to the Codification. We consider the applicability and impact of all ASUs. ASUs not listed below were assessed and determined to be either not applicable or are not expected to have a material impact on the Consolidated Financial Statements.

Recently ~~Issued~~Adopted Accounting Pronouncements

In ~~November~~December 2023, the FASB issued ASU 2023-0709, ~~“Segment Reporting:~~ "Improvements to ~~Reportable~~Income ~~Segment~~Tax Disclosures,”" which is intended to ~~improve~~enhance ~~reportable~~income ~~segment~~tax ~~disclosure~~disclosures ~~requirements,~~around ~~primarily~~the ~~through~~rate ~~enhanced~~reconciliation ~~disclosures~~and ~~about~~income ~~significant~~taxes ~~segment expenses~~paid. The purpose of the amendment is to provide readers of the financial statements with information to better understand an entity’s overall performance and assess potential future cash flows. We adopted this standard which is effective beginning with our 2024 fiscal year Form 10-K, and it has been applied to all prior periods presented in the Consolidated Financial Statements.

6668

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures,” which is intended to enhance income tax disclosures around the rate reconciliation and income taxes paid. The purpose of the amendment is to provide readers of the financial statements with information to better assess the differences between the effective tax rate and the statutory tax rate across multiple jurisdictions, enabling them to understand tax implications around operational opportunities and potential future cash flows. ~~The~~We ~~guidance~~adopted this standard which is effective beginning with our 2025 fiscal year ~~Consolidated~~Form ~~Financial~~10-K, ~~Statements.~~and Weit ~~are~~has ~~currently~~been ~~evaluating~~applied ~~the~~retrospectively ~~potential~~in ~~impact~~the ~~of adopting this new guidance on our~~ Consolidated Financial Statements ~~and related disclosures~~.

InRecently ~~November~~Issued ~~2024,~~Accounting the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses,” which is intended to enhance disclosures regarding significant expenses. The purpose of the amendment is to provide readers of the financial statements with information to better understand an entity’s overall performance, assess potential future cash flows, and compare an entity's performance over time and with that of other entities. The guidance is effective beginning with our 2027 fiscal year Consolidated Financial Statements. We are currently evaluating the potential impact of adopting this new guidance on our Consolidated Financial Statements and related disclosures.Pronouncements

In November 2024, the FASB issued ASU 2024-03, "Disaggregation of Income Statement Expenses," which is intended to enhance disclosures regarding significant expenses. The purpose of the amendment is to provide readers of the financial statements with information to better understand an entity's overall performance, assess potential future cash flows, and compare an entity's performance over time and with that of other entities. The guidance is effective beginning with our 2027 fiscal year Form 10-K. We are currently evaluating the potential impact of adopting this new guidance on our Consolidated Financial Statements and related disclosures.

Note 4: Net Sales

Disaggregation of Net sales

The following table presents our Net sales disaggregated by reportable segment and product line.

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Performance Materials segment	$	~~609~~606.69	$	~~586~~609.06	$	~~548~~586.50
Road Technologies product line	342.3		369.8		241.3
Pavement Technologies product line	302.6		300.9		312.1
Industrial Specialties product line (1)	265.9		532.3		633.8
Road Markings product line	97.9		101.0		113.4
Performance Chemicals segment	$	~~608~~400.25	$	~~902~~401.19	$	~~875~~425.15
Advanced Polymer Technologies segment	$	~~188~~160.62	$	~~204~~188.06	$	~~244~~204.70
Net sales	$	1,~~406~~167.46	$	1,~~692~~200.1	$	1,~~668~~215.35

The following table presents our Net sales disaggregated by geography, based on the delivery address of our customer.

(1) The reduction in the industrial specialties product line from 2023 to 2024 was due to the repositioning action taken to improve the Performance Chemicals reportable segment, refer to Note 15 for more information.


	Years Ended December 31,
In millions	2025		2024		2023
North America (1)	$	665.1	$	651.5	$	672.7
Asia Pacific (1)	298.5		325.0		323.3
Europe, Middle East, and Africa	158.9		172.4		179.9
South America	45.1		51.2		39.6
Net sales	$	1,167.6	$	1,200.1	$	1,215.5

	Years Ended December 31,
In millions	2024		2023		2022
North America (1)	$	820.9	$	1,069.5	$	983.2
Asia Pacific (1)	346.0		364.0		398.7
Europe, Middle East, and Africa	187.0		215.5		242.2
South America	52.5		43.1		44.2
Net sales	$	1,406.4	$	1,692.1	$	1,668.3

_______________

(1) Countries with Net sales in excess of 10 percent of consolidated Net sales for the years ended December 31, ~~2024~~2025, ~~2023~~2024, and ~~2022~~2023 are the U.S., which totaled $~~736~~585.0 million, $~~972~~571.15 million, and $~~897~~602.13 million, respectively, and China, which totaled $~~184~~153.31 million, $~~202~~175.76 million, and $~~220~~189.62 million, respectively.

Contract Balances

The contract assets primarily relate to our rights to consideration for products produced but not billed at the reporting date from contracts with certain customers. The contract assets are recognized as accounts receivables when we have an enforceable right to payment for performance completed to date and the customer has been billed. Contract liabilities represent obligations to transfer goods to a customer for which we have received consideration from our customer. For all periods presented, we had no contract liabilities.

6769

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

The following table provides information about contract assets from contracts with certain customers.

	Year Ended December 31,
In millions	~~2024~~2025		~~2023~~2024
Contract asset at beginning of period	$	116.25	$	611.42
Additions	15.36		1815.13
Reclassification to accounts receivable, billed to customers	(2015.02)		(1320.30)
Contract asset at end of period (1)	$	6.59	$	116.25
_______________
(1) Included within "Prepaid and other current assets" on the consolidated balance sheets.

Note 5: Fair Value Measurements

Recurring Fair Value Measurements

The following information is presented for assets and liabilities that are recorded on the consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that are recorded at fair value between the three-level fair value hierarchy during the periods reported.


In millions	Level 1 (1)		Level 2 (2)		Level 3 (3)		Total
December 31, 2025
Assets:
Deferred compensation plan investments (4)	$	3.9	$	—	$	—	$	3.9
Total assets	$	3.9	$	—	$	—	$	3.9
Liabilities:
Deferred compensation arrangement (4)	$	15.9	$	—	$	—	$	15.9


Total liabilities	$	15.9	$	—	$	—	$	15.9


In millions	Level 1 (1)		Level 2 (2)		Level 3 (3)		Total
December 31, 2024
Assets:

Deferred compensation plan investments (4)	$	3.7	$	—	$	—	$	3.7
Total assets	$	3.7	$	—	$	—	$	3.7
Liabilities:
Deferred compensation arrangement (4)	$	15.9	$	—	$	—	$	15.9

Total liabilities	$	15.9	$	—	$	—	$	15.9

In millions	Level 1 (1)		Level 2 (2)		Level 3 (3)		Total
December 31, 2023
Assets:
Deferred compensation plan investments (4)	$	3.0	$	—	$	—	$	3.0
Total assets	$	3.0	$	—	$	—	$	3.0
Liabilities:
Deferred compensation arrangement (4)	$	15.5	$	—	$	—	$	15.5
Total liabilities	$	15.5	$	—	$	—	$	15.5

_______________

(1) Quoted prices in active markets for identical assets.

(2) Quoted prices for similar assets and liabilities in active markets.

(3) Significant unobservable inputs.

(4) Consists of a deferred compensation arrangement through which we hold various investment securities recognized on our consolidated balance sheets. Both the asset and liability related to investment securities are recorded at fair value and are included within "Other assets" and "Other liabilities" on the consolidated balance sheets, respectively. In addition to the investment securities, we also had company-owned life insurance related to the deferred compensation arrangement recorded at cash surrender value in "Other assets" of $1618.52 million and $1416.95 million at December 31, ~~2024~~2025 and ~~2023~~2024, respectively.

6870

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

Nonrecurring Fair Value Measurements

~~There~~During ~~were~~the noyear ~~nonrecurring~~ended December 31, 2025, we measured our Advanced Polymer Technologies reporting units' goodwill and our Performance Chemicals road markings long-lived assets at fair value in connection with impairment testing. These measurements onare ~~the~~Level ~~consolidated~~3 ~~balance~~and ~~sheetsduring~~were determined using both the ~~years~~income ~~ended~~approach ~~December 31,~~and ~~2024~~market approach for Goodwill and ~~2023~~both quoted market prices in active markets and a discounted value of estimated future cash flows for our long-lived assets. Refer to Note 7 and Note 8 for more information, including key assumptions.

Strategic Investments

Equity Method Investments

The aggregate carrying value of all strategic equity method investments was $153.41 million and $1615.04 million at December 31, ~~2024~~2025 and ~~2023~~2024, respectively. AsDuring the fourth quarter of ~~December 31~~2025, ~~2024~~we ~~and~~sold ~~2023,~~a ~~respectively,~~strategic weequity ~~had~~method ~~approximately~~investment for $56.38 million, ~~and~~resulting in a $57.61 million ofloss, ~~unfunded~~recorded ~~commitments~~within "Other (income) expense, ~~associated~~net" ~~with~~on athe ~~venture~~consolidated ~~capital~~statement ~~fund~~of ~~investment~~operations. ~~accounted~~We ~~for~~recognized ~~under~~an ~~the~~additional ~~equity~~$0.1 million ~~method~~gain ofassociated ~~accounting,~~with ~~which~~an weequity ~~anticipate~~method ~~will~~investment besale ~~paid~~during ~~over~~the ayears ~~period~~ended ofDecember 31, 102025, ~~years~~and 2024, respectively.

~~During~~As ~~the first quarter~~ of ~~2023~~December 31, we2025 ~~sold~~and a2024, ~~strategic~~respectively, ~~equity~~we ~~method~~had ~~investment~~approximately ~~for~~ $313.5 million, ~~resulting~~and ~~in a~~ $195.3 million ~~gain~~of unfunded commitments, ~~recorded~~associated ~~within~~with ~~"Other~~a ~~(income)~~venture ~~expense,~~capital ~~net"~~fund oninvestment accounted for under the ~~consolidated~~equity ~~statement~~method of ~~operations.~~accounting, Wewhich ~~recognized~~we ananticipate ~~additional~~will ~~$0.1 million~~be ~~gain~~paid ~~associated~~over ~~with~~a ~~the~~period ~~equity~~of ~~method~~10 ~~investment~~years ~~sale~~beginning ~~during~~from the ~~period~~fourth ~~ended~~quarter ~~December 31,~~of ~~2024~~2022. There were no adjustments to the carrying value of equity method investments for impairment for the periods ended, December 31, ~~2024~~2025 and ~~2023~~2024.

Measurement Alternative Investments

The aggregate carrying value of all measurement alternative investments where fair value is not readily determinable totaled $7180.90 million and $8371.29 million at December 31, ~~2024~~2025 and ~~2023~~2024, respectively. ~~For~~During the year ended December 31, ~~2024~~2025, ~~the~~strategic ~~Company identified triggering events indicating that~~ investments ~~being~~ accounted for under the measurement alternative ~~may~~method beincreased ~~impaired, and recognized impairment charges of~~ $1120.50 million~~, recorded in Other (income) expense, net on the consolidated statement of operations~~. ~~There were no adjustments to the carrying value of the measurement alternative method investments for impairment or observable price changes for the periods ended December 31, 2023.~~

For the years ended December 31, 2025 and 2024, the Company identified triggering events indicating that investments being accounted for under the measurement alternative may be impaired, and recognized impairment charges of $11.9 million and $2.1 million, respectively, recorded in "Other (income) expense, net" on the consolidated statement of operations.

Restricted Investment

Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing plant at maturity. The trust, presented as Restricted investment on our consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Because the provisions of the trust provide us the ability, and it is our intent, to hold the investments to maturity, the investments held by the trust are accounted for as held to maturity ("HTM"); therefore, they are held at their amortized cost. The investments held by the trust earn interest at the stated coupon rate of the invested bonds. Interest earned on the investments held by the trust is recognized and presented as Interest income on our consolidated statement of operations. As interest from the bonds is received and as bonds mature, any proceeds not reinvested are held in highly liquid securities and treated as restricted cash.

At December 31, ~~2024~~2025 and ~~2023~~2024, the carrying value of our restricted investment was $8184.64 million and $7981.1 6 million, net of an allowance for credit losses of $0.2 million and $0.2 million, and included restricted cash of $1834.20 million and $1518.42 million, respectively. The fair value at December 31, ~~2024~~2025 and ~~2023~~2024 was $8084.30 million and $7680.73 million, respectively, based on Level 1 inputs.

The following table shows the total amortized cost of our HTM debt securities by credit rating, excluding the allowance for credit losses and cash. The primary factor in our expected credit loss calculation is the composite bond rating. As the rating decreases, the risk present in holding the bond is inherently increased, leading to an increase in expected credit losses.

	HTM Debt Securities
In millions	AA+		AA-	A	A-	BBB+	Total
December 31, 2024	$	13.2	10.3	23.3	6.8	10.0	$	63.6
December 31, 2023	$	13.3	10.4	13.2	17.0	10.0	$	63.9

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025


	HTM Debt Securities
In millions	AA+		AA-	A	A-	BBB+	Total
December 31, 2025	$	13.2	10.5	13.1	3.8	10.0	$	50.6
December 31, 2024	$	13.2	10.3	23.3	6.8	10.0	$	63.6

Debt and Finance Lease Obligations

At December 31, ~~2024~~2025 and ~~2023~~2024, the carrying value of finance lease obligations was $~~100~~98.08 million and $~~101~~100.10 million, respectively, and the fair value was $~~102~~100.2 million and $~~105~~102.72 million, respectively. The fair value of our finance lease obligation associated with our Performance Materials' Wickliffe, Kentucky manufacturing plant, is based on the period-end quoted market prices for the obligations, using Level 2 inputs. The fair value of all other finance lease obligations approximates their carrying values.

The carrying value of our variable rate debt, excluding debt issuance fees and adjusted for our $200.0 million floating-to-fixed interest rate swap, was $~~555~~362.28 million, and $~~821~~555.42 million as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively. The carrying value of our variable rate debt is a reasonable estimate of the fair value.

At December 31, ~~2024~~2025 and ~~2023~~2024, the carrying value of our fixed rate debt was $550.0 million and $550.0 million, respectively, and the fair value was $~~503~~535.27 million and $~~494~~503.62 million, respectively, based on Level 2 inputs.

Note 6: Inventories, net

	December 31,
In millions	~~2024~~2025		~~2023~~2024
Raw materials	$	9745.67	$	~~128~~49.32
Production materials, stores and supplies	2527.05		2625.0
Finished and in-process goods	~~186~~141.26		~~255~~157.24
Subtotal	$	~~308~~214.8	$	~~409~~231.56
Less: LIFO reserve	(8228.08)		(~~100~~35.7)
Inventories, net	$	~~226~~186.80	$	~~308~~195.89

As of December 31, ~~2024~~2025, approximately 4134 percent, 1115 percent, and 4851 percent of our Inventories, net, were accounted for under the FIFO, average cost, and LIFO methods, respectively. As of December 31, ~~2023~~2024, approximately 2728 percent, 813 percent, and 6559 percent of our Inventories, net, were accounted for under the FIFO, average cost, and LIFO methods, respectively. The repositioning actions taken to improve our Performance Chemicals reportable segment has reduced overall LIFO inventory (refer to Note 15 for more detail).

During the ~~year~~years ended December 31, 2025 and 2024, changes to inventory quantities carried on a LIFO basis, ~~primarily~~resulted in ~~our~~a ~~Performance~~pre-tax ~~Chemicals~~increase ~~reportable segment domestic inventory, were reduced which led to liquidations~~ of ~~LIFO inventory quantities~~$10.0 ~~These~~million ~~reductions~~and ~~resulted in a~~ pre-tax decrease of $6.93 million for the years ended December 31, 2025 and 2024, respectively, recorded in Cost of sales on our consolidated statement of operations. ~~No such reductions occurred during the year ended December 31, 2023.~~

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, 2025

Note 7: Property, Plant, and Equipment, net

	December 31,
In millions	~~2024~~2025		~~2023~~2024
Machinery and equipment	$	1,~~296~~307.43	$	1,~~244~~253.63
Buildings and leasehold improvements	~~224~~212.35		~~217~~224.41
Land and land improvements	2624.25		26.32
Construction in progress	6831.90		9268.87
Total cost	$	1,~~615~~575.83	$	1,~~581~~572.13
Less: accumulated depreciation (1)	(956.9)		(818.9)
Less: accumulated depreciation	(967.2)		(929.4)
Property, plant, and equipment, net (2)	$	658.9	$	762.2
Property, plant, and equipment, net (1)	$	608.1	$	642.9

_______________

(1) AsIncludes afinance ~~result~~leases offor the ~~Performance~~years ~~Chemicals~~ended ~~repositioning~~December 31, as2025, ~~further~~and ~~described~~2024 inrelated ~~Note~~to ~~15,~~machinery weand ~~accelerated~~equipment ~~the~~of ~~depreciation~~$92.6 ofmillion ~~certain~~and ~~property,~~$93.7 ~~plant~~million, and ~~equipment~~net ~~assets~~carrying invalue ~~2024~~of $17.8 million and ~~2023~~$20.3 ~~This~~million; ~~resulted~~buildings inand leasehold improvements of $9228.69 million and $4639.32 million, ofand ~~additional~~net ~~expense~~carrying ~~for~~value ~~the~~of ~~years~~$19.2 million ~~ended~~and ~~December~~$29.9 31million, ~~2024~~respectively. ~~and~~Amortization ~~2023,~~expense ~~respectively,~~associated ~~which~~with these finance leases is included inwithin ~~Restructuring~~depreciation ~~and~~expense. ~~other~~The ~~(income)~~payments ~~charges,~~remaining ~~net~~under ~~within~~these ~~the~~finance ~~consolidated~~lease ~~statement~~obligations ofare ~~operations~~included within Note 13.

70Depreciation expense, excluding accelerated depreciation included in Restructuring and other (income) charges, net, was $66.9 million, $65.1 million, and $65.1 million for the years ended December 31, 2025, 2024, and 2023, respectively.

Long Lived Asset Impairment Charge

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

(2) Includes finance leases related to machinery and equipment of $93.7 million and $94.2 million, and net carrying value of $20.3 million and $22.7 million; buildings and leasehold improvements of $39.2 million and $39.2 million, and net carrying value of $29.9 million and $32.3 million, respectively. Amortization expense associated with these finance leases is included within depreciation expense. The payments remaining under these finance lease obligations are included within Note 13.

Depreciation expense, excluding accelerated depreciation included in Restructuring and other (income) charges, net, was $71.6 million, $81.5 million, and $70.9 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Note 8: Goodwill and Other Intangible Assets, net

Goodwill

	Reporting Units
In millions	Performance Materials		Performance Chemicals		Advanced Polymer Technologies		Total
Balance as of December 31, 2022	$	4.3	$	514.2	$	—	$	518.5
Balance as of December 31, 2024 (1)	$	4.3	$	—	$	170.9	$	175.2
Segment change reallocation	—		(165.0)		165.0		—
Foreign currency translation	—		—		12.9		12.9
Foreign currency translation	—		0.2		8.8		9.0
Goodwill impairment charge	—		—		(183.8)		(183.8)
Balance as of December 31, 2023	$	4.3	$	349.4	$	173.8	$	527.5
Balance as of December 31, 2025	$	4.3	$	—	$	—	$	4.3
Goodwill impairment charge	—		(349.1)		—		(349.1)
Foreign currency translation	—		(0.3)		(2.9)		(3.2)
Balance as of December 31, 2024
Goodwill	4.3		349.1		170.9		524.3
Accumulated impairment losses	—		(349.1)		—		(349.1)
	$	4.3	$	—	$	170.9	$	175.2

_______________

(1) Includes accumulated impairment losses of $306.6 million related to the Performance Chemicals reportable segment.

Impairment Assessment(s) and Goodwill Impairment Charge

Annual Impairment Assessment

Our fiscal year ~~2024~~2025 annual goodwill impairment assessment for our Performance Materials reporting unit was performed as of October 1, ~~2024~~2025. WeQualitatively, we determined that the fair value of our reporting units were in excess of their carrying value and therefore concluded that no goodwill impairment existed.

~~The~~There ~~results~~were ofno ~~our~~events ~~October~~or ~~1st~~circumstances ~~annual~~indicating ~~review calculated~~ that ~~our~~goodwill ~~APT~~might ~~reporting~~be ~~unit~~impaired ~~headroom, defined~~ as ~~the percentage difference between the fair value~~ of ~~a reporting unit and its carrying value~~ December 31, ~~is 12 percent~~2025. Since the fair value of our APT reporting unit is higher than the carrying value, we have concluded that no impairment to goodwill is necessary. Our analysis includes significant assumptions such as revenue growth rate, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margin, and discount rate, which are judgmental, and variations in any assumptions could result in materially different calculations of fair value.

~~There~~Interim ~~were~~Goodwill noImpairment ~~events~~Charge or- ~~circumstances~~Advanced ~~indicating~~Polymer ~~that goodwill might be impaired as of December 31, 2024.~~Technologies

~~Goodwill~~During ~~Impairment~~the ~~Charge~~second quarter of 2025, the announcements and subsequent modifications of international tariffs escalated global trade tensions and contributed to increased consumer uncertainty, which negatively impacted parts of our businesses, particularly Advanced Polymer Technologies ("APT"). As a result, we conducted an analysis of the APT reporting unit's goodwill and long-lived assets. This analysis incorporated revised expectations regarding the pace and strength of industrial demand recovery in key markets. In addition, the macroeconomic changes experienced during the quarter contributed to unfavorable movements in key valuation inputs, including an increase in the risk-free rate used in calculating the discount rate.

Beginning in fiscal year 2023, we began to see depressed volumes in our industrial end markets, constraining our ability to offset the continued crude tall oil (“CTO”) price inflation we were experiencing, and negatively impacting earnings and cash flow within our Performance Chemicals reporting unit, particularly in our industrial specialties product line. As a result, we concluded that a triggering event occurred in the third quarter of 2023. Our ~~third quarter 2023 impairment~~ analysis included significant assumptions, such as the ~~execution~~revenue ofgrowth ~~several~~rates, ~~measures~~EBITDA ~~in 2023 to pursue greater cost efficiency~~margins, ~~including a reorganization to streamline certain functions~~ and ~~reduce~~discount ~~ongoing costs~~rate, ~~and~~which ~~expectations~~are ofjudgmental. ~~decreased~~Variations ~~CTO costs beginning~~ in ~~the~~any ~~second~~assumptions ~~half~~could ofresult ~~2024.~~in Wematerially ~~concluded~~different ~~that~~calculations ~~no impairment was necessary as a result~~ of ~~that~~fair ~~third quarter 2023 interim analysis or at our annual impairment assessment, dated October 1, 2023~~value.

71Based on the results of the quantitative analysis, we concluded that the carrying value of the APT reporting unit exceeded its fair value. As a result, we recorded a non-cash goodwill impairment charge of $183.8 million, representing all of the goodwill associated with the APT reporting unit. The charge is included within "Goodwill impairment charge" on the consolidated statements of operations for the twelve months ended December 31, 2025. Specific to our long-lived assets, we determined that the undiscounted cash flows were in excess of the carrying values and therefore concluded that no impairment existed. Our analysis included significant assumptions such as the revenue growth rates, EBITDA margins, and EBITDA exit multiple, which are judgmental. Variations in any assumptions could result in materially different calculations of undiscounted cash flows.

Goodwill Impairment Charge - Performance Chemicals

During the second quarter of 2024, our contracted long-term supplier of CTO provided new information regarding the cost of CTO for the second half of 2024, which significantly exceeded our forecasted costs, resulting in a triggering event for our Performance Chemicals reporting unit. We performed an analysis of the reporting unit’s goodwill, intangibles, and long-lived assets. Our analysis included significant assumptions such as: revenue growth rates, EBITDA margins, and discount rate, which are judgmental, and variations in any assumptions could result in materially different calculations of fair value.

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

~~During~~Our analysis reassessed the ~~second~~expected ~~quarter~~cash flows in light of ~~2024,~~current ~~our~~performance ~~contracted~~and ~~long-term~~expected ~~supplier~~lack of ~~CTO~~near ~~provided~~term ~~new~~recovery ~~information~~in ~~regarding~~our ~~the~~industrial ~~cost~~specialties ofproduct ~~CTO~~line, ~~for~~resulting in lower volume and profitability expectations. As a result, we concluded that the ~~second~~carrying ~~half~~amount of ~~2024,~~the ~~which~~Performance ~~significantly~~Chemicals reporting unit exceeded ~~our~~its ~~forecasted~~fair ~~costs~~value, resulting in a ~~triggering~~non-cash ~~event~~goodwill ~~for~~impairment ~~our~~charge ~~Performance~~of ~~Chemicals reporting unit~~$306.6 Wemillion, ~~performed~~which anrepresented ~~analysis~~all of the ~~reporting~~goodwill ~~unit’s~~within ~~goodwill,~~the ~~intangibles,~~Performance ~~and~~Chemicals' ~~long-lived~~reportable ~~assets~~segment. ~~Our~~The ~~analysis~~charge was included ~~significant~~within ~~assumptions~~"Goodwill ~~such~~impairment ~~as:~~charge" ~~revenue~~on ~~growth~~the ~~rate,~~consolidated ~~EBITDA~~statements ~~margin,~~of ~~and~~operations ~~discount~~for ~~rate~~the year ended December 31, ~~which~~2024. ~~are~~Specific ~~judgmental~~to our long-lived assets, ~~and~~we ~~variations~~determined inthat ~~any~~the ~~assumptions~~undiscounted ~~could~~cash ~~result~~flows were in ~~materially~~excess ~~different~~of ~~calculations~~the ofcarrying ~~fair~~values ~~value~~and therefore concluded that no impairment existed.

Our analysis reassessed the expected cash flows in light of current performance and expected lack of near term recovery in our industrial specialties product line, resulting in lower volume and profitability expectations. As a result, we concluded that the carrying amount of the Performance Chemicals reporting unit exceeded its fair value, resulting in a non-cash goodwill impairment charge of $349.1 million, which represented all of the goodwill within the Performance Chemicals' reportable segment. The charge was is included within Goodwill impairment charge on the consolidated statements of operations for the year ended December 31, 2024. Specific to our long-lived assets, we determined that the undiscounted cash flows were in excess of the carrying values and therefore concluded that no impairment existed.

Other Intangible Assets

In millions	Customer contracts and relationships		Brands (1)		Developed Technology		Total
Gross Asset Value
December 31, 2022	$	388.5	$	89.2	$	88.5	$	566.2
December 31, 2023	$	396.5	$	92.6	$	91.7	$	580.8
Foreign currency translation	8.0		3.4		3.2		14.6
December 31, 2023	396.5		92.6		91.7		580.8
Retirements (2)	(129.0)		—		(1.9)		(130.9)
Foreign currency translation	(2.6)		(1.2)		(1.1)		(4.9)
December 31, 2024	$264.9	~~264.9~~	$91.4	~~91.4~~	$88.7	~~88.7~~	$445.0	~~445.0~~
Retirements	—		—		(4.1)		(4.1)
Foreign currency translation	11.8		5.0		4.8		21.6
Impairment (3)	(82.8)		(14.2)		(19.6)		(116.6)
December 31, 2025	$	193.9	$	82.2	$	69.8	$	345.9
Accumulated Amortization
December 31, 2022	$	(113.8)	$	(23.9)	$	(23.7)	$	(161.4)
December 31, 2023	$	(179.4)	$	(30.3)	$	(35.0)	$	(244.7)
Amortization (4)	(63.5)		(5.7)		(10.1)		(79.3)
Foreign currency translation	(2.1)		(0.7)		(1.2)		(4.0)
December 31, 2023	(179.4)		(30.3)		(35.0)		(244.7)
Amortization (4)	(38.9)		(5.5)		(9.9)		(54.3)
Retirements (2)	129.0		—		1.9		130.9
Foreign currency translation	0.9		0.4		0.6		1.9
December 31, 2024	$(88.4)	~~(88.4)~~	$(35.4)	~~(35.4)~~	$(42.4)	~~(42.4)~~	$(166.2)	~~(166.2)~~
Other intangibles, net (3)	$	176.5	$	56.0	$	46.3	$	278.8
Amortization	(15.0)		(5.5)		(10.1)		(30.6)
Retirements	—		—		3.2		3.2
Foreign currency translation	(4.3)		(1.7)		(2.7)		(8.7)
Impairment (3)	19.2		4.9		8.4		32.5
December 31, 2025	$	(88.5)	$	(37.7)	$	(43.6)	$	(169.8)
Other intangibles, net (5)	$	105.4	$	44.5	$	26.2	$	176.1

_______________

(1) Represents trademarks, trade names, and know-how.

(2) As a result of the Performance Chemicals repositioning, ~~as further described in Note 15,~~ we retired certain customer contract and relationships, and developed technology finite-lived intangible assets.

(3) ~~The~~Impairment ~~weighted~~related ~~average~~to ~~amortization~~the ~~period~~Performance ~~remaining~~Chemicals ~~for~~road ~~all~~markings ~~intangibles~~asset ~~is 10~~group.7 ~~years,~~See ~~while~~Note ~~the~~7 ~~weighted average amortization period remaining~~ for ~~customer~~more ~~contracts and relationships, brands, and developed technology is 11~~information.8 ~~years, 10.4 years, and 7.0 years, respectively.~~

(4) As a result of the Performance Chemicals repositioning, ~~as further described in Note 15,~~ we accelerated the amortization of certain customer contract and relationship finite-lived intangible assets. This resulted in $22.1 million and $37.4 million of additional expense for the years ended December 31, 2024 and 2023, which is included inwithin the discontinued operations statement of operations within Restructuring and other (income) charges, net. ~~within~~Refer ~~the~~to ~~consolidated~~Note ~~statements~~20 offor ~~operations~~more information.

72(5) The weighted average amortization period remaining for all intangibles is 10.6, while the weighted average amortization period remaining for customer contracts and relationships, brands, and developed technology is 11.2, 11.0, and 7.7, respectively.

Index

Ingevity Corporation

Notes to the Consolidated Financial Statements

December 31, ~~2024~~2025

Intangible assets subject to amortization were allocated among our business segments as follows:

	December 31,
In millions	~~2024~~2025		~~2023~~2024
Performance Materials	$	~~1.2~~—	$	1.52
Performance Chemicals (1)	~~102~~8.5		~~137~~102.5
Advanced Polymer Technologies	~~175~~167.16		~~197~~175.1
Other intangibles, net	$	~~278~~176.81	$	~~336~~278.18

_______________

(1) ~~Refer~~The toreduction ~~footnote 4~~ in ~~the~~Performance ~~preceding~~Chemicals ~~Other~~from ~~Intangible~~2024 ~~Assets~~to ~~table~~2025 ~~for~~was ~~more~~primarily ~~information~~due onto the ~~change~~Performance inChemicals ~~amortization~~road inmarkings ~~2024~~long lived asset impairment charge.

The amortization expense related to our intangible assets in the table above is shown in the table below.

	Years Ended December 31,
In millions	~~2024~~2025		~~2023~~2024		~~2022~~2023
Selling, general, and administrative expenses	$	3230.26	$	4132.92	$	3341.69
Restructuring and other (income) charges, net (1)	22.1		37.4		—
Total amortization expense	$	30.6	$	32.2	$	41.9
Total amortization expense	$	54.3	$	79.3	$	33.6

~~_______________~~Based on the current carrying values of intangible assets, estimated pre-tax amortization expense for the next five years is as follows: 2026 - $20.4 million, 2027 - $20.4 million, 2028 - $20.4 million, 2029 - $20.4 million and 2030 - $14.8 million. The estimated pre-tax amortization expense may fluctuate due to changes in foreign currency exchange rates.

(1) Amounts recorded to Restructuring and other (income) charges, net are not included within segment depreciation and amortization.

Based on the current carrying values of intangible assets, estimated pre-tax amortization expense for the next five years is as follows: 2025 - $30.0 million, 2026 - $29.3 million, 2027 - $29.3 million, 2028 - $29.3 million and 2029 - $29.3 million. The estimated pre-tax amortization expense may fluctuate due to changes in foreign currency exchange rates.

Note 9: Financial Instruments and Risk Management

Net Investment Hedges

During 2022, we terminated our fixed-to-fixed cross-currency interest rate swaps, accounted for as net investment hedges, and received net proceeds of $14.7 million. The proceeds are presented within cash provided by investing activities within the consolidated statement of cash flows. The $14.7 million gain is reported as a component of the CTA within AOCI on the consolidated balance sheet. Gains from net investment hedges are reclassified to earnings only when the related CTA are required to be reclassified, usually upon the sale or liquidation of the investment (i.e., the legal entity).

The fair value of our net investment hedge was a net asset (liability) of zero at December 31, 2024 and 2023. During the years ended December 31, 2024, 2023, and 2022, we recognized net interest income associated with this financial instrument of zero, zero, and $1.1 million, respectively.

Cash Flow Hedges

Foreign Currency Exchange Risk Management

We manufacture and sell our products in several countries throughout the world and thus, we are exposed to changes in foreign currency exchange rates. To manage the volatility relating to these exposures, we net the exposures on a consolidated basis to take advantage of natural offsets. To manage the remaining exposure, from time to time, we utilize forward currency exchange contracts and zero cost collar option contracts to minimize the volatility to earnings and cash flows resulting from the effect of fluctuating foreign currency exchange rates on export sales denominated in foreign currencies (principally the euro). These contracts are generally designated as cash flow hedges. As of December 31, ~~2024~~2025, open foreign currency exchange contracts hedge a portion of forecasted transactions until January ~~2026~~2027. Designated cash flow hedges entered to minimize foreign currency exchange risk of fo

Filing Compare · Ingevity Corp